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General Introduction
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Introduction
Cardiovascular disease (CVD) is a collective term to describe disorders of the heart and 
blood vessels such as angina pectoris, myocardial infarction, stroke and transient ischemic 
attack. One of the underlying cause of CVD is atherosclerosis, which is a slow, chronic 
and continuing process that starts with the formation of fatty streaks at an early age and 
eventually results in plaque formation within the vessel walls [1]. Endothelial dysfunction 
and inflammatory responses play a central role in the development of atherosclerosis, 
resulting in an increased permeability of the endothelial layer. This allows atherogenic low-
density lipoprotein (LDL) particles to migrate into the underlying intima layer, where they 
subsequently can be oxidized. Accumulated oxidized LDL particles in the endothelial wall 
will stimulate the expression of adhesion molecules, attracting monocytes that can migrate 
into the intima layer and can transformed into macrophages. Oxidized LDL particles are 
taken up by macrophages and will form lipid-loaded foam cells, creating a viscous cycle 
of inflammatory responses with secretion of cytokines and growth factors. Ultimately, an 
advanced complicated lesion is formed, covered by a fibrous cap consisting of fibrous tissue, 
smooth muscle cells, platelets and macrophages, which can obstruct arterial blood flow. 
When an atherosclerotic lesion ruptures, it can form a thrombus and cause a myocardial or 
cerebrovascular infarction [2, 3]. 
The risk to develop atherosclerotic lesions is influenced via many factors, such as cigarette 
smoking, high blood pressure, diabetes mellitus and obesity. Another important CVD 
risk factor is an unfavourable lipoprotein profile, which is characterized by increased 
LDL-cholesterol (LDL-C) concentrations, increased triacylglycerol (TAG) concentrations 
and/or decreased high-density lipoprotein cholesterol (HDL-C) concentrations. For this 
reason, reducing LDL-C concentrations is the major target in CVD prevention [4]. Elevated 
serum LDL-C concentrations can be lowered via lifestyle changes and if necessary via 
pharmacological treatment. The most widely prescribed drugs are statins, which are able to 
lower LDL-C concentrations up to 50%. More dramatic decreases in LDL-C concentrations can 
be achieved by targeting PCSK9, which is a protein secreted by hepatocytes and regulates 
LDL receptor breakdown. Antibodies to PCSK9 are in clinical trial development and LDL-C 
reductions of 60% were seen in hypercholesterolemic patients, while reductions up to 70% 
were achieved in statin-treated patients [5, 6]. 
Subjects suffering from mild hypercholesterolemia do not qualify for pharmacological 
treatment and are able to achieve more modest LDL-C reductions through dietary changes. 
In addition, subjects on statins not meeting their LDL-C goals or subjects suffering from 
statin intolerance might also benefit from dietary changes to lower LDL-C concentrations 
[7]. Changing the composition of the diet and adding specific foods or food components 
(so-called functional foods) to the daily diet improves an unfavourable lipoprotein profile. 
Nowadays, functional foods are widely incorporated with a variety of health-promoting 
activities. 
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Plant sterols and plant stanols as cholesterol-lowering functional foods
The enrichment of foods with plant sterol and plant stanol esters is one of the first examples 
of functional foods that demonstrated a clear health benefit, i.e. lowering serum total and 
LDL cholesterol concentrations. Plant sterols and plant stanols share structural similarities 
with cholesterol. They consist of a steroid nucleus with a double bond present at C5-C6 
while only the side-chain configuration differs. Plant stanols are the saturated derivative of 
plant sterols (Figure 1.1). Plant sterols and plant stanols are naturally occurring constituents 
of plants and are present in our daily diet. They are found in vegetable oils, such as corn oil, 
soybean oil, and rapeseed oil and they are also present in cereals, nuts, fruit and vegetables. 
The average intake of plant sterols and plant stanols in Western countries is approximately 
300 mg/day, but can be as high as 600 mg/day in vegetarians. The most abundant plant 
sterols in the human diet are β-sitosterol, campesterol and stigmasterol, while plant stanols 
are less abundant and consist mainly of sitostanol and campestanol [8]. Serum plant 
sterol and plant stanol concentrations are the result of intestinal absorption and biliary 
secretion, since humans cannot synthesize plant sterols and plant stanols. Their fractional 
absorption rate is very low (0.5-2.0% for plant sterols and 0.04-0.2% for plant stanols) and 
biliary secretion is high, which results in serum concentrations of plant sterols and plant 
stanols that are less than 1% of that of serum cholesterol. On average, plasma sitosterol 
concentrations range from 0.16 to 0.67 mg/dL and campesterol concentrations from 0.28 to 
1.12 mg/dL [9], while plasma plant stanol concentrations are approximately 100 times lower 
and vary between 2 and 12 ug/dL in the normal population [10]. 
HO Sitosterol 
HO Cholesterol 
HO 
HO HO 
Sitostanol 
Campestanol Campesterol 
Figure 1.1 Chemical structures of cholesterol, plant sterols and plant stanols.
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The LDL-C lowering effect of plant sterols and plants stanols has been demonstrated in 
numerous studies and has resulted in the recommendations to consume plant sterol and 
plant stanol enriched products in current dietary guidelines [11]. Plant sterols or plant 
stanols are able to reduce serum LDL-C concentrations by decreasing intestinal cholesterol 
absorption, which results in an increased endogenous cholesterol synthesis rate and an up-
regulation of LDL receptor expression. Large meta-analyses have shown that consuming 
approximately 2.5 g/day of plant sterols or plant stanols lowers serum LDL-C concentrations 
up to 10%. At doses up to 3.0 g/day, plant sterols and plant stanols have been shown to 
have a comparable LDL-C lowering efficacy, while there are discrepancies between the 
efficacy of plant sterols and plant stanols at higher intakes. However, studies specifically 
designed to answer this question are lacking and therefore conclusions regarding relative 
efficacy of plant sterols and plant stanols at higher intakes cannot be drawn. Plant sterol and 
plant stanol enriched products have been shown to lower LDL-C concentration in different 
populations and incorporated into different matrices as extensively reviewed [11, 12]. While 
reduced LDL-C concentrations after plant sterol and plant stanol consumption have been 
unequivocally proven, there is a lack of hard endpoint studies evaluating the clinical benefit 
from the consumption of plant sterol and plant stanol enriched products.
Potential atherogenicity of plant sterol and plant stanol consumption 
Consuming plant sterol enriched products will increase serum plant sterol concentrations, 
while the consumption of plant stanols will decrease plant sterol concentrations. A recent 
meta-analysis reported average increases in sitosterol concentrations of 31% (CI: 26-37%) 
and increases in campesterol concentrations of 37% (CI: 29-45) after consumption of plant 
sterol enriched products [13]. Phytosterolemia is a rare genetic sterol storage disease that 
is characterized by dramatic increases in serum plant sterol concentrations, ranging from 
10-65 mg/dL, while serum cholesterol concentrations are normal or only slightly increased. 
Patients suffering from this disease often develop tendon and tuberous xanthomas and 
some patients develop premature atherosclerosis, while other patients do not show any 
signs of CVD, complicating the association between increased plant sterol concentrations 
and CVD risk [14]. The disease is caused by a mutation in the ABCG5/8 half transporters, 
resulting in a decreased secretion of absorbed sterols from the enterocytes back into 
the lumen, as well as a reduction from the liver into bile. In healthy subjects, increases 
after plant sterol consumption remain within the normal range (<1.0 mg/dL) and are only 
marginal as compared to plant sterol concentrations observed in phytosterolemic subjects. 
However, the potential impact of these elevated circulating plant sterol concentrations 
on cardiovascular risk is currently hotly debated. Several prospective and cross-sectional 
epidemiological studies evaluated the potential relationship between circulating plant 
sterol concentrations and CVD risk with contradictive results. Genser et al. performed a 
systematic review based upon 17 epidemiological studies (n=11.182) and did not find an 
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association between serum concentrations of plant sterols and elevated risk of CVD [15]. 
Serum plant sterol concentrations are surrogate markers for intestinal absorption and might 
underlie the potential association between increased plant sterol concentrations and CVD 
risk as shown by Silbernagel et al. in a recent study [16]. They identified an atherogenic role 
for high intestinal cholesterol absorption rather than for increased circulating plant sterol 
concentrations, based on the cholestanol-to-cholesterol ratio. Cholestanol is a derivative of 
cholesterol and produced by the liver and often used as a surrogate marker for cholesterol 
absorption. However, the validity of this marker has recently been questioned since 
cholestanol is also present in diet (less than 2 mg/day) and it does not reflect cholesterol 
absorption under certain conditions such as impaired biliary secretion [17, 18]. Although 
cholestanol concentrations correlated with fraction cholesterol absorption in a recent 
overview of plant stanol studies, individual studies do not always show this correlation. 
Silbernagel et al. implied that increased plant sterol concentrations are merely a marker for 
high cholesterol absorption rates without being atherogenic themselves. However, since 
this assumption heavily relies on serum cholestanol concentrations as a surrogate marker 
for cholesterol absorption, verification in future research is desirable. 
Oxidation of cholesterol, plant sterols and oxysterol concentrations 
Besides plant sterols acting as a surrogate marker, another possibility to explain the potential 
association between plant sterol concentrations and CVD risk might be increases in plasma 
oxyphytosterol concentrations. Plant sterols are – analogue to cholesterol – susceptible to 
oxidation and can result in the formation of oxyphytosterols, while plant stanols do not have 
a double bond in their ring structure and can therefore not be oxidized.
Oxycholesterol and oxyphytosterol concentrations can result from dietary absorption or 
from endogenous oxidation from non-oxidized sterols. Plant sterols most likely can only be 
oxidized at the 7-position of the sterol ring, while cholesterol can be oxidized both at the 
sterol ring and on their side-chain [19]. Figure 1.2 shows the most important oxycholesterol 
and oxyphytosterol structures present in most tissues. In general, ring-oxidation products 
are formed non-enzymatically, e.g. through reactive oxidative species (ROS)-mediated 
oxidation while side-chain oxidation products are formed enzymatically. Exceptions to this 
are 7α-OH-sterols and 25-OH-cholesterol, which both can be formed enzymatically and 
non-enzymatically. ROS-mediated oxidation of a cholesterol or a plant sterol molecule 
starts with the abstraction of an allylic hydrogen atom at carbon-7 of the sterol ring. 
The generated radical can further react with oxygen to form a cholesterol or plant sterol 
peroxyl radical and after further abstraction of hydrogen, the relatively stable 7α- and/
or 7β-hydroxyperoxides are formed. These hydroxyperoxides products can be reduced to 
form 7α- and or 7β-OH products or be dehydrated to form 7-keto-products, which are the 
major non-enzymatic oxycholesterols and oxyphytosterols present in the human body [20]. 
For cholesterol, 24-, 25- and 27-OH-cholesterols are generated by enzymatic oxidation of 
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the side-chain. 27-OH-cholesterol is produced by sterol 27-hydroxylase (CYP27A1), a P450 
enzyme mostly expressed in the liver and macrophages that is involved in many processes, 
including the breakdown of cholesterol to bile acids. Cholesterol 24-hydroxylase (CYP46A1) 
is also a P450 enzyme, located in neural cells of the brain and retina and is able to produce 
24-OH-cholesterol. 25-OH-cholesterol is a regulator of the sterol regulatory element binding 
protein (SREBP) pathway for cholesterol synthesis and is produced both non-enzymatically 
as well as enzymatically by cholesterol 25-hydroxylase [21]. Oxycholesterols formed through 
P450-oxidation are involved in functional processes in the body, such as sterol synthesis/
breakdown and the metabolism of potential harmful compounds. On the other hand, ROS-
mediated oxycholesterols mainly reflect oxidation status of the body and will often be 
accompanied by many other, potentially toxic, oxidized compounds [22]. Regarding plant 
sterols, oxidation only occurs at the 7-position of the ring structure, indicating that the 
majority of oxidized plant sterols will result from radical oxidation by ROS and not through 
enzymatic oxidation. However, information regarding oxyphytosterol metabolism is very 
scarce and enzymes responsible for plant sterol oxidation might be identified in future 
research. 
HO 
HO O 
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7 -hydroxysterol 7-ketosterol 
HO 
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Figure 1.2. Plant sterol and cholesterol oxidation products. In general, cholesterol and plant sterol oxidation 
products oxygenated at the sterol ring are produced non-enzymatically, while cholesterol oxidation products 
oxygenated at the side chain require enzymes. 25- and 7α-OH-cholesterols can be produced enzymatically and 
non-enzymatically.
Besides in vivo formation, oxyphytosterols are also found in food products, such as 
heated vegetable oils, infant milk formulas, parenteral nutrition, French fries, potato chips 
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and coffee beans. However, the main source of dietary oxyphytosterols are plant sterol 
enriched products, where one serving can provide up to 1.7 mg oxyphytosterols per day 
if a recommended daily intake of 20-25 gram of spread is consumed. This exceeds the 
intake of other oxyphytosterol-containing products, such as heated vegetable oils, where 
oxyphytosterol intake was estimated to be 0.7 mg per day or less [23-26]. Circulating 
oxyphytosterols have been identified in phytosterolemic subjects [27], in healthy subjects 
[28, 29] and in aortic tissue of CVD patients [30]. Concentrations in healthy subjects are very 
low, i.e. a range of 0.3-4.5 ng/mL, which is 10-100 times lower than plasma oxycholesterol 
concentrations. Whether circulating oxyphytosterols originate from dietary absorption, 
endogenous oxidation from non-oxidized plant sterols or a combination of both remains 
to be determined. Since there is hardly anything known regarding oxyphytosterols (i.e. 
absorption, endogenous oxidation of plant sterols and dietary influence), we carried out 
two intervention studies to increase our basic knowledge on oxyphytosterol metabolism. 
In a large randomised cross-over trial, we examined the effects of consuming plant sterol 
or stanol ester enriched margarines on fasting and postprandial plasma oxyphytosterol 
concentrations in healthy subjects (chapter 3 and 5). We also investigated the difference 
between subjects with low and high plasma oxyphytosterol concentrations to increase 
our understanding of potential determinants of circulating oxyphytosterol concentrations 
(chapter 4). In a subsequent study, we also evaluated whether plasma oxyphytosterol 
concentrations are influenced by antioxidant supplementation in a population characterized 
by increased oxidative stress (chapter 7).  
Effects of plant sterol and plant stanol consumption on postprandial metabolism and 
sequential meal consumption
Atherosclerosis has been suggested to be a postprandial disease, where remnant lipoproteins 
play a large role and evidence is accumulating towards non-fasting TAG as another important 
CVD risk factor [31, 32]. Except for a couple of hours in the early morning, humans are in 
a non-fasting state for most part of the day. The (postprandial) transport of lipoproteins is 
shown in Figure 1.3. After consumption of a (fatty) meal, dietary triglycerides are hydrolysed 
via enzymatic lipases to free fatty acids and monoglycerides (MAGs) and, together with other 
lipophilic substances such as bile salts and cholesterol, are formed into mixed micelles. Fatty 
acids and MAGs are absorbed in the enterocytes and resynthesized to form TAGs in the 
endoplasmatic reticulum. They are then packed with apolipoprotein (apo) B48 particles, 
A-1 and A-IV into chylomicrons, secreted into lymph and pass into the blood via the 
thoracic duct. In the circulation, chylomicrons acquire apoCII and apoE from HDL particles. 
Chylomicron-TAGs are hydrolysed by lipoprotein lipase (LPL) present on endothelial cells 
which uses apoCII as a co-factor, and the released FAs are absorbed by adipose or skeletal 
muscle and used for energy generation or storage as TAGs. Phospholipids, cholesterol 
and apolipoproteins are transferred to HDL particles and the remaining cholesterol-rich 
chylomicron is transferred into a remnant particle. Chylomicron remnants are taken up by 
14
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the liver via surface cell receptors (LDL-receptor via apoB and LDL-receptor related protein 
(LRP) via apoE), which completes the exogenous lipoprotein transport. On the other hand, 
the endogenous lipoprotein transport involves the production of TAG-rich VLDL particles by 
the liver. VLDLs contain predominantly TAGs, smaller amounts of cholesterol and apoB100, 
CII and E. Similar to chylomicrons, they undergo lipolysis via LPL, which results in the 
formation of intermediate-density lipoproteins (IDL) that can be taken up by the liver or be 
converted into LDL particles. VLDL and LDL particles are removed from the circulation via 
LDL-receptor and LRP-mediated clearance [33]. LDL-receptor mediated uptake is no longer 
possible when apoB100 is modified (for example through oxidative stress) and LDL is then 
taken up by scavenger receptors present on macrophages, contributing to the development 
of atherosclerosis [34]. HDL particles are responsible for reverse cholesterol transport (RCT). 
For this, nascent HDL particles acquire cholesterol from non-hepatic cells by interacting with 
ABCA1 and ABCG1, after which cholesterol is esterified by lecithin:cholesterol acyltransferase 
(LCAT) and mature HDL particles are formed. Cholesterol ester transfer protein (CETP) can 
transfer cholesterol esters from HDL to VLDL, LDL and chylomicron particles in exchange for 
Storage/oxidation 
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Liver 
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CM 
VLDL 
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LDL 
Intestine 
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LDLr & LRP 
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Figure 1.3. Schematic overview of the lipoprotein metabolism. LDLr: low-density lipoprotein receptor, LRP: 
lipoprotein receptor-related protein, SR-B1: scavenger receptor class B member 1, CM: chylomicron, VLDL: very 
low-density lipoprotein, IDL: intermediate low-density lipoprotein, LDL: low-density lipoprotein, HDL: high-density 
lipoprotein, LPL: lipoprotein lipase, CE: cholesterol ester, TAG: triglycerides, FFA: free fatty acids, CETP: cholesterol 
ester transfer protein, LCAT: lecithin-cholesterol acyltransferase.
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TAG. The transfer of cholesterol from HDL-C to LDL-C predominates, with minor transfer to 
VLDLs and chylomicrons [35].
Postprandial lipemia is a normal response of the human body, which is determined by 
intestinal and hepatic TAG secretion (into chylomicron and VLDL particles), TAG clearance by 
specific lipases and remnant-receptor driven removal of particles from the circulation. This 
response is transitory, but can become pathological when the extent of the TAG response 
is increased after meal consumption, which will then result in an accumulation of TAG-rich 
lipoproteins (TRLs) and their remnants. An accumulation of TRLs in the circulation will result 
in smaller chylomicron and VLDL remnant particles with a higher density that are more 
atherogenic than their larger counterparts. Smaller high dense remnants can more easily 
infiltrate into the arterial wall, are more prone to oxidation and are cleared more slowly. 
In addition, postprandial accumulation of TAG-rich lipoproteins enhances the exchange of 
TAGs for cholesterol esters from LDL-C and HDL-C, leading to a TAG enrichment of both 
HDL-C and LDL-C, giving rise to the formation of smaller and denser HDL-C and LDL-C 
particles (see insert Figure 1.3) [36]. Recent guidelines state that increased non-fasting 
TAG concentrations are markers for CVD, but cut-off values are lacking. In addition, there 
is no consensus with respect to the optimal study design to assess postprandial lipemia. 
Dietary and lifestyle changes remain the first line of approach to reduce (non-fasting) TAG 
concentrations, but studies addressing postprandial lipid and lipoprotein responses after 
plant sterol and stanol ester intake are scarce. Since there is a need for more detailed 
knowledge regarding postprandial effects of plant sterol and stanol ester consumption on 
lipoprotein metabolism, we assessed the effects of plant sterol and stanol ester consumption 
on postprandial lipoprotein metabolism (chapter 6).  
Outline thesis
This thesis describes the results of two human intervention studies, investigating the 
effects of plant sterol and plant stanol consumption in the fasting and postprandial state 
and evaluating the effect of antioxidant supplementation on plasma plant sterol oxidation 
products. In chapter 2, an overview of the available literature is provided on the use of 
plant sterols and plant stanols in the treatment of dyslipidaemia. Chapter 3 describes the 
effects of plant sterol and plant stanol consumption on fasting plasma oxyphytosterol 
concentrations in healthy human subjects. Potential factors that might explain inter-
individual difference in plasma oxyphytosterol concentrations are investigated in chapter 
4. In the postprandial study described in chapter 5, plasma oxyphytosterol concentrations 
are evaluated after consumption of a plant sterol or stanol enriched mixed meal in healthy 
subjects. In chapter 6, the effects of plant sterol or stanol consumption on postprandial 
metabolism are evaluated. In chapter 7, the results are described of a human intervention 
study, carried out in subjects with type 2 diabetes or impaired glucose tolerance, in which 
the effects of antioxidant supplementation on plasma oxyphytosterol concentrations were 
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studied. In chapter 8, the main results and conclusion are described and discussed and 
future directions within this field are addressed. 
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Abstract 
Plant sterols and stanols are naturally occurring constituents of plants and as such normal 
components of our daily diet. The consumption of foods enriched in plant sterols and stanols 
may help to reduce low-density (LDL) cholesterol concentrations. Meta-analyses have 
shown that consuming approximately 2.5 gram plant sterols or stanols per day lowers serum 
LDL-cholesterol concentrations up to 10%, with little additional benefit achieved at higher 
intakes. However, recent studies evaluating plant stanol intakes up to 9 g/d have indicated 
that LDL-cholesterol concentrations can be reduced up to 17%, which suggests that more 
pronounced reductions can be achieved at higher intakes. Studies describing effects of high 
plant sterol intakes on serum LDL-cholesterol concentrations are not consistent. Besides 
the effects of higher than advocated intakes on serum LDL-cholesterol concentrations 
several topics will be discussed in this review. First, besides the well-characterized effect 
of plant sterols and stanols on serum LDL-cholesterol concentrations, evidence is now 
emerging of their effects on triacylglycerol metabolism, which makes them highly attractive 
for interventions in metabolic syndrome-like populations. Secondly, there is an ongoing 
debate whether increased plant sterol concentrations are associated with an increased 
cardiovascular disease risk or not. For this there are at least two possible explanations. First, 
the potential atherogenicity of increased plant sterol concentrations might be ascribed to 
the formation of plant sterol oxidation products (so-called oxyphytosterols) or secondly 
elevated serum plant sterol concentrations should only be seen as surrogate markers for 
characterizing subjects with a high intestinal cholesterol absorption. Finally, we will discuss 
recent studies, which suggest that plant sterols and stanols are able to improve endothelial 
dysfunction in subjects at risk, although evidence is limited and more research is needed.
Plant sterols and stanols 
Dyslipidaemia is a major risk factor for developing cardiovascular disease (CVD), which 
includes hypercholesterolemia as well as hypertriglyceridemia. By lowering low-density 
lipoprotein (LDL) cholesterol concentrations, CVD risk is considerably reduced. It has been 
estimated that each percentage reduction in LDL-cholesterol can reduce CVD risk by 2% 
[1]. The impact of lowering circulating LDL-cholesterol concentrations on CVD risk can also 
be deduced from genetic studies. Carriers of the PCSK9 SNP (PCSK9142x or PCSK9679x), for 
example, have lifelong on average 28% lower serum LDL-cholesterol concentrations and an 
88% lower CVD risk [2]. PCSK9 is involved in the degradation of the LDL receptor and the 
above-mentioned loss of function mutation consequently results in lower serum cholesterol 
concentrations [3]. The consumption of food products enriched with plant sterols and 
stanols may help to reduce increased LDL-cholesterol concentrations and as such the risk 
of CVD. Evidence for this LDL-cholesterol lowering effect has evolved so strongly over the 
past decade that plant sterols and stanols are now part of the NCEP guidelines, which 
encourages the daily incorporation of 2 g of plant sterols into a healthy diet low in saturated 
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fatty acids to reduce CVD risk for subjects with elevated LDL-cholesterol concentrations [4]. 
Plant sterols are naturally occurring constituents of plants and are common components 
of our daily diet. They are structurally related to cholesterol and the cellular functions of 
plant sterols in plants are analogous to those of cholesterol in animals. Both cholesterol and 
plant sterols consist of a steroid nucleus with a double bond present at C5-C6 and only the 
side-chain configuration differs. The average intake of plant sterols in Western countries is 
approximately 250 mg/day, mainly derived from vegetable oils, cereals, nuts, seeds, fruits 
and vegetables [5]. The most abundant plant sterols in the human diet are β-sitosterol, 
campesterol, and stigmasterol. Plant stanols are the saturated derivatives of plant sterols. 
The major plant stanols are sitostanol and campestanol, which are considerably less 
abundant in nature than plant sterols are [6]. Since humans are unable to synthesize plant 
sterols and stanols, their serum concentrations are the results of intestinal absorption and 
biliary secretion. In contrast to the absorption rate of cholesterol, which is around 50%, 
the absorption rate of plant sterols is much lower; i.e. about 10-15% for campesterol and 
campestanol, 4-7% for sitosterol and 1% for sitostanol [7]. Once present in the circulation, 
plant sterols and stanols are taken up by the liver and rapidly secreted into bile by hepatic 
ABCG5/G8 transporters. Although cholesterol is also secreted into bile, the rate of plant 
sterol and stanol secretion into bile is much faster [8]. Due to their low absorption and high 
biliary secretion serum concentrations of plant sterols and stanols are less than 1% of that of 
serum cholesterol [9]. On average, plasma sitosterol concentrations range from 0.12 to 0.62 
mg/dL and campesterol concentrations from 0.27 to 1.08 mg/dL [10].
While the effect of plant sterols and stanols on serum LDL-cholesterol is well characterized 
and has been reviewed extensively [6, 7, 11, 12], evidence is emerging of effects beyond 
LDL-cholesterol lowering. Plant sterols have been studied in relation to immune modulation 
[13, 14], triacylglycerol metabolism [15] and cancer prevention [16]. In this review we 
will therefore only briefly discuss the effects of plant sterols and stanols on serum LDL-
cholesterol concentrations and cholesterol metabolism. The focus will be on the effects of 
plant sterols and stanols on triacylglycerol metabolism. Furthermore, we will address recent 
studies suggesting that plant stanol esters have larger effects on serum LDL-cholesterol 
concentrations when provided in amounts higher than currently advocated. The issue of 
promoting higher daily plant sterol and / or stanol intakes is especially relevant regarding 
the ongoing debate whether elevated serum plant sterol concentrations are associated with 
cardiovascular risk or not. Two explanations for this possible relationship will be discussed. 
First, we will discuss the possible atherogenicity of plant sterols as a result from plant sterol 
oxidation, i.e. formation of the so-called oxyphytosterols. Secondly, we will consider the 
possibility that serum plant sterols should only be considered as markers for cholesterol 
absorption, which means that subjects with elevated serum plant sterol concentrations 
absorb also more (dietary) cholesterol. Finally, we will briefly discuss the evidence whether 
plant sterol and stanol consumption influences endothelial function and characteristics of 
the microcirculation.
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LDL-cholesterol lowering effect
Several meta-analyses have clearly indicated the LDL-cholesterol lowering effect of plant 
sterols and stanols. Here, we will provide a short overview of the main conclusions from 
these meta-analyses. The very first meta-analysis by Law [6], already published in 2000, 
summarized the results of 10 studies, in which plant sterols and stanols were mainly 
consumed when added to fat spreads. It was found that at doses of >2 g/d, the average 
reduction in LDL-cholesterol ranged from 0.43-0.54 mmol/L, or 9-14%. Three larger meta-
analyses have been performed thereafter, which unanimously concluded that a non-linear 
dose-response relationship existed between the intake of functional foods enriched with 
plant sterols and stanols and decreases in serum LDL-cholesterol concentrations [7, 11, 12]. 
The meta-analysis by Katan et al. [7] identified 41 trials, with mainly fat-based foods such as 
spreads, mayonnaise and salad dressings. At an intake of 2 g/d, it was estimated that serum 
LDL-cholesterol was reduced by 10%, with little additional benefit at intakes higher than 2.5 
g/d. An updated meta-analysis by Abumweis et al. [11] identified 59 studies that consisted 
of 95 relevant strata. Evidence was found for a dose-response effect with LDL-cholesterol 
reductions of respectively 0.29 mmol/L, 0.32 mmol/L and 0.42 mmol/L for plant sterol or 
stanol intakes of 1.5-2.0 g/d, 2.1-2.5 g/d and 2.5 g/d. This meta-analysis also highlighted 
the importance of the food matrix. Finally, Demonty et al. [12] aimed to quantify the dose-
response relationship between LDL-cholesterol reductions and plant sterol or stanol intake, 
and the impact of different intervention characteristics such as plant sterol type (sterol 
vs. stanol) and food format. Eighty-four eligible trials with 141 strata were identified. The 
mean plant sterol / stanol intake was 2.15 g/d (range 0.45-9.00 g/d), which was consumed 
for 21 to 182 days. In 74 strata plant sterols were used while in 53 strata the experiments 
were conducted with plant stanols. The dose-response equation predicted a serum LDL-
cholesterol lowering effect of 9% at the recommended daily intake of 2 g/d. In agreement 
with the estimation made by Katan et al. [7], the LDL-cholesterol lowering effect levelled off 
at an intake of 3 g/d and was 10.7%. Thus, also this meta-analysis indicated that intakes of 
plant sterols and stanols higher than 2.5 g/d offered little additional benefit. The results of 
these three large meta-analyses are in contrast with the outcomes of two recently published 
placebo-controlled intervention studies. Mensink et al. [17] showed a linear dose-response 
relationship between plant stanol intake and the reduction in LDL-cholesterol. Plant stanol 
intakes were 0, 3, 6 or 9 g/d and LDL-cholesterol decreased linearly up to 17.0% at the 
highest intake. This observation completely agreed with a study by Gylling et al., [18] who 
found a reduction of 17.4% after an intake of 8.8 g/d of plant stanols. Results from studies 
with high plant sterol intakes, are less consistent, Ayesh et al. [19] found an LDL-cholesterol 
reduction of 23% at an intake of 8.6 g/d of plant sterols. This effect may however been 
slightly overestimated, as the cholesterol content of the control and experiment margarines 
were not comparable. Clifton et al. [20] provided 6.6 g/d of plant sterols to 35 subjects and 
reported an LDL-cholesterol reduction of 12.4%. In contrast, Davidson et al. [21] found no 
additional effect on LDL-cholesterol when an intake of 9 g/d of plant sterols was compared 
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with that of 3 g/d. The characteristics of the described studies performed with a high dose 
plant sterol or stanol intake are given in table 2.1.
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CHAPTER 2
Up till now, 5 studies have provided far more plant sterols or stanols than currently 
advocated and it is important to monitor the effects of these high intakes on fat-soluble 
antioxidant concentrations. Several studies have found reduced concentrations of especially 
the lipophylic hydrocarbon carotenoids, like β-carotene and lycopene after plant sterol 
and stanol intake [22]. However, most high-dose studies did not show larger reduction 
in antioxidant concentrations than found at recommended intakes. Moreover, several 
parameters reflecting liver and kidney function were unchanged during the intervention 
periods. More studies for a longer duration and in other population groups are however 
warranted before advocating higher intakes than currently recommended. The high intake 
studies carried out so far should be regarded as proof-of-principle experiments, in which it is 
shown that LDL-cholesterol lowering can be extended over the currently advocated intakes, 
although evidence regarding is still contradictive.  
Plant sterols and stanols are currently incorporated into a wide variety of food products. 
There is an ongoing discussion concerning the types of food that yields the most efficient 
LDL-cholesterol reduction. Abumweis et al. reported a larger reduction in LDL-cholesterol 
when plant sterols and stanols were incorporated into food products like fat spreads, 
mayonnaise and salad dressing or milk and yoghurt as compared with food products, such 
as cereal and chocolate bars, orange juice, non-fat beverages and bread [11]. On the other 
hand, the meta-analysis by Demonty et al. indicated that the food characteristics (fat-based 
vs. non fat-based formats, dairy vs. non-dairy formats, free plant sterol/stanols vs. esterified 
forms, and plant sterols vs. stanols) did not influence its LDL-cholesterol lowering efficacy 
[12]. The frequency of intake may also be important. Plat et al. compared the effects of 
once per day compared to a 3-times/d intake of plant stanols and reported no difference in 
LDL-cholesterol lowering between the treatments [23]. Demonty et al., however, concluded 
that most evidence pointed towards a larger efficacy of plants sterols and stanols when 
consumed at multiple time points [12]. In this respect, when consumed once a day, the time 
of consumption may be essential. Abumweis et al. showed that consumption of a single 
dose of plant sterols in the morning failed to lower LDL-cholesterol concentrations [24]. It 
seems that plant sterols or stanols should be consumed during or after a meal, preferably a 
larger meal like lunch or dinner [11]. 
Effects beyond LDL-cholesterol lowering 
Besides the well-characterized LDL-cholesterol lowering effects, studies are emerging 
showing that plant sterols and stanols can also affect other lipid parameters. Until recently, 
almost all studies reported that plant sterol or stanol intake did not change serum high-
density (HDL) cholesterol or triacylglycerol (TAG) concentrations. In some studies, slight 
changes were found, but these changes were most likely due to other dietary changes 
and not to plant sterol or stanol intake per se [25]. However in a recent meta-analysis, 
Naumann and co-workers analysed data from five well-controlled intervention studies with 
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plant stanols performed at their department and reported that changes in HDL cholesterol 
depended on baseline concentrations. In subjects with low concentrations at the start of 
the study, slight increases were observed, while decreases were seen in subjects with high 
baseline concentrations. Without this differentiation, the mean change in HDL cholesterol 
in the intervention groups was zero. Results of this meta-analysis also suggested that plant 
stanols lowered fasting TAG concentrations, especially in individuals with elevated baseline 
TAG concentrations [26]. A reason why this effect was not observed in earlier studies could 
have been due to a lack of statistical power, as most participants in the trials had normal 
to low baseline TAG concentrations. Therefore, Theuwissen et al. [15] designed a study to 
specifically evaluate the effect of plant stanol supplementation on serum TAG changes in a 
population with elevated fasting serum TAG concentrations. Figure 2.1 indeed shows that 
serum TAG concentrations hardly changed in subjects with baseline TAG concentrations <2.3 
mmol/L (change of 0.09 mmol/L compared to controls), while a significant TAG reduction 
was observed in subjects with higher baseline TAG concentrations (change of -0.53 mmol/L 
compared to controls). 
-0.6 
-0.4 
-0.2 
0 
0.2 
0.4 
0.6 
Control'
Stanols'
Baseline TAG 
1.7-2.3 mmol/L 
Baseline TAG 
> 2.3 mmol/L 
Figure 2.1. Changes in TAG concentrations (mmol/L) for subjects with moderate (1.7-2.3 mmol/L) and high baseline 
(>2.3 mmol/L) concentrations.
Also in a study performed with metabolic syndrome patients, who are characterized by 
increased serum TAG concentrations, a significant reduction of 32% in fasting serum TAG 
concentrations was found after consumption for 9 weeks of 2 g/d of plant stanols provided 
via a yoghurt drink [27]. These findings show that functional foods enriched with plant 
stanols are not only useful to lower serum LDL-cholesterol concentrations, but may also 
be beneficial to lower serum TAG concentrations in specific population groups. These 
effects may not be exclusive for plant stanol esters. A daily intake of 1.6 g of plant sterols 
provided via a low-fat drinkable yoghurt reduced serum TAG concentrations with 12.9% in 
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hypercholesterolemic subjects with normal TAG concentrations [28]. In addition, Judd et al. 
showed that 3.6 g/d of plant sterols reduced not only serum LDL-cholesterol, but also serum 
TAG concentrations in healthy volunteers [29]. Thus, these two studies indicate that plant 
sterols may reduce serum TAG concentrations when provided in a low-fat format. More 
interestingly, these effects were found in populations without elevated baseline serum 
TAG concentrations, which contrasts the findings of Naumann et al., [26] suggesting that 
effects were hardly present in subjects with normal serum TAG concentrations. It should, 
however, be taken into account that at least 50 other studies with plant sterol esters in 
normotriglyceridemic subjects did not show these effects. Table 2.2 shows an overview of 
the described studies that showed an effect of plant sterol or stanol ester consumption on 
serum TAG concentrations. A meta-analysis with all published studies that measured serum 
TAG concentrations after plant sterol or stanol consumption is lacking. It would be valuable 
to carry out such a meta-analysis according to the same principles as has been used to 
examine effects on LDL-cholesterol concentrations [11], also focusing on factors like the 
food matrix and intake frequency. 
The most widely accepted mechanism via which plant sterols and stanols reduce LDL-
cholesterol is through the displacement of cholesterol from mixed micelles, since plant sterols 
and stanols are more hydrophobic than cholesterol [30]. This replacement reduces micellar 
cholesterol concentrations and consequently cholesterol absorption. It has also been shown 
in Caco-2 cells that plant stanols were able to up-regulate the expression of ABC-transporters, 
which could lead to an increased excretion of cholesterol by the enterocyte back into the 
lumen [31].  Each of these two proposed mechanisms will result in a reduced intestinal 
cholesterol absorption and thus in a reduced cholesterol flux through the chylomicrons to the 
liver. A reduced flux to the liver will lead to a compensatory increase in hepatic endogenous 
cholesterol synthesis and an up-regulated hepatic LDL receptor expression, ultimately 
resulting in reduced serum LDL-cholesterol concentrations. A possible mechanism via which 
plant sterols and stanols might lower serum TAG concentrations is by reducing hepatic 
production of large TAG-rich VLDL-1 particles. This hypothesis was evaluated by Plat et al. 
[32], who showed in two independent studies that plant stanol esters significantly lowered 
serum VLDL-1 particle concentrations. One study was carried out in normocholesterolemic 
subjects, and the other study in subjects with the metabolic syndrome subjects. Obviously, 
effects were much more pronounced in the metabolic syndrome subjects, who had higher 
circulating VLDL-1 particle concentrations [32]. Although supportive, these data do not 
prove that the postulated hypothesis that the serum TAG-lowering effect of plant stanols is 
caused by a reduction in the hepatic production of large TAG-rich VLDL-particles. It is also 
possible that serum VLDL-1 particle concentrations are reduced via an increased clearance 
rate of VLDL-1. This, however, demands further study. The mechanism by which ezetimibe, 
like plant sterols and stanols a potent intestinal cholesterol absorption inhibitor, lowers 
serum TAG concentrations in humans involves a reduced production of VLDL particles, 
thereby lowering VLDL pool size [33, 34] with a concomitant reduction in hepatic lipid 
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content [35]. Whether plant sterols and stanols also affect intra-hepatic fat accumulation 
warrants further research. 
A reduction of 32% in serum TAG concentrations, as seen in the study by Plat et al., [27] 
is in the same magnitude as described for fish oils [36, 37]. Fish oils are nowadays one 
of the very few nutritional strategies to lower serum TAG concentrations. An interesting 
question is whether effects of plant sterols and stanols on serum TAG concentrations 
are additional to the effects of fish oils. Demonty et al. performed a study in which they 
compared a diet rich in plant sterols esterified with sunflower oil, a diet rich in plant sterols 
esterified with fish-oil and a diet rich in regular fish oil supplementation. No change in TAG 
concentration was seen after the diet enriched with plant sterols esterified with sunflower 
oil, while a marked decrease was seen after the fish-oil supplementation and an even more 
pronounced decrease was seen after the diet enriched with fish-oil esters of plant sterols. 
The authors attribute this stronger TAG decrease of the combination therapy to the plant 
sterol content of the intervention. However, it is difficult to make this conclusion, as the 
design of the study does not allow making these assumptions. The composition of the fish-
oil supplementation was not the same for both interventions; the combination therapy 
contained, next to plant sterols, also a much higher content of fish oils. Therefore, it is 
not possible to determine whether the additional TAG reducing effect in the combination 
therapy stems from the additional plant sterol or higher fish oil content of the intervention. 
More studies are warranted to provide evidence that even larger effects in serum TAG 
concentrations can be achieved by combination strategies and to help find mechanistic 
explanations underlying the observed effects. Finally, Ford et al. [38] estimated that about 
one-third of the population is characterized by elevated fasting serum TAG concentrations. 
Moreover, Sarwar et al. [39] identified in 29 prospective studies that elevated fasting TAG 
concentrations are an independent risk factor for CVD. The high prevalence and increased 
risk of elevated TAG concentrations indicates the need and potential clinical benefit for TAG 
lowering interventions. 
Potential atherogenicity
Among others, Naumann et al. have shown that the increase in serum plant sterol 
concentrations is positively related to plant sterol intake, while plant stanol ester 
consumption lowers serum plant sterol concentrations [40]. The implication of increased 
serum plant sterol concentrations is not clear, but speculations about a potential undesirable 
effect were first brought up after the identification of the disease phytosterolemia. 
Phytosterolemia is a rare autosomal-recessively inheritable sterol storage disease that has 
only been identified in ± 200 patients worldwide (personal communication D. Lütjohann). 
The disease is characterized by very high plant sterol concentrations ranging from 10-65 mg/
dL while the reference range in non-affected subjects is below 1 mg/dL. Despite high serum 
plant sterol concentrations, serum cholesterol concentrations are normal or only slightly 
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increased. Patients with this disease exhibit tendon and tuberous xanthomas and have a 
strong predisposition to develop premature coronary atherosclerosis [41]. The cause of this 
disease is a mutation in the ABCG5/8 half transporters, which results in a decreased secretion 
of absorbed sterols from the enterocytes back into the lumen, as well as a reduced plant 
sterol excretion from the liver into bile [42]. The fact that these patients are confronted with 
severe vascular diseases at a relatively young age, despite normal cholesterol concentrations, 
raised the issue about the atherogenicity of increased plant sterol concentrations. Although 
many clinical trials have unequivocally shown that plant sterols and stanols lower serum 
LDL-cholesterol concentrations, effects on clinical endpoints related to CVD are not clear. Of 
course, the reduction in LDL-cholesterol is a strong indication that CVD risk will be lowered. 
However, the potential association between elevated plant sterol concentrations and CVD 
risk might influence the outcome. 
The potential association between circulating plant sterol concentrations and CVD risk has 
been investigated in several prospective and cross-sectional epidemiological studies with 
contradictive results. Some large prospective cohort studies have shown that elevated 
concentrations of plant sterols are associated with an increased risk of CVD [43, 44]. 
Elevated plant sterol concentrations have also been associated with a family history of 
premature CVD in hypercholesterolemic subjects [45, 46]. More recent studies have also 
related increased serum plant sterol concentrations with an increased mortality risk. For 
example, Silbernagel et al. [47] have shown that serum campesterol concentrations were 
associated with increased all cause and cardiovascular mortality in a large cohort of subjects 
who were referred to the hospital for an angiogram. In addition, Teupser et al. [48] have 
observed that single nucleotide polymorphisms (SNPs) in the gene encoding for ABCG8 
were not only associated with increased serum campesterol concentrations, but also with 
a risk for coronary artery disease. This indicates that genetic variants affecting plant sterol 
metabolism may also be related to the susceptibility to develop coronary artery disease. 
However, despite this list of studies suggesting possible atherogenic effects of plant sterols, 
a number of other prospective studies did not find an association between serum plant 
sterol concentrations and CVD risk [49, 50], while two studies even indicated that elevated 
plant sterol concentrations were associated with a decreased CVD risk [51, 52]. In Table 2.3 
and 2.4, an overview is provided in which characteristics are given of the studies that have 
examined the potential association between increased plant sterol concentrations and CVD 
risk.
It has been postulated that the ongoing controversy about the potential atherogenicity of 
plant sterols may be due to the formation of oxyphytosterols, the oxidized forms of plant 
sterols. Oxyphytosterols can be formed during physical processes, such as heating and 
radiation, by non-enzymatic processes, such as reactions with reactive oxygen species 
(ROS) or enzymatically by specific cytochrome P450 mono-oxygenases. The side-chain of 
cholesterol can be oxidized enzymatically and the nucleus non-enzymatically, the latter 
probably being a radical driven process. For plant sterols, only the nucleus can be oxidized 
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CHAPTER 2
at the double bond at the C5-C6 position [53]. Due to sterical hindrance because of different 
structures, the side-chains of plant sterols is - unlike the side chain of cholesterol - not 
accessible for oxidizing enzymes and can, as far as known yet, not be oxidized [54]. The 
ring-oxidation products of cholesterol are potentially atherogenic, as indicated by animal 
studies [55]. Plant stanols do not have a double bond in the steroid nucleus and can 
therefore not be oxidized [53]. Interest in oxyphytosterol concentrations as mediators of 
CVD risk originates from the presence of elevated oxyphytosterol concentrations in serum 
of phytosterolemic patients [56]. In this study, it was shown that about 1.4% of sitosterol 
was present in its oxidized form. No oxyphytosterols could be identified in serum of healthy 
volunteers, which was probably due to a lack of sensitivity of the method. In a later study, 
Grandgirard et al. used a quantification method with a lower detection limit and was able to 
identify oxyphytosterols in plasma from healthy volunteers as well [57]. The question now 
is whether oxyphytosterols are atherogenic as has been suggested for oxysterols, or not. In 
vitro experiments from our group using human coronary arterial endothelial cells (HCAECs) 
have indicated that especially oxyphytosterols increased MCP-1 expression (unpublished 
results). Therefore the question whether the existing discrepancy in associations between 
elevated plant sterol concentrations and CVD risk is related to differences in oxyphytosterol 
concentrations, certainly deserves attention.
A second possible explanation for the association between elevated serum plant sterol 
concentrations and CVD risk relates to the finding that increased serum plant sterol 
concentrations are a marker for increased intestinal cholesterol absorption. Recently, 
Silbernagel et al. have determined concentrations of cholesterol absorption and synthesis 
markers in a large cohort of subjects undergoing angiography [58]. In this cohort, increased 
concentrations of both campesterol and cholestanol (markers of fractional cholesterol 
absorption) were associated with an increased severity of coronary artery disease (CAD), 
while a negative association was found for the cholesterol synthesis marker lathosterol. As 
this association was also evident for cholestanol, also a marker for fractional cholesterol 
absorption, a specific atherogenic role of (oxidized) plant sterols may be not likely, whereas it is 
more likely that the higher fractional intestinal cholesterol absorption may be the underlying 
reason for this association. This study also identified a positive association between an 
increased campesterol-to-lathosterol ratio and the severity of CAD. Since the campesterol-
lathosterol ratio combines cholesterol absorption and synthesis, the question remains 
what the merit is of this ratio? Weingärtner et al. [59] found that the ratio campesterol-to-
lathosterol was associated with CAD severity in patients with severe aortic valve stenosis. 
However, in this particular study the increase in the ratio was driven by a continuous lower 
lathosterol concentration, instead of higher cholesterol absorption markers, for which no 
differences were found. This means that a one-directional change of this ratio can thus 
result from two different processes. Since these two studies indicated a positive association 
between this ratio and CAD severity, by means of two different underlying and causative 
metabolic changes, no real value can be ascribed to this ratio. To our opinion, changes in 
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the absolute markers are favourable over using the described ratio. This implies that the 
finding by Silbernagel et al., [58] in which the so-called ‘absorbers’ display an increased 
severity of CAD, still holds true. Weingärtner and co-workers also isolated aortic valve cusps 
via elective aortic valve replacement and found a positive correlation between plant sterol 
concentrations in aortic valve cusps and the degree of aortic valve stenosis [59]. In an earlier 
study, this group also observed a positive association between the intake of plant sterols 
with sitosterol and campesterol concentrations in both serum and in aortic valve cusps 
[60]. Although these associations do not prove causality, they may suggest some role or 
another for plant sterols in the pathogenesis of aortic valve disease. However, in another 
study Weingärtner et al. [61] found no correlation between cholesterol absorption markers 
and carotid intima-media thickness (cIMT), while they did find a significant correlation 
between cholesterol synthesis markers and cIMT. This contrasts the suggestion that (sterol) 
absorbers as identified by elevated plant sterol concentrations are at risk. Thus, the question 
remains what causes the apparent inconsistency between studies examining the association 
between serum plant sterols and CVD risk. It has been suggested that age could play a role. 
Strandberg et al. have suggested that higher plant sterol concentrations may increase CVD 
risk at a younger age, but could be protective in older subjects [52]. In that prospective 
study in middle-aged men with an average of 61 years, higher plant sterol concentrations 
at baseline were associated with a decreased CVD risk 22 years later. Also the LASA study 
showed a reduced CVD risk associated with increased plant sterol concentrations at an older 
age [51]. In LASA, the average age of the subjects was 75 years, which is higher than in most 
other studies. The suggestion that increased plant sterol concentrations may protect at an 
older age should however be considered carefully, since it can also be argued that subjects 
with a low cholesterol absorption (low plant sterol concentrations) and a high cholesterol 
synthesis may have died before inclusion in these studies. Therefore, Strandberg et al. [52] 
concluded that the relationship between non-cholesterol sterols and CVD risk might be 
an example of  ‘reverse epidemiology’. This paradox states that factors which are harmful 
at younger age, such as overweight and high LDL-cholesterol concentrations, might look 
beneficial at older age [62]. Although other studies in which a negative association between 
serum plant sterols with CVD risk was observed were performed in younger populations 
[61], this concept is still very interesting to explore into more detail. 
Endothelial function
Recent evidence suggests that consumption of plant sterols or stanols might affect endothelial 
function. This effects might either be caused by the plant sterols directly or indirectly as 
a consequence of the reduced serum LDL-cholesterol concentrations. Unfortunately, the 
number of studies that have investigated these effects is limited. Endothelial dysfunction is 
a reflection of an early, but still reversible phase in the development of atherosclerosis and 
studies have indicated that the presence of endothelial dysfunction is predictive for future 
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cardiovascular events. In other words, preservation or improvement of endothelial function 
in response to treatment may decrease the risk for future cardiovascular events. Endothelial 
function can be determined via a wide variety of available techniques and flow-mediated 
dilatation (FMD) is probably the most commonly used and validated technique to measure 
endothelial function [63].  It is well known that statin therapy reduces LDL-cholesterol, which 
is associated with normalization of endothelial function [64]. It is however also possible, 
that effects are due to the pleiotropic effects of statins [65]. Effects of plant sterols and 
stanols on endothelial function have been examined in several studies. Results, however, 
are not conclusive. De Jongh et al. [66] performed a study in 41 children (5-12 years old), 
which were diagnosed with heterozygous familial hypercholesterolemia and had already 
impaired endothelial function. Although the consumption of 2.3 g/d of plant sterols for 
4 weeks decreased serum LDL-cholesterol concentrations by 14%, this decrease was not 
associated with an improvement in endothelial function. Jakulj et al. [67] evaluated the 
effect of plant stanol supplementation on endothelial function in 42 children (7-12 years old) 
with heterozygous familial hypercholesterolemia. Serum LDL-cholesterol concentrations 
decreased with 9.2% after a 4 week intervention in which the children consumed 2.0 g/d 
of plant stanols. Again, despite a significant reduction in serum LDL-cholesterol, endothelial 
function did not improve. Although these two studies do suggest that plant sterol and stanol 
consumption is an effective strategy to lower serum LDL-cholesterol in children with familial 
hypercholesterolemia, both studies did not provide any evidence for an effect on endothelial 
function. In line with these two studies in children, Hallikainen et al. [68] investigated the 
effects of consuming 2.0 g/d of plant stanol and sterol esters for 10 weeks on endothelial 
function in hypercholesterolemic adult subjects. The intervention reduced LDL-cholesterol 
by 9-12% as compared to controls, but there was no change in endothelial function as 
measured by FMD. Brachial artery diameter was also determined, which did not change 
after the control treatment or the plant stanol treatment. The brachial artery diameter 
was however diminished after the plant sterol treatment, but the clinical relevance of such 
a reduction remains unclear. Also Raitakari et al. [69] assessed in hypercholesterolemic 
subjects FMD and carotid arterial compliance to determine the effect of consuming 2 g/d 
of plant stanols for a period of 12 weeks on endothelial function and arterial elasticity. The 
intervention reduced the serum LDL-cholesterol by 9%, but FMD and arterial elasticity did 
not change. However, subgroup analyses showed that endothelial function and arterial 
elasticity were improved in subjects who were characterized with below average values for 
these parameters at the start of the study. Similar results were found by De Jong et al., 
[70] who investigated long-term (85 weeks) plant sterol or stanol ester consumption on 
endothelial function and arterial stiffness in patients on statin treatment. They did not find an 
effect on vascular function in the whole study population, but in a subgroup of patients with 
more pronounced CVD, as indicated by high baseline levels of matrix metalloproteinase-9, 
an improvement in endothelial function and arterial stiffness was observed. These results 
seem promising for a possible role of plant sterols and stanols in improving vascular 
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function for subjects with suboptimal vascular function. The possible effects of plant sterols 
and stanols on endothelial function are only minor in comparison to the effects of statins, 
which have a strong ability of improving endothelial function. Plausible explanations for 
this discrepancy in improving endothelial function between statins and plant sterols and 
stanols could be ascribed to the more potent LDL-cholesterol lowering effects of statins as 
compared to those of plant sterols and stanols [66]. Another possibility is that statins exert 
pleiotropic effects on the vasculature [71]. Since these pleiotropic effects have not been 
found for plant sterols and stanols, this latter option could be a likely explanation for the 
difference in potency between statins and plant sterols and stanols regarding their ability to 
improve endothelial function. 
Besides effects on the larger vessels as measured via techniques like FMD, plant sterol and 
stanol consumption might change the microcirculation. Cardiovascular disease is known 
to be a disease of the large vessels, but evidence is accumulating that disturbances in 
the microcirculation also predict future CVD risk [72]. Studies have shown that a larger 
retinal venular diameter is associated with several established atherosclerotic risk factors 
[73]. Until now, only one study has investigated the long-term effects of plant sterol and 
stanol consumption on the retinal vasculature. Kelly et al. [74] performed a study in which 
subjects were asked to consume 2.5 g/d of plant sterols or plant stanols for a period of 85 
weeks. They identified a non-significant increase in venular diameter after consumption of 
plant sterols, when compared to the changes in the plant stanol and control group. Linear 
regression analysis however showed a significant positive association between increases 
in cholesterol-standardized serum campesterol concentrations and increases in venular 
diameter. The functional consequences of the findings in terms of CVD risk are however 
unknown. Kelly et al. observed an increase in venular diameter of 2.3 µm in the sterol 
group when compared to the change in both the stanol and control group. Kawasaki et 
al. [75] showed that subjects suffering from the metabolic syndrome had on average an 
increase of 4.69 µm in their venular diameter, when compared to healthy subjects. Ikram 
et al. estimated that an increase in venular diameter of 0.4 µm was associated with a one 
point increase in carotid plaque-score and that current smokers had on average a 10 µm 
larger venular diameter than non-smokers [73]. Therefore, these findings warrant further 
investigation in terms of the functional consequences of diet-induced changes in venular 
diameter.
To summarize, the role of plant sterols and stanols as cholesterol lowering agents is well 
characterized. Several meta-analyses have shown that consumption of 2.5 g/d of plant 
sterols and stanols can lower serum LDL-cholesterol concentrations up to ~10%, while 
recent studies have shown that additional benefit can be achieved at higher intakes. Besides 
their cholesterol lowering effect, evidence is now emerging that plant sterols and stanols 
are also able to exert beneficial effects on triacylglycerol metabolism, which makes them 
more attractive for metabolic syndrome-like populations. On the other hand, there is an 
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ongoing debate whether increased serum plant sterol concentrations are associated with 
an increased CVD risk. Finally. Some studies suggested that plant sterols and stanols might 
improve endothelial dysfunction in those at risk, although evidence is still limited and more 
research is needed. 
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Abstract
Consumption of plant sterols and plant stanols reduces low-density lipoprotein cholesterol 
(LDL-C) concentrations. At the same time, plasma plant sterol concentrations will increase 
after plant sterol consumption, but decrease after plant stanol consumption. In contrast 
to plant stanols, plant sterols can undergo oxidation and form oxyphytosterols. Findings 
from in vitro and animal studies suggest that oxyphytosterols might be atherogenic. The 
objective was to examine whether plant sterol and stanol consumption changes fasting 
plasma oxyphytosterol concentrations. A randomised, double blind, cross-over study 
was performed in which 43 healthy subjects (18-70 years) consumed for 4 weeks a plant 
sterol enriched (3.0 g/d of plant sterols), a plant stanol enriched (3.0 g/d of plant stanols), 
and a control margarine separated by wash-out periods of 4 weeks. Oxyphytosterol 
concentrations were determined in BHT-enriched plasma via GC-MS. Compared to control, 
serum LDL-C concentrations were reduced after plant sterol (-8.1%; p<0.001) and plant 
stanol consumption (-7.8%; p<0.001). Plant sterol consumption did not change plasma 
oxyphytosterol concentrations. On the other hand, intake of the plant stanol margarine 
reduced 7β-OH-campesterol by 0.07 ng/mL (~14%; p<0.01) and by 0.07 ng/mL (~15%; 
p<0.01) compared with the control and sterol margarines, respectively. When standardized 
for serum cholesterol, effects on these oxyphytosterols were comparable. In addition, plant 
stanol intake reduced cholesterol-standardized 7-keto-campesterol levels compared with 
plant sterol intake (p<0.05). Daily consumption of a plant sterol enriched margarine does 
not increase oxyphytosterol concentrations, while plant stanol consumption may reduce 
the concentrations of the oxidative plant sterol metabolites 7β-OH-campesterol and 7-keto-
campesterol. This trial is registered at clinicaltrials.gov as NCT01559428.
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Introduction
Plant sterols are structurally related to cholesterol and only the side-chain configuration at 
the C24 position differs. Thus, both components consist of a steroid nucleus with a double 
bond present at C5-C6. This double bond is missing in plant stanols, the hydrogenated 
form of plant sterols. Humans are unable to synthesize plant sterols and stanols, which 
mean that serum plant sterols are by definition diet-derived. On average, serum sitosterol 
concentrations range from 0.12 to 0.62 mg/dL and campesterol concentrations from 0.27 to 
1.08 mg/dL [1]. Serum plant stanol concentrations are approximately 100 times lower and 
vary between 2 and 10 µg/dL in the normal population [2]. 
Although plant sterol and plant stanol ester enriched products lower serum (low-density 
lipoprotein cholesterol (LDL-C) concentrations to the same extent at the recommended 
intake of approximately 2.5 g/day, they have a different effect on serum plant sterol 
concentrations; i.e. increased plant sterol consumption will elevate serum plant sterol 
concentrations, while an increased plant stanol consumption will lower serum plant 
sterol concentrations [3]. The relevance of increased serum plant sterol concentrations 
relates in great detail to the ongoing debate whether plant sterol concentrations are 
positively associated with cardiovascular disease (CVD) risk or not. The atherogenicity of 
increased plant sterol concentrations was first suggested after the identification of the rare 
autosomal-recessively inheritable sterol storage disease phytosterolemia. These patients 
are characterized by extremely high plant sterol concentrations ranging from 10-65 mg/dL 
and a strong predisposition for premature coronary atherosclerosis [4, 5]. Moreover, some 
epidemiological studies have suggested that also in the general population plasma plant sterol 
concentrations are positively associated with an increased risk to develop CVD [6-8]. Results 
are however far from conclusive, since there are also numerous studies that did not show 
this association [9]. How these inconsistencies between study outcomes can be explained is 
not known. One possibility is that the potential association between circulating plant sterols 
and CVD risk may not relate to plant sterols per se, but to the fact that serum plant sterols 
are a marker for intestinal cholesterol absorption [10]. In other words, it is possible that an 
increased absorption of cholesterol associates with CVD risk [11]. Alternatively, it is possible 
that oxidation of plant sterols - i.e. the formation of oxyphytosterols - is important to explain 
the potential association between plant sterol concentrations and CVD risk. Like cholesterol, 
plant sterols can undergo oxidation, as they possess a double bond between C5-C6 in the 
steroid nucleus (Figure 3.1). 
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Figure 3.1. Non-enzymatically formed oxysitosterol structures. Similar structures are also formed for campesterol 
and other plant sterols.
Ring-oxidation products of cholesterol may be atherogenic [12-14], while not much is 
known about the biological effects of ring-oxyphytosterols. Oxyphytosterols first received 
attention as potential mediators of CVD risk after it was shown that about 1.4% of circulating 
sitosterol in serum of phytosterolemic patients was present in its oxidized form [15]. Plant 
stanols do not have a double bond in the steroid nucleus and can therefore not oxidize [16]. 
In light of the widespread use of plant sterol enriched products, it is important to identify 
whether an increased intake of plant sterols will result in increased plasma oxyphytosterol 
concentrations. Another interesting question is whether an increased plant stanol intake 
will not only decrease serum plant sterol concentrations, but will also change those of 
the oxyphytosterols. Therefore, the objective of this study was to examine the effects of 
consuming plant sterol or stanol ester enriched margarines on fasting serum oxyphytosterol 
concentrations in healthy volunteers.
Subjects and Methods
Subjects
Subjects were recruited through announcements in local newspapers and university buildings 
in Maastricht, the Netherlands, between February and April 2010. They were invited for 
two screening visits if they met the following criteria: aged between 18 and 70 years, BMI 
between 20 and 30 kg/m2, no active cardiovascular disease or severe medical condition that 
might interfere with the study, no use of lipid-lowering medication or a medically prescribed 
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diet, stable body weight during the last three months, and no consumption of plant sterol- 
or plant stanol enriched products in the previous month. During the screening visits, weight 
and height were measured and two fasting blood samples were drawn to determine plasma 
glucose and serum lipid and lipoprotein concentrations. Forty-seven subjects (18 male and 
29 female) were enrolled in the study. Two subjects did not complete the study due to time 
constraints and difficulties performing the venipuncture. In addition, two subjects were 
excluded before the analyses of the results: one male subject was not fasted during one 
blood sampling day and one female subject did not comply with margarine consumption. 
Baseline characteristics are shown in Table 3.1. All participants gave written informed 
consent before entering the study. The protocol was approved by the medical ethical 
committee of the Maastricht University Medical Centre+ (MUMC+). This trial is registered at 
clinicaltrials.gov as NCT01559428.
Table 3.1. Baseline characteristics of the subjects (n=43)
Age (years) 41 ± 18
Male / Female (n) 17 / 26
BMI (kg/m2) 24.8 ± 2.8
Weight (kg) 73.2 ± 11.0
Height (m) 1.72 ± 0.1
Glucose (mmol/L) 5.25 ± 0.54
Total cholesterol (mmol/L) 5.72 ± 1.12
LDL cholesterol (mmol/L) 3.53 ± 1.06
HDL cholesterol (mmol/L) 1.69 ± 0.37
Triacylglycerol (mmol/L) 1.14 ± 0.46
Values are means ± SD
Diet and design
Subjects participated in a randomised placebo-controlled crossover trial, which consisted 
of three intervention periods of 4 weeks, separated by washout periods of 4 weeks. They 
were allocated to the intervention periods in a randomised order, based upon a computer-
generated table with random numbers. During each period, subjects were asked to replace 
their own spread with the test margarine (70% fat) of which 20 gram had to be consumed 
on a daily basis. The daily intake of 20 gram of margarine provided no, or 3.0 g of plant 
48
CHAPTER 3
sterols or stanols per day, referred to as the control, sterol or stanol period. The margarines 
were packed in tubs of 140 grams each, providing margarine for 7 days. The margarines 
were similar in colour and taste and the tubs were colour coded to blind both subjects 
and investigators. All volunteers received instructions to consume the margarines divided 
over two meals, i.e. at lunch and diner. The margarines were all rapeseed oil based with 
(saturated) soy sterols as source of the plant sterols / stanols. Plant sterols and stanols were 
provided as fatty acid esters by transesterification of free plant sterols and stanols with 
rapeseed oil fatty acids. The plant sterol ester mixtures contained mainly sitosterol ester 
(43%), campesterol ester (25%) and stigmasterol ester (20%). Plant stanol mixtures were 
obtained by saturation of these sterols, resulting in sitostanol ester (76%) and campestanol 
ester (22%) (Raisio group, Raisio, Finland). Plant sterol, plant stanol and oxyphytosterol 
content of the margarines are shown in Table 3.2.
Table 3.2. Plant sterol, plant stanol and oxyphytosterol content of the margarines1 
Control margarine Plant sterol margarine Plant stanol margarine
Sitosterol 0 64.8 1.4
Campesterol 0 38.1 2.4
Stigmasterol 0 29.6 0
Sitostanol 0 3.8 114.3
Campestanol 0 1.7 33.0
7α-OH-sitosterol 0.35 6.15 0.19
7α-OH-campesterol 0.09 2.48 0.08
7β-OH-sitosterol 0.80 11.39 0.51
7β-OH-campesterol 0.30 2.77 0.09
7-keto-sitosterol 1.67 5.41 2.31
7-keto-campesterol 1.67 5.54 2.23
1Plant sterol and stanol content in μg/mg and oxyphytosterol content in ng/mg
Subjects visited the university at the start of each period, and after 3 and 4 weeks of 
intervention. They received 4 tubs of margarine at the start of each period, the amount 
needed for 4 weeks. At the end of each week, the used margarine tubs had to be set aside and 
returned to the department to be weighed to determine compliance. Subjects completed 
a validated food frequency questionnaire (FFQ) at the end of all three intervention periods 
[17], and a dietician checked these questionnaires to calculate energy and nutrient intakes 
using the Dutch food composition table. Subjects were asked not to change their habitual 
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diet, level of physical exercise or use of alcohol throughout the three intervention periods 
in the study. 
Blood sampling 
Blood was sampled after an overnight fast. The same person performed all venipuncture 
at approximately the same time of the day. Blood was sampled at the start of each period 
and after 3 and 4 weeks of intervention. A clotting tube (Becton, Dickinson and Company, 
Franklin Lakes, NY, USA) was sampled at each occasion and serum was obtained by low-
speed centrifugation at 1300x g for 15 min at room temperature, at least half an hour after 
venipuncture. Serum was stored at −80 °C and used for analysis of lipid and (apo)lipoprotein 
concentrations, and for plant sterol and plant stanol concentrations. An EDTA tube (Becton, 
Dickinson and Company, Franklin Lakes, NY, USA) was sampled at the start of each period and 
after 4 weeks and plasma was obtained by low-speed centrifugation at 1300x g for 15 min 
at 4 ºC, and then stored at −80 °C. To avoid auto-oxidation, oxyphytosterol concentrations 
were determined in butylated hydroxytoluene (BHT)-enriched plasma; for this 10 µl BHT 
(25 mg/mL ethanol) was added per 1 mL of EDTA plasma, immediately after centrifugation. 
Analyses
Total cholesterol (CHOD-PAP method; Roche Diagnostics, Mannheim, Germany), high-
density lipoprotein cholesterol (HDL-C) (CHOD-PAP method; Roche Diagnostics, Mannheim, 
Germany) after precipitation of apoB-containing lipoproteins with phosphotungstic acid 
and magnesium ions, and triacylglycerol (TAG) concentrations, with correction for free 
glycerol, were analysed in serum enzymatically (GPO-Trinder; Sigma-Aldrich Corp., St. 
Louis, MO, USA). All samples from one subject were analysed within one run at the end 
of the study. LDL-C concentrations were calculated according to the Friedewald equation 
[18]. Apolipoprotein concentrations (apoA-1 and apoB100) were analysed using highly 
sensitive immunoturbidimetric assays (Horiba ABX, Montpellier, France). Lipid and (apo)
lipoprotein concentrations from weeks 3 and 4 were averaged for data analysis. Plant sterol 
(sitosterol, campesterol), plant stanol (sitostanol, campestanol), cholesterol precursor 
(lathosterol), cholestanol and oxyphytosterol concentrations from week 4 were analysed 
by gas-liquid chromatography-mass spectroscopy (GC-MS) as described previously [19, 
20]. Plant sterol, plant stanol and lathosterol concentrations were expressed as 102x µmol/
mmol total cholesterol. The measured oxyphytosterols were 7α-hydroxy(OH)-sitosterol, 
7α-OH-campesterol, 7β-OH-sitosterol, 7β-OH-campesterol, 7-keto-sitosterol, and 7-keto-
campesterol according the procedure as described by Husche et al. (20) and expressed as 
ng/mL. Oxyphytosterol concentrations were standardized for cholesterol concentrations 
and expressed as nmol/mmol cholesterol. 
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Statistics
To detect a change of 17 ng/mL in plasma oxyphytosterol concentrations with a power 
of 80% and a known within-subject variation on the response of 34 ng/mL (20), a sample 
size of 47 subjects was necessary, given an anticipated dropout rate of 10%. All data are 
presented as means ± standard deviations (SD). Effects of the experimental products were 
evaluated by a univariate analysis of variance (ANOVA) followed by Bonferroni’s correction 
for multiple comparisons. Results were considered to be statistically significant if p < 0.05. 
Results were analysed to assess whether gender effects or carryover effects existed, and 
both effects were not present in the data. All statistical analyses were performed using SPSS 
18.0 for Mac Os X (SPSS Inc., Chicago, IL, USA). 
Results 
Dietary intakes
As shown in Table 3.3, the average daily intakes of total energy (MJ/day), protein (energy%), 
carbohydrates (CHO, energy%), total fat (energy%), fatty acids (saturated fatty acids (SAFA), 
monounsaturated fatty acids (MUFA), and polyunsaturated fatty acids (PUFA), energy%), 
fibre (g/day), cholesterol (mg/day) and vitamin E (mg/day) did not differ between the three 
intervention periods.  
Serum lipids and lipoproteins
Serum lipid and lipoprotein concentrations are shown in Table 3.4.  Compared with the 
control period, serum total cholesterol concentrations decreased by 0.30 ± 0.51 mmol/L 
(-5.3%; p<0.001) in the sterol period and by 0.29 ± 0.42 mmol/L (-5.3%; p<0.001) in the 
stanol period. These reductions could almost completely be ascribed to decreases in serum 
LDL-C concentrations. In the sterol period, serum LDL-C concentrations decreased by 0.29 
± 0.43 mmol/L (-8.1%) and in the stanol period by 0.26 ± 0.41 mmol/L (-7.8%; p<0.001 for 
both periods). Serum HDL-C concentrations were not different between the three periods. 
This shift towards a more beneficial partitioning of cholesterol was also reflected in the total 
cholesterol/HDL cholesterol ratio, which decreased in the sterol period by 0.14 ± 0.36 (-3.1%; 
p<0.05) and in the stanol period by 0.18 ± 0.35 (-4.9%; p<0.01). Serum apolipoprotein B100 
concentrations were reduced in the sterol period by 0.05 ± 0.09 g/L (-4.4%) and in the stanol 
period by 0.05 ± 0.08 g/L (-5.1%; p<0.01 for both periods). No differences were found in 
serum TAG and apolipoprotein A1 concentrations between the three periods. 
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Table 3.3. Daily dietary intake during the study 
Control period Plant sterol period Plant stanol period
Energy (MJ) 10.6 ± 3.4 10.6 ± 3.2 10.5 ± 3.2
Fat (energy%)
  SAFA1
  MUFA
  PUFA
37.5 ± 7.2
12.1 ± 3.1
14.4 ± 3.2
7.9 ± 2.4
37.4 ± 6.5
12.2 ± 3.0
14.6 ± 2.7
8.2 ± 2.0
37.4 ± 6.6
11.9 ± 3.0
14.6 ± 3.0
8.0 ± 1.8
Protein (energy%) 15.5 ± 3.6 15.4 ± 3.4 15.4 ± 3.2
CHO (energy%) 45.3 ± 9.5 44.4 ± 7.5 44.6 ± 8.1
Alcohol (energy%) 2.9 ± 2.9 2.6 ± 2.6 2.8 ± 3.2
Fibre (g/day) 23.5 ± 7.8 24.0 ± 7.5 23.3 ± 7.6
Cholesterol (mg/day) 221 ± 111 209 ± 92 205 ± 77
Vitamin E (mg/day) 13.1 ± 5.3 13.6 ± 5.8 13.3 ± 5.7
Values are means ± SD. All subjects (n=43) received the three dietary periods in random order.
1SAFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, CHO: 
carbohydrates
Serum plant sterols, plant stanols, lathosterol and cholestanol
Cholesterol-standardized serum plant sterol, plant stanol, lathosterol and cholestanol levels 
are shown in Table 3.4. Sitosterol levels increased in the sterol period by 86.6 ± 199 102x µmol/
mmol cholesterol (49%; p<0.01) compared with the control period and by 138 ± 248 102x 
µmol/mmol cholesterol (167%; p<0.001) compared with the stanol period. For campesterol, 
these values were 132 ± 137 102x µmol/mmol cholesterol (66%; p<0.001) and 214 ± 138 
102x µmol/mmol cholesterol (179%; p<0.001). In addition, campesterol levels decreased in 
the stanol period by 82.3 ± 53.3 102x µmol/mmol cholesterol (37.3%) compared with the 
control period (p<0.001). 
Sitostanol levels increased in the stanol period by 182 ± 114 102x µmol/mmol cholesterol 
(511%; p<0.001) compared with the control period and by 170 ± 117 102x µmol/mmol 
cholesterol (404%; p<0.001) compared with the sterol period. For campestanol, these 
values were 103 ± 70 102x µmol/mmol cholesterol (398%; p<0.001) and 96 ± 66 102x µmol/
mmol cholesterol (295%; p<0.001). Lathosterol levels, a marker for cholesterol synthesis, 
increased in the sterol period by 189 ± 454 102x µmol/mmol cholesterol (24.1%; p<0.01) and 
in the stanol period by 147 ± 322 102x µmol/mmol cholesterol (17.5%; p<0.05) compared 
with the control period. Cholestanol levels, a marker for cholesterol absorption, decreased 
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in the sterol period by 112 ± 292 102x µmol/mmol cholesterol (5.2%; p<0.05) and in the 
stanol period by 96 ± 205 102x µmol/mmol cholesterol (4.9%; p<0.05) compared with the 
control period.
Plasma oxyphytosterols 
Absolute oxyphytosterol concentrations (ng/mL) in BHT-enriched EDTA plasma are shown 
in Table 3.5. 7β-OH-campesterol concentrations were decreased in the stanol period by 
0.07 ± 0.17 ng/mL (13.6%) compared with the control period (p<0.01) and by 0.07 ± 0.14 
Table 3.4. Effect of consumption of plant sterol and plant stanol enriched margarines on 
serum lipid and lipoprotein concentrations, and on serum plant sterol, plant stanol and 
lathosterol levels
Control period Plant sterol period Plant stanol period
Total cholesterol (mmol/L) 5.56 ± 1.07 5.26 ± 1.081 5.27 ± 1.111
LDL cholesterol (mmol/L) 3.36 ± 1.06 3.08 ± 1.001 3.10 ± 1.051
HDL cholesterol (mmol/L) 1.69 ± 0.39 1.65 ± 0.39 1.68 ± 0.39
Total cholesterol/HDL 3.46 ± 1.00 3.32 ± 0.932 3.28 ± 0.963
Triacylglycerol (mmol/L) 1.14 ± 0.40 1.18 ± 0.44 1.08 ± 0.41
ApoB100 (g/L) 0.97 ± 0.25 0.93 ± 0.243 0.92 ± 0.263
ApoA1 (g/L) 1.57 ± 0.31 1.55 ± 0.31 1.55 ± 0.27
Sitosterol* 140 ± 69 226 ± 2553 88 ± 354
Campesterol 214 ± 83 346 ± 1721 131 ± 591,4
Sitostanol 4.3 ± 3.3 5.5 ± 5.7 22.4 ± 11.71,4
Campestanol 2.8 ± 1.6 3.5 ± 2.0 13.1 ± 7.71,4
Lathosterol 115 ± 57 134 ± 563 130 ± 552
Cholestanol 165 ± 0.33 153 ± 322 155 ± 322
Values are means ± SD and *sterols are expressed as 102x µmol/mmol cholesterol. All subjects (n=43) received 
the three dietary periods in random order.
Significantly different compared with control period:  1(p<0.001), 2(p<0.05), 3(p<0.01)
Significantly different compared with sterol period  4(p<0.001)
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ng/mL (15.0%) compared with the sterol period (p<0.01). Concentrations of the other 
oxyphytosterol were comparable between the three periods.
Cholesterol-standardized oxyphytosterol levels (nmol/mmol cholesterol) showed 
comparable results, i.e. a decreased 7β-OH-campesterol level in the stanol period compared 
with the control and sterol period (p<0.01 and p<0.05, respectively). In addition, 7-keto-
campesterol levels were reduced in the stanol period compared with the sterol period 
(p<0.05). 
Table 3.5. Effect of consumption of plant sterol and plant stanol enriched margarines on 
plasma oxyphytosterol concentrations
A Control period Plant sterol period Plant stanol period
7α-OH-sitosterol 0.21 ± 0.09 0.22 ± 0.11 0.26 ± 0.35
7α-OH-campesterol 0.09 ± 0.05 0.09 ± 0.06 0.08 ± 0.05
7β-OH-sitosterol 1.17 ± 0.35 1.09 ± 0.52 1.09 ± 0.58
7β-OH-campesterol 0.32 ± 0.16 0.32 ± 0.15 0.25 ± 0.111,2
7-keto-sitosterol 2.49 ± 0.58 2.35 ± 0.78 2.35 ± 0.60
7-keto-campesterol 0.48 ± 0.19 0.49 ± 0.28 0.44 ± 0.22
B
7α-OH-sitosterol 0.10 ± 0.05 0.11 ± 0.06 0.12 ± 0.16
7α-OH-campesterol 0.04 ± 0.03 0.05 ± 0.03 0.04 ± 0.02
7β-OH-sitosterol 0.54 ± 0.17 0.56 ± 0.26 0.50 ± 0.26
7β-OH-campesterol 0.15 ± 0.08 0.17 ± 0.08 0.12 ± 0.051,3
7-keto-sitosterol 1.18 ± 0.34 1.22 ± 0.45 1.10 ± 0.30
7-keto-campesterol 0.23 ± 0.10 0.26 ± 0.15 0.21 ± 0.104
Panel A:  Values are means ± SD and are expressed as ng/mL. Panel B: Values are means ± SD and are expressed 
as nmol/mmol cholesterol. All subjects (n=43) received the three dietary periods in random order.
Significantly different compared with sterol period  1(p<0.01), 4(p<0.05)
Significantly different compared with control period  2(p<0.01), 3(p<0.05)
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Discussion
There is an ongoing debate whether there is a relation between circulating serum plant 
sterol concentrations and cardiovascular risk. Based on findings from animal studies [21-
23], we hypothesized that plant sterols themselves are not, but become atherogenic, when 
oxidized. We here show that in healthy volunteers, despite the increase in non-oxidized 
plant sterols concentrations, absolute concentrations of oxyphytosterols do not increase 
after consumption of plant sterol enriched margarines. However, plant stanol consumption 
reduced 7β-OH-campesterol concentrations and – when standardized for cholesterol also 
7-keto-campesterol levels – compared with the control as well as with the plant sterol 
enriched margarine.
Oxyphytosterol concentrations in humans have only been determined in a few - merely cross-
sectional - studies. In 2001, Plat et al. identified oxyphytosterols in serum of phytosterolemic 
patients, but not in serum of healthy subjects [15]. A few years later, Grandgirard et al. 
used a method with a lower detection limit and detected α- and β-epoxysitosterol, 7-keto-
sitosterol and sitostanetriol in plasma of healthy subjects in a range of 5-57 ng/mL [24]. We 
found oxyphytosterol concentrations in a range of 0.08-2.49 ng/mL, but measured different 
oxyphytosterols. 7-keto-sitosterol, however, was measured in both studies and while we 
measured a mean concentration of 2.5 ng/mL, Grandgirard et al. found a mean concentration 
of 6.1 ng/mL. The amount BHT added to the samples differed between our and Grandgirard’s 
study (1% vs. 0.05%), which might explain the discrepancies in oxyphytosterol concentrations. 
Menéndez-Carreño measured the same oxyphytosterols as we did, but found somewhat 
higher oxyphytosterol concentrations in serum of healthy volunteers (0.25 – 4.48 ng/mL) 
[25]. This difference between our results with Menéndez-Carreño’s data is probably due to 
the use of different methods, emphasizing the need for standardization of oxyphytosterol 
analyses. Recently, Husche et al. determined oxyphytosterol concentrations in plasma from 
16 volunteers, who were given plant sterol enriched margarine for 4 weeks, providing 3.0 
gram of plant sterols per day. Oxyphytosterol concentrations did not change after plant 
sterol consumption, except for an 85% increase in 7β-OH-sitosterol concentrations [20]. 
In our study 7β-OH-sitosterol concentrations did not change after consumption of a plant 
sterol enriched margarine, despite the fact that baseline 7β-OH-sitosterol concentrations 
were comparable between the two studies (1.20 ± 0.54 ng/mL vs. 1.17 ± 0.35 ng/mL). The 
study of Husche et al., however, was not placebo-controlled, which might have influenced 
the results. The range of the different oxyphytosterol concentrations in Husche’s study and 
our study was comparable (0.07-3.01 ng/mL vs. 0.08-2.49 ng/mL) and this consistency in 
baseline oxyphytosterol concentrations may help to define normal serum values. 
So far oxyphytosterol concentrations have been reported as absolute values in literature. 
The question arises whether concentrations, as for non-oxidized plant sterols, should 
be standardized for cholesterol concentrations or not. Plant sterols concentrations are 
standardized for cholesterol, as plant sterols are transported by lipoproteins. This may be 
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true for oxyphytosterols as well. When oxyphytosterols are standardized for cholesterol 
concentrations, conclusions were very comparable to those of the absolute changes, i.e. 
there was a significant decrease in 7β -OH-campesterol concentrations in the stanol period 
compared to the sterol and control period. In addition, 7-keto-campesterol was significantly 
decreased in the stanol compared with the sterol period. Alternatively, oxyphytosterols 
levels can also be expressed as the proportion of circulating plant sterol concentrations, 
which more or less indicates the percentage of substrate that is oxidized. The percentage 
oxidized plant sterols of total plant sterols is the highest in the stanol period and the 
lowest in the sterol period, but this is mostly due to a change in plant sterol concentrations 
and not in oxyphytosterol concentrations. For this reason, it was chosen to only express 
oxyphytosterols in absolute and cholesterol-standardized levels (Table 5).
Theoretically, oxyphytosterols can be derived from absorption of oxidized plant sterols present 
in food, as well as from endogenous synthesis (either from enzymatic or non-enzymatic ring-
oxidation processes). Since this study cannot distinguish between endogenously formed 
and diet-derived oxyphytosterols, we can only speculate about the origin of the measured 
circulating oxyphytosterols. Although phytosterolemic patients follow a strict plant sterol-
poor (and consequently also oxyphytosterol poor) diet, they still have elevated plasma (oxy)
phytosterol concentrations [4]. This could indicate that plasma oxyphytosterols originate 
from in vivo oxidation of the high circulating non-oxidized serum plant sterol concentrations. 
A second potential indication for the in vivo formation of oxyphytosterols might be found in 
the oxyphytosterol content of the margarines. Oxyphytosterols in the diet are mainly derived 
from plant sterol enriched products [16]. Our plant sterol enriched margarine contained ~34 
ng oxyphytosterols per milligram margarine, while the oxyphytosterol content of the other 
two margarines was ~5 ng/mg margarine (Table 2). However, this higher oxyphytosterol 
content did not translate into increased serum concentrations, which might suggest that 
serum concentrations are not related to absorption of oxyphytosterols from the diet. On 
the other hand, while non-oxidized plant sterol concentrations increased, oxyphytosterol 
concentrations did not increase, which could imply that oxyphytosterols are not formed in 
vivo but origin from intestinal absorption. In this respect, the relative absorption of different 
oxyphytosterols might give more insight into the origin of circulating oxyphytosterols. 
The sterol enriched margarines contained twice as much sitosterol oxidation products as 
campesterol oxidation products, while concentrations of sitosterol oxidation products in 
plasma were four to five times as high as campesterol concentration products. This may 
suggest that sitosterol oxidation products are preferentially absorbed or formed in vivo. 
However, in humans, non-oxidized campesterol is better absorbed than non-oxidized 
sitosterol and serum concentrations are also higher [26]. Human data is lacking, but animal 
studies have consistently shown that – analogue to the non-oxidized sterols – campesterol 
oxidation products are better absorbed than sitosterol oxidation products [27, 28]. This may 
suggest that in vivo formation of plant sterol oxidation products is more likely than intestinal 
absorption, or perhaps that excretion of sitosterol oxidation products is low. To definitively 
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answer the question whether plasma oxyphytosterols result from absorption or from in vivo 
formation, future studies should be performed in which for example labeled non-oxidized 
plant sterols are consumed and subsequent enrichment in labeled plasma oxyphytosterols 
is measured. In addition, little is known about tissue distribution of oxyphytosterols and 
whether serum oxyphytosterol concentrations relate to tissue concentrations. These 
questions should be addressed in future studies to elucidate the physiological role of 
circulating oxyphytosterols in humans. 
We observed a decrease in absolute 7β-OH-campesterol concentrations or cholesterol 
standardized 7β-OH-campesterol and 7-keto-campesterol after plant stanol enriched 
margarine consumption. Again, it is not known whether this is due to effects on in vivo 
formation or on absorption. Also, it may be a chance finding. However, if true, it is interesting 
that 7β-OH-cholesterol (cholesterol oxidation product) is regarded as the most atherogenic 
oxysterol and has been identified as the strongest predictor of a rapid progression of carotid 
atherosclerosis in humans [29]. Whether 7β-OH-campesterol might also be regarded as an 
atherogenic compound remains to be determined.   
Potential differences in dietary oxyphytosterol intake between treatments cannot be 
eliminated as the study is performed in a free-living setting, but due to the crossover design 
and low oxyphytosterol content in daily diet this is not very likely. 
In conclusion, we have shown that a daily consumption of a plant sterol enriched margarine 
for a period of 4 weeks does not increase plasma oxyphytosterol levels. We further found 
that plant
stanol consumption reduced the absolute and cholesterol-standardized 7β-OH-campesterol 
levels and the cholesterol-standardized 7-keto-campesterol level. The reproducibility and 
possible clinical implication of these reductions remain to be determined and deserve 
further investigation. 
The project was funded by the Netherlands Organisation for Scientific Research (TOP grant 
No. 91208006). The authors’ responsibilities were as follows—SB, RPM and JP: designed 
the research and wrote the manuscript; SB: conducted the research; CH and DL; performed 
the sterol analyses; JP had primary responsibility for the final content. All authors read and 
approved the final manuscript and none of the authors had a conflict of interest.
References
1. Chan YM, Varady KA, Lin Y, et al. Plasma concentrations of plant sterols: physiology and relationship with 
coronary heart disease. Nutr Rev 2006;64:385-402.
2. Gylling H, Miettinen TA. The effects of plant stanol ester in different subject groups. Euro Cardiol 2010;6:18-
21.
3. Naumann E, Plat J, Mensink RP. Changes in serum concentrations of noncholesterol sterols and lipoproteins in 
healthy subjects do not depend on the ratio of plant sterols to stanols in the diet. J Nutr 2003;133:2741-7.
57
PHYTOSTEROL CONSUMPTION & FASTING OXYPHYTOSTEROLS
4. Salen G, Horak I, Rothkopf M, et al. Lethal atherosclerosis associated with abnormal plasma and tissue sterol 
composition in sitosterolemia with xanthomatosis. J Lipid Res 1985;26:1126-33.
5. Sudhop T, von Bergmann K. Sitosterolemia--a rare disease. Are elevated plant sterols an additional risk factor? 
Z Kardiol 2004;93:921-8.
6. Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. Plasma sitosterol elevations are associated 
with an increased incidence of coronary events in men: results of a nested case-control analysis of the 
Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovas 2006;16:13-21.
7. Matthan NR, Pencina M, LaRocque JM, et al. Alterations in cholesterol absorption/synthesis markers 
characterize Framingham offspring study participants with CHD. J Lipid Res 2009;50:1927-35.
8. Silbernagel G, Fauler G, Hoffmann MM, et al. The associations of cholesterol metabolism and plasma plant 
sterols with all-cause and cardiovascular mortality. J Lipid Res 2010;51:2384-93.
9. Baumgartner S, Mensink RP, Plat J. Plant sterols and stanols in the treatment of dyslipidemia: new insights into 
targets and mechanisms related to cardiovascular risk. Curr Pharm Design 2011;17:922-32.
10. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 
1986;43:92-7.
11. Plat J, Lutjohann D, Mensink RP. What is the real meaning of increased serum plant sterol concentrations? Br 
J Nutr 2012;108:943-5.
12. Bjorkhem I, Meaney S, Diczfalusy U. Oxysterols in human circulation: which role do they have? Curr Opin 
Lipidol 2002;13:247-53.
13. Poli G, Sottero B, Gargiulo S, Leonarduzzi G. Cholesterol oxidation products in the vascular remodeling due to 
atherosclerosis. Mol Aspects Med 2009;30:180-9.
14. Vejux A, Malvitte L, Lizard G. Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and 
phospholipidosis. Braz J Med Biol Res 2008;41:545-56.
15. Plat J, Brzezinka H, Lutjohann D, Mensink RP, von Bergmann K. Oxidized plant sterols in human serum and lipid 
infusions as measured by combined gas-liquid chromatography-mass spectrometry. J Lipid Res 2001;42:2030-
8.
16. Hovenkamp E, Demonty I, Plat J, Lutjohann D, Mensink RP, Trautwein EA. Biological effects of oxidized 
phytosterols: a review of the current knowledge. Prog Lipid Res 2008;47:37-49.
17. Plat J, Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and 
hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 2000;148:101-12.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol 
in plasma, without use of the preparative ultracentrifuge. Clin chem 1972;18:499-502.
19. De Jong A, Plat J, Bast A, Godschalk RW, Basu S, Mensink RP. Effects of plant sterol and stanol ester consumption 
on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade 
inflammation in patients on current statin treatment. Eur J Clin Nutr 2008;62:263-73.
20. Husche C, Weingartner O, Pettersson H, et al. Validation of an isotope dilution gas chromatography-mass 
spectrometry method for analysis of 7-oxygenated campesterol and sitosterol in human serum. Chem Phys 
Lipids 2011;164:425-31.
21. Plat J, Theuwissen E, Lutjohann D, Mensink RP. Are oxidized plant sterols underlying CHD risk in sitosterolemia? 
Atherosclerosis suppl 2009;10:Abstract.
22. Liang YT, Wong WT, Guan L, et al. Effect of phytosterols and their oxidation products on lipoprotein profiles 
and vascular function in hamster fed a high cholesterol diet. Atherosclerosis 2011;219:124-33.
23. Staprans I, Pan XM, Rapp JH, Grunfeld C, Feingold KR. Oxidized cholesterol in the diet accelerates the 
development of atherosclerosis in LDL receptor- and apolipoprotein E-deficient mice. Arterioscl Throm Vas 
2000;20:708-14.
58
CHAPTER 3
24. Grandgirard A, Martine L, Demaison L, et al. Oxyphytosterols are present in plasma of healthy human subjects. 
Br J Nutr 2004;91:101-6.
25. Menendez-Carreno M, Steenbergen H, Janssen HG. Development and validation of a comprehensive two-
dimensional gas chromatography-mass spectrometry method for the analysis of phytosterol oxidation 
products in human plasma. Anal Bioanal Chem 2012;402:2023-32.
26. Lutjohann D, Bjorkhem I, Beil UF, von Bergmann K. Sterol absorption and sterol balance in phytosterolemia 
evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 1995;36:1763-73.
27. Grandgirard A, Sergiel JP, Nour M, Demaison-Meloche J, Ginies C. Lymphatic absorption of phytosterol oxides 
in rats. Lipids 1999;34:563-70.
28. Tomoyori H, Kawata Y, Higuchi T, et al. Phytosterol oxidation products are absorbed in the intestinal lymphatics 
in rats but do not accelerate atherosclerosis in apolipoprotein E-deficient mice. J Nutr 2004;134:1690-6.
29. Salonen JT, Nyyssonen K, Salonen R, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. 
Circulation 1997;95:840-5.
Chapter 4
Oxyphytosterol formation in humans: 
identification of high vs. low oxidizers
Sabine Baumgartner, Ronald P. Mensink, Gertjan den Hartog, 
Aalt Bast, Otto Bekers, Constanze Husche, Dieter Lütjohann and 
Jogchum Plat
Biochemical Pharmacology 2013; 86(1): 19-25
60
CHAPTER 4
Abstract
Animal studies suggest that oxyphytosterols are atherogenic. However, we have previously 
shown that plasma oxyphytosterol concentrations did not increase after consuming a diet 
enriched in plant sterol esters (3 g/day), while minor reductions were seen after consuming a 
plant stanol ester-enriched diet. Large variations in oxyphytosterol concentrations between 
individuals however existed. The aim of this study was to identify factors that may explain 
inter-individual differences in plasma oxyphytosterol concentrations. For this, 43 subjects 
consumed for 4 weeks in random order a plant sterol, stanol and control margarine. Plasma 
oxyphytosterol concentrations were determined in butylated hydroxytoluene (BHT)-enriched 
EDTA plasma via GC-MS and serum oxidized low-density lipoprotein (oxLDL) concentrations 
were analysed via ELISA. Trolox equivalent antioxidant capacity (TEAC) values, α-tocopherol 
concentrations and iron/copper status were determined to assess plasma oxidative and 
anti-oxidative capacity. Serum (non-oxidized) sitosterol and campesterol concentrations did 
not correlate with plasma oxysitosterol and oxycampesterol concentrations during any of 
the three dietary interventions. Moreover, plasma oxyphytosterol concentrations remained 
relatively stable over time. Six subjects could be arbitrarily classified as having consistent 
low or high plasma oxyphytosterol concentrations, which was also reflected in oxLDL 
concentrations. However, oxidative and anti-oxidative capacity markers, such as iron/copper 
status, α-tocopherol concentrations and TEAC values, could not explain these differences. In 
conclusion, subjects seem to have consistent plasma oxyphytosterol concentrations, which 
resulted in the identification of ‘low and high oxidizers’. Differences, however, could not be 
attributed to the oxidative and anti-oxidative capacity markers analysed.
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Introduction
Cholesterol oxidation products (oxycholesterols) can be derived from dietary intake and 
from in vivo oxidation by specific enzymes or by reactive oxygen species (ROS) [1]. Increased 
oxycholesterol concentrations are found in plasma of patients suffering from cardiovascular 
disease (CVD) [2] and in atherosclerotic plaques [3]. Further, a positive correlation has been 
observed between ROS-induced oxycholesterol concentrations in serum and established 
CVD risk factors, such as obesity and increased triglyceride concentrations [4]. In addition, 
recent studies have also suggested that oxycholesterols contribute to the development of 
degenerative diseases such as age-related macular degeneration [5]. Although these findings 
are suggestive, causal relations between elevated plasma oxycholesterol concentrations 
and pathological conditions have not been established so far. 
Plant sterols are structurally related to cholesterol and can be oxidized to oxyphytosterols [6]. 
While the biological role of oxycholesterols has been studied into large detail [1, 7], studies 
evaluating the formation, kinetics and (patho)physiological effects of oxyphytosterols are 
scarce. Oxycholesterols and oxyphytosterols exert cytotoxic and apoptotic effects in vitro, as 
indicated by an inhibition of cell growth and a reduction of cell viability [8]. Oxycholesterols 
may be more cytotoxic than oxyphytosterols [9], while pathways underlying the cytotoxicity of 
oxycholesterols and oxyphytosterols seem to be different, i.e. antioxidants protected against 
the damaging effects of oxycholesterols, but not against the toxicity of oxyphytosterols [10]. 
Studies in rodents have demonstrated that oxycholesterols and oxyphytosterols accumulate 
in tissues, but discrepancies exist regarding their potential atherogenicity [11-14]. 
What is clearly lacking is a comprehensive understanding of the aetiology behind the 
formation of oxyphytosterols and their effects in humans. Circulating oxyphytosterol 
concentrations have only been measured occasionally in human studies [15-18] and large 
variations in serum oxyphytosterol concentrations are observed when comparing the 
results of these studies. In a previous study, we have shown that plasma oxyphytosterol 
concentrations in healthy volunteers did not increase after consuming a diet enriched in 
plant sterol esters (3 g/day) for 4 weeks, while minor reductions were seen after consuming 
a plant stanol ester enriched [19]. More importantly, we identified large variations in 
oxyphytosterol concentrations between healthy human subjects, which remained stable 
over time. The aim of this study was now to identify factors that relate to these inter-
individual differences in plasma oxyphytosterol concentrations.
Subjects and Methods
Subjects, diets and design
The protocol of this placebo-controlled double-blind dietary intervention study has been 
reported into detail [19]. Briefly, subjects were recruited in Maastricht and surroundings. 
Subjects met the following criteria: 18-70 years of age; body mass index (BMI) between 
20-30 kg/m2; no active cardiovascular disease or severe medical condition during the past 5 
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years that might interfere with the study; no use of lipid-lowering medication or a medically 
prescribed diet; stable body weight during the last three months; and no consumption of 
plant sterol or plant stanol enriched products in the previous month. In addition, serum 
total cholesterol concentrations were <7.8 mmol/L; serum triglyceride concentrations 
<3.0 mmol/L and plasma glucose concentrations <6.1 mmol/L, as determined during two 
screening visits. Baseline characteristics are shown in Table 4.1. All participants gave written 
informed consent before entering the study. The protocol was approved by the medical 
ethical committee of the Maastricht University Medical Centre+ (MUMC+), and the study 
was registered at clinicaltrials.gov as NCT01559428. 
Table 4.1. Baseline characteristics 
Age (y) 41 ± 18
Male / female (n) 17 / 26
BMI (kg/m2) 24.8 ± 2.8
Total cholesterol (mmol/L) 5.72 ± 1.12
LDL cholesterol (mmol/L) 3.53 ± 1.06
HDL cholesterol (mmol/L) 1.69 ± 0.37
Triacylglycerol (mmol/L) 1.14 ± 0.46
Values are means ± SD
The study had a crossover design and consisted of three intervention periods of 4 weeks, 
separated by washout periods of 4 weeks. Subjects were stratified for gender and allocated 
to the intervention periods in a randomised order, based upon a computer-generated table 
with random numbers. During each intervention period, subjects were asked to replace 
their own spread with the test margarine (70% fat) of which 20 gram had to be consumed 
on a daily basis. The daily consumption of 20 gram of margarine provided no, or 3.0 gram of 
plant sterols or stanols (provided as fatty-acid esters), referred to as control, sterol or stanol 
period. Margarine composition has previously been described into detail [19]. 
Blood sampling
Blood was sampled after an overnight fast after 3 and 4 weeks of intervention. A clotting 
tube (Becton, Dickinson and Company, Franklin Lakes, NY, USA) was sampled and serum 
was obtained by low-speed centrifugation at 1300x g for 15 min at room temperature, at 
least half an hour after venipuncture. Serum was stored at −80 °C and used for analysis 
of lipid and lipoprotein concentrations, of plant sterol and plant stanol concentrations, 
of oxidized low-density lipoprotein (oxLDL) concentrations, of α-tocopherol (vitamin E) 
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concentrations, of iron status parameters, i.e. total iron, ferritin and transferrin and of 
copper status parameters, i.e. copper and ceruloplasmin. An EDTA and NaF tube (Becton, 
Dickinson and Company, Franklin Lakes, NY, USA) were sampled. EDTA and NaF plasma was 
obtained by low-speed centrifugation at 1300x g for 15 min at 4 ºC, and then stored at −80 
°C. To avoid auto-oxidation, oxyphytosterol concentrations were determined in butylated 
hydroxytoluene (BHT)-enriched EDTA plasma; for this 10 µl BHT (25 mg/mL ethanol) was 
added per 1 mL of EDTA plasma, immediately after centrifugation. The trolox equivalent 
antioxidant capacity (TEAC) assay was performed in de-proteinated NaF plasma; for this 
10% TCA was added to the plasma (1:1) followed by centrifugation (13.000 rpm, 5 minutes 
at 4 °C). 
Analyses
All analyses were performed in samples from week 4 of each intervention period, and 
samples from one subject were always analysed within one run to avoid bias caused by 
between run variations. Serum total cholesterol, plant sterol (sitosterol, campesterol) 
and plant stanol (sitostanol, campestanol) concentrations were analysed by gas-liquid 
chromatography-mass spectroscopy (GC-MS) as described previously [17, 20]. Plant sterol 
and plant stanol concentrations were expressed as 102x µmol/mmol total cholesterol. 
The measured oxyphytosterols were 7α-hydroxy(OH)-sitosterol, 7α-OH-campesterol, 
7β-OH-sitosterol, 7β-OH-campesterol, 7-keto-sitosterol, and 7-keto-campesterol by GC-
MS according the procedure as described by Husche et al. [17] and expressed as ng/mL. 
Oxyphytosterol concentrations were also standardized for cholesterol concentrations and 
expressed as nmol/mmol cholesterol. OxLDL concentrations were analysed by a commercially 
available sandwich ELISA (Mercodia, Uppsala, Sweden) and α-tocopherol concentrations 
by reversed-phase HPLC as described before [21]. The TEAC value is a measurement for 
the total antioxidant status, relating the free radical scavenging properties of a solution 
or a compound to that of the synthetic antioxidant trolox. The assay was performed as 
previously described [22]. Total iron concentrations were determined with a fixed-timed 
endpoint assay on a Beckman Coulter LX20 PRO Clinical Chemistry analyser (Beckman 
Coulter, Fullerton, USA). Transferrin and ceruloplasmin concentrations were analysed by 
particle-enhanced immunonephelometry on the BN Prospect from Siemens Healthcare 
Diagnostics (Siemens, Munich, Germany). The transferrin saturation (%) was calculated 
as Iron (µmol/) / (transferrin (g/L) * 25)*100%. Ferritin concentrations were determined 
using an immunoturbidimetric assay on a Cobas 6000 system (Roche Diagnostics, Basel, 
Switzerland) and copper concentrations using the Thermo Scientific XSERIES 2 ICP-MS 
(Inductive Coupled Plasma-Mass Spectrometry) (Thermo Fischer Scientific, Florida, US).
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Statistics
Effects of the experimental products were evaluated by a univariate analysis of variance 
(ANOVA) followed by Bonferroni’s correction for multiple comparisons with subject number 
as a random factor. Pearson correlation coefficients were used to examine linear relationships 
between parameters. Results were considered statistically significant if p<0.05. All statistical 
analyses were performed using SPSS 18.0 for Mac Os X (SPSS Inc., Chicago, IL, USA). 
Results
Serum plant sterols and plasma oxyphytosterols
As reported previously [19], cholesterol-standardized serum sitosterol and campesterol 
levels increased in the sterol period compared with the control period (49%; p<0.01 and 
66%; p<0.001, respectively) and the stanol period (167%; p<0.001 and 179%; p<0.001, 
respectively). In addition, cholesterol-standardized serum campesterol levels decreased in 
the stanol period compared with the control period (37%; p<0.001). Plasma oxyphytosterol 
levels were not changed after consumption of the plant sterol enriched margarine. On the 
other hand, plant stanol consumption reduced cholesterol-standardized 7β-OH-campesterol 
levels by 12% (p<0.05) and 21% (p<0.01) compared with the control and sterol period 
respectively, and 7-keto-campesterol levels by 12% (p<0.05) compared with the sterol 
period. 
Serum (non-oxidized) sitosterol concentrations did not correlate with plasma oxysitosterol 
(oxidized sitosterol) concentrations (r=0.08; p=0.45) during the control period. This was also 
true for serum campesterol and plasma oxycampesterol concentrations (r=0.12; p=0.59). 
Differences in serum plant sterol concentrations between the control period and sterol or 
stanol period n did not correlate with those in plasma oxyphytosterol concentrations (r=0.23; 
p=0.13 and r=0.01; p=0.96 respectively). Figure 4.1 (Panel A) shows individual differences in 
plasma oxyphytosterols (sum of oxysitosterol and oxycampesterol) and serum plant sterols 
(sum of sitosterol and campesterol) concentrations between the sterol and control periods, 
while panel B shows these differences between the stanol and control periods. 
The individual changes in oxyphytosterol concentrations were ranked from the largest 
decrease to the highest increase (upper panels) and the accompanying changes in plant 
sterol concentrations in the same individual are plotted in the lower panels. As expected, 
the patterns of changing plasma oxyphytosterol concentrations and serum plant sterols 
concentrations did not correspond, i.e. an increase in serum plant sterol concentrations 
is not by definition accompanied by an increase in plasma oxyphytosterol concentrations 
(Figure 4.1, panel A). Similarly, a decrease in serum plant sterol concentrations was not 
accompanied by a corresponding decrease in plasma oxyphytosterol concentrations in the 
same individual (Figure 4.1, panel B).
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Figure 4.1. Individual differences between sum oxyphytosterol concentrations and sum plant sterol concentrations 
after plant sterol (panel A) and plant stanol consumption (panel B) when compared to control period (n=43). 
Plasma oxysitosterol concentrations at the end of the control and sterol period were 
significantly correlated (Figure 4.2; panel A, r=0.51; p<0.001), and this was also true for 
serum oxycampesterol concentrations (panel B, r=0.45, p<0.01). Significant correlations 
between dietary periods were also seen for the individual oxidation products (7α-OH, 7β-OH 
and 7-keto) of sitosterol and campesterol (data not shown). This suggests that differences 
in plasma oxyphytosterol concentrations between subjects were consistent during the 
different dietary interventions. By comparing the various oxyphytosterol correlation graphs 
(of all six individual oxyphytosterols, during all three dietary interventions), three subjects 
could arbitrarily be classified as having consistent low plasma oxyphytosterol concentrations 
and three subjects as having consistent high plasma oxyphytosterol concentrations. 
To further explore this difference in oxyphytosterol concentrations between these so-called 
low and high oxidizers, serum oxLDL concentrations were determined. Figure 4.3 shows 
oxyphytosterol and oxLDL concentrations in the entire group and in the low and high oxidizers 
in the control period. In line with the findings for plasma oxyphytosterol concentrations, 
similar differences between low and high oxidizers in oxLDL concentrations were shown. 
Figure 3 illustrates that differences in oxyphytosterol concentrations are also reflected in 
oxLDL concentrations, although the groups are somewhat overlapping. The correlation 
between sum oxyphytosterol and oxLDL concentrations in the control period did not reach 
significance (r=0.13, p=NS). On the other hand, there was a significant correlation between 
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sum oxyphytosterol and oxLDL concentrations in the sterol period (r=0.36; p<0.05) and 
stanol period (r=0.32; p<0.05). More specifically, these significant correlations were only 
present for 7β-OH-sitosterol, 7β-OH-campesterol, 7-keto-sitosterol and 7-keto-campesterol 
(ROS-induced oxyphytosterols) and not for 7α-OH-sitosterol and 7α-OH-campesterol, which 
are in contrast to the other oxyphytosterols not only formed via ROS but also enzymatically 
produced (data not shown).
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Figure 4.2. Correlations between sum oxycampesterol concentrations (panel A, r=0.51; p<0.001) and between sum 
oxysitosterol concentrations (panel B, r=0.45; p<0.01) in control and sterol period (n=43).
Anti-oxidative and pro-oxidative markers 
Plasma α-tocopherol concentrations, TEAC values and iron and copper status markers 
were determined to identify factors that could relate to circulating plasma oxyphytosterol 
concentrations. As shown in Table 4.2, plasma α-tocopherol concentrations decreased in 
the stanol period by 3.73 ± 10.6 μmol/L compared with the control period (7.9%; p<0.05), 
while TEAC values and iron and copper status did not differ between the three dietary 
periods. This implies that a possible correlation between any of these parameters and 
plasma oxyphytosterol concentrations cannot be attributed to diet-induced changes in these 
anti-oxidative and pro-oxidative markers. No correlations between plasma oxyphytosterol 
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concentrations with α-tocopherol concentrations or TEAC values, both accepted markers of 
anti-oxidative capacity, were observed during any of the three dietary periods. 
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Figure 4.3. Oxidative stress markers in low and high oxidizers vs. group average.
1Oxyphytosterol is the sum of 7α-sitosterol, 7β-OH-sitosterol, 7-keto-sitosterol, 7α-campesterol, 7β-OH-
campesterol and 7-keto-campesterol concentrations. All analyses have been performed in each individual in the 
control period. 
Next, iron status, a contributor to metal-induced oxidation in vivo, was determined by 
measuring total iron, ferritin and transferrin saturation. Correlations between all three 
iron status markers and oxLDL, and between iron status markers and oxyphytosterol 
concentrations during the control period are shown in Figure 4.4. In line with expectations, 
there were positive correlations between all three iron status markers and plasma oxLDL 
concentrations (total iron r=0.37; p<0.05, ferritin r=0.37; p<0.05, transferrin saturation 
r=0.35; p<0.05). These correlations were comparable during all three dietary periods, except 
for oxLDL and ferritin concentration during the sterol period, which showed no statistically 
significant correlation (r=0.15; p=0.34). In contrast, no correlations were observed between 
any of the three iron status markers and oxyphytosterol concentrations during each of 
the three dietary periods. Finally, copper and ceruloplasmin (copper-binding protein) 
68
CHAPTER 4
concentrations did not correlate with oxLDL concentrations or with plasma oxyphytosterol 
concentrations during any of the three dietary periods. 
Table 4.2. Effect of consumption of plant sterol and plant stanol enriched margarines on 
plasma α-tocopherol concentrations, TEAC values and on iron and copper status markers
Control 
period
Plant sterol 
period
Plant stanol 
period
α-tocopherol (μmol/L) 44.5 ± 12.5 41.9 ± 13.3 40.8 ± 15.31
TEAC values 658.5 ± 101.9 676.0 ± 118.9 675.7 ± 102.1
Total iron (μmol/L) 17.9 ± 7.7 17.1 ± 7.5 16.7 ± 7.4
Ferritin (μg/L) 62.3 ± 51.8 65.8 ± 51.7 63.2 ± 54.1
Transferrin saturation (%) 30.7 ± 16.7 28.7 ± 14.2 28.3 ± 15.1
Copper (μmol/L) 18.4 ± 8.0 19.0 ± 8.0 18.5 ± 7.6
Ceruloplasmin (g/L) 0.30 ± 0.11 0.31 ± 0.11 0.31 ± 0.10
Values are means ± SD. All subjects (n=43) received the three dietary periods in random order.
1Significantly different compared with control period (p<0.05)
69
OXYPHYTOSTEROLS: HIGH AND LOW OXIDIZERS
0	  
20	  
40	  
60	  
To
ta
l	  i
ro
n	  
(μ
m
ol
/L
)	  
0	  
100	  
200	  
300	  
Fe
rr
i8
n	  
(μ
g/
L)
	  
Tr
an
sf
er
ri
n	  
sa
tu
ra
8o
n	  
(%
)	  
0	  
25	  
50	  
75	  
100	  
0	   2	   4	   6	   8	   10	  
0	  
20	  
40	  
60	  
0	  
100	  
200	  
300	  
0	  
25	  
50	  
75	  
100	  
0	   20	   40	   60	   80	   100	  
OxLDL	  concentra8on	  (U/L)	   Oxyphytosterol	  concentra8on	  (ng/mL)	  
A	   B	  r=0.37;	  p<0.05	  
r=0.43;	  p<0.05	  
r=0.37;	  p<0.05	  
r=-­‐0.05;	  NS	  
r=-­‐0.02;	  NS	  
r=-­‐0.03;	  NS	  
Figure 4.4. Correlations between iron status markers and oxLDL concentrations (panel A) and between iron status 
makers and sum oxyphytosterol concentrations (panel B) in control period (n=43).
Discussion
This study demonstrates that in healthy volunteers plasma oxyphytosterol concentrations 
do not correlate with serum non-oxidized plant sterol concentrations. This lack of correlation 
was expected, as we have earlier found in the same study that an increased consumption of 
plant sterols does not increase plasma oxyphytosterol concentrations [19]. However, what 
we also showed is that plasma oxyphytosterol concentrations remained relatively stable 
during the 20 week study period. This consistency in low or high plasma oxyphytosterol 
concentrations was also reflected in serum oxLDL concentrations, a frequently used 
oxidative stress marker, which suggests a relationship between plasma oxyphytosterol 
concentrations and oxidative stress. Although the evidence is scarce, it is possible that 
oxyphytosterols – just like oxycholesterols – are atherogenic components. In animal studies, 
oxycholesterols and oxyphytosterols have been shown to accumulate in serum and liver, 
but the implications of this are still under debate [11-14]. What is lacking is a clear insight 
in the factors that influence formation of oxyphytosterols in humans, as well as the exact 
locations of oxidation within the human body. To identify factors that relate to these inter-
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individual differences in plasma oxyphytosterol concentrations, we searched for similarities 
and differences between oxLDL and oxyphytosterol concentrations.
In vivo oxidation is often catalysed by iron ions. Ferrous ions (Fe2+) generate highly reactive 
hydroxyl radicals from hydrogen peroxide. These can oxidize lipids, nucleic acids, and proteins 
[23]. Increased iron stores are associated with oxidative stress, but associations between 
iron stores with oxidative stress-related diseases, such as type II diabetes and cardiovascular 
diseases remain contradictive [24, 25]. We here show a positive correlation between iron 
stores and serum oxLDL concentrations. However, plasma oxyphytosterol concentrations 
were not correlated with iron stores. This suggests that oxidation of plant sterols and 
oxidation of LDL particles are not – at least not entirely – regulated by the same mechanisms. 
This might in part be explained by the fact that serum oxLDL concentrations represent 
essentially a fatty acid oxidation process and the antibody used binds to malondialdehyde 
(MDA)-modified apolipoprotein B particles. In contrast, oxidation of plant sterols represents 
sterol oxidation. Sterols are less susceptible to oxidative attack than polyunsaturated 
fatty acyl moieties, and will therefore be accompanied by other oxidized compounds [1]. 
Nevertheless, plasma oxycholesterol concentrations were positively associated with serum 
ferritin concentrations in a large cohort of Finnish men [26]. This is the first study that 
relates iron stores to plasma oxyphytosterols concentrations and our findings suggest that 
oxidation of plant sterols – in contrast to oxycholesterol and oxLDL formation – might not 
be iron-mediated. In contrast to the positive correlations between iron markers and oxLDL 
concentrations, we did not find this correlation for markers of copper status. As for iron, 
there was also no correlation between copper markers and oxyphytosterol concentrations. 
Epidemiological data regarding the role of copper in oxidative processes and CVD risk are 
not consistent and are still a matter of debate [27]. Copper is part of superoxide dismutase 
(SOD); an enzymatic antioxidant and copper deficiency (e.g. decreased SOD status) is 
associated with specific pathologies [28]. On the other hand, not only deficiencies but also 
copper overload is associated with inflammation and markers of oxidative stress in the body 
[29]. Ceruloplasmin is the major copper-containing plasma protein and depending on the 
circumstances can act as an antioxidant or pro-oxidant [27]. The fact that in this study serum 
copper and ceruloplasmin concentrations did not correlate with serum oxLDL or plasma 
oxyphytosterol concentrations seems in contrast with in vitro studies in which oxidation 
tendency of LDL particles is studied by means of copper-ions [30]. However, there is strong 
evidence that different oxidative products are generated during in vitro copper-induced 
oxidation of LDL compared with in vivo oxidation of these particles [1]. As described before, 
the role of copper in in vivo oxidative processes is contradictive and our results suggest that 
in this population of healthy volunteers, copper does not play a role (anti-oxidative or pro-
oxidative) in the oxidation of LDL or plant sterols.
Both TEAC values and α-tocopherol concentrations, markers for anti-oxidative capacity, were 
not associated with plasma oxyphytosterol concentrations, indicating that a relationship 
between oxyphytosterols and oxidative stress is not straightforward. On the other hand, 
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serum oxLDL concentrations, a validated marker for oxidative stress, also did not correlate 
with TEAC values. Although these correlations imply that there is no association between 
anti-oxidative capacity and oxyphytosterol concentrations, it must be kept in mind that 
these are cross-sectional correlations and it would be interesting to assess oxyphytosterol 
concentrations after antioxidant supplementation. 
Altogether the obtained results imply that for now, we cannot answer the question which 
factors contribute to the large inter-individual differences in fasting plasma oxyphytosterol 
concentrations. We have been able to exclude some parameters that seemed most 
logical to consider. In general, this search is complicated by the fact that information 
regarding oxy(phyto)sterol metabolism is scarce; not much is known about normal plasma 
concentrations in healthy subjects and in specific diseases, what the consequences are of 
increased concentrations, and whether plasma concentrations reflect tissue concentrations. 
To summarize, this study shows that plasma oxyphytosterol concentrations are linked to 
oxLDL concentrations, that concentrations remain relatively stable over time and that 
oxidation of plant sterols – in contrast to oxidation of LDL – might not be iron-mediated. 
Thus, many questions regarding oxyphytosterol metabolism still remain that deserve to be 
answered in future studies.
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Abstract
Epidemiological studies have reported inconsistent results on the relationship between 
increased plant sterol concentrations with cardiovascular risk, which might be related to the 
formation of oxyphytosterols (plant sterol oxidation products) from plant sterols. However, 
determinants of oxyphytosterol formation and metabolism are largely unknown. It is known, 
however, that serum plant sterol concentrations increase after daily consumption of plant 
sterol enriched products, while concentrations decrease after plant stanol consumption. 
Still, we have earlier reported that fasting oxyphytosterol concentrations did not increase 
after consuming a plant sterol- or a plant stanol enriched margarine (3.0 g/d of plant 
sterols or stanols) for 4 weeks. Since humans are in a non-fasting state for most part of 
the day, we have now investigated effects on oxyphytosterol concentrations during the 
postprandial state. For this, subjects consumed a shake (50 g of fat, 12 g of protein, 67 g of 
carbohydrates), containing no, or 3.0 g of plant sterols or plant stanols. Blood samples were 
taken up to 8 hours and after 4 hours subjects received a second shake (without plant sterols 
or plant stanols). Serum oxyphytosterol concentrations were determined in BHT-enriched 
EDTA plasma via GC-MS/MS. 7β-OH-campesterol and 7β-OH-sitosterol concentrations were 
significantly higher after consumption of a mixed meal enriched with plant sterol esters 
compared to the control and plant stanol ester meal. These increases were seen only 
after consumption of the second shake, illustrative for a second meal effect. Non-oxidized 
campesterol and sitosterol concentrations also increased after plant sterol consumption, in 
parallel with 7β-OH concentrations and again only after the second meal. Apparently, plant 
sterols and oxyphytosterols follow the same second meal effect as described for dietary 
cholesterol. However, the question remains whether the increase in oxyphytosterols in the 
postprandial phase is due to absorption or endogenous formation.
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Introduction
A daily consumption of 2-3 gram plant sterols or plant stanols reduces fasting serum low-
density lipoprotein cholesterol (LDL-C) concentrations up to 10% [1]. At the same time, 
however, serum plant sterol concentrations increase after daily consumption of plant sterol 
enriched products, while concentrations decrease after consumption of plant stanol enriched 
products [2]. We have previously reported increases of 36-50% in serum concentrations of 
the various plant sterols [3], which is in line with a recent meta-analysis that reported average 
increases of 31% (95% CI: 26-37%) and 37% (95% CI: 29-45%) in sitosterol and campesterol 
concentrations after consumption of plant sterol enriched products at an average dose of 
1.6 g/d [4]. Although these concentrations are only marginal as compared to those observed 
in phytosterolemic subjects, the potential impact of these elevated circulating plant sterol 
concentrations on cardiovascular risk is strongly debated, as epidemiological studies have 
reported inconsistent results regarding the potential association of increased plant sterol 
concentrations and CVD risk [5, 6]. The controversy around the potential atherogenicity of 
plant sterols might relate to the question whether plant sterols are oxidized or not. We 
and others have previously shown that in transgenic mouse models plant sterol enriched 
diets lower atherosclerotic lesion development [7-9] while enrichment with oxidized 
plant sterols (oxyphytosterols) resulted in larger and more severe atherosclerotic lesions 
[10]. Data regarding origin, metabolism, pathophysiological effects and effects of specific 
diets on oxyphytosterol metabolism in humans are however scarce. Oxyphytosterols have 
been identified in serum of healthy and phytosterolemic subjects, and in aortic tissue of 
patients undergoing elective aortic valve replacement [11]. Previously, we have reported 
the effect of consuming a plant sterol or a plant stanol enriched margarine (3.0 g/d of 
plant sterols or stanols) for 4 weeks on fasting oxyphytosterol concentrations. No effects 
on fasting oxyphytosterol concentrations were observed after plant sterol consumption, 
while 7β -OH-campesterol concentrations – and when standardized for cholesterol also 
7-keto-campesterol levels – were reduced after plant stanol consumption. Since humans 
are in a non-fasting state for the major part of the day, we have now examined the 8-hour 
postprandial oxyphytosterol response after consuming plant sterol or plant stanol ester 
enriched margarine as part of a mixed meal. 
Materials and Methods
Subjects
Samples were derived from a subgroup (N=10) randomly selected from a, double-blind 
placebo-controlled cross-over intervention study with 43 healthy subjects. Subject 
characteristics of the complete study population have previously been reported into 
detail when effects of plant sterol and plant stanol consumption on fasting lipoprotein and 
oxyphytosterol concentrations were reported [3]. The 10 healthy subjects (3 males and 
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7 females) were 44 ± 19 years old, had a body mass index (BMI) of 24.3 ± 2.8 kg/m2, a 
total cholesterol concentration of 5.4 ± 0.8 mmol/L and a triglyceride concentration of 1.1 
± 0.4 mmol/L. Statistical analyses showed no differences between this subgroup and the 
remaining 33 subjects regarding baseline characteristics and fasting responses after plant 
sterol or plant stanol consumption. All participants gave their written informed consent 
before entering the study. The medical ethical committee of the Maastricht University 
Medical Centre+ (MUMC+) approved the protocol and the trial is registered at clinicaltrials.
gov as NCT01559428.
Diet and Design
Subjects participated in a 20 weeks intervention study, which consisted of three intervention 
periods of 4 weeks, separated by washout periods of 4 weeks. Subjects consumed 20 gram of 
test margarine on a daily basis, which provided no, or 3.0 gram of plant sterols or stanols per 
day. At the end of each of the three intervention periods, a postprandial test was performed 
(Figure 5.1). For this, an intravenous cannula was placed and a fasting blood sample was 
collected. Subjects consumed a shake containing no, or 3.0 gram of plant sterols or plant 
stanols provided as their fatty acid esters, depending on the preceding 4-week intervention 
period. Subsequent blood samples were drawn up to 8 hours and subjects received a 
second shake (without cholesterol, plant sterol esters or plant stanol esters) after 4 hours. 
The compositions of the shakes are shown in Table 5.1. Subjects were not allowed to eat 
anything else, but were allowed to drink water (±500 mL) throughout the entire test day. 
Plant sterol enriched shake 
Plant stanol enriched shake 
Control shake 
Lunch shake 
Time  0                60                   120                 180                  240                  300                 360                  420                  480 
(min) 
Blood sampling 
Shake consumption 
First meal response Second meal response 
Figure 5.1. Outline of the postprandial meal test
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Table 5.1. Composition of the breakfast shakes enriched with plant sterol or plant stanol 
esters and the lunch shake
Breakfast shake; 
control period
Breakfast 
shake; 
sterol period
Breakfast 
shake; 
stanol period
Lunch 
shake
Energy (MJ) 3.15 3.15 3.14 3.16
Fat (energy%) 59.6 59.6 59.5 60.1
  SAFA* 24.7 24.7 27.8 23.4
  MUFA 20.9 20.9 18.8 22.2
  PUFA 10.1 10.1 9.1 12.2
Protein (energy%) 6.2 6.2 6.2 4.2
CHO (energy%) 35.2 35.2 35.3 36.4
Cholesterol (mg) 250.2 250.2 250.2 17.3
Plant sterols  (g) - 3.0 - -
Plant stanols (g) - - 3.0 -
Oxyphytosterol (mg) 0.10 0.68 0.11 0.10
  Σ oxycampesterol (mg) 0.04 0.22 0.05 0.04
  Σ oxysitosterol (mg) 0.06 0.46 0.06 0.06
  7β-OH-campesterol (mg) 0.01 0.06 0.00 0.01
  7β-OH-sitosterol (mg) 0.02 0.23 0.01 0.02
  7-keto-campesterol (mg) 0.03 0.11 0.05 0.03
  7-keto-sitosterol (mg) 0.03 0.11 0.05 0.03
* SAFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, CHO: 
carbohydrates
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Blood sampling and analyses
A clotting tube and an EDTA tube (Becton, Dickinson and Company, Franklin Lakes, NY, 
USA) were sampled at each time point. Serum was obtained from the clotting tube by 
low-speed centrifugation at 1300x g for 15 min at room temperature, at least half an hour 
after venipuncture and was used for the analysis of plant sterol concentrations. Plasma was 
obtained by low-speed centrifugation of the EDTA tube at 1300x g for 15 min at 4 ºC and 
was used for the analysis of plasma oxyphytosterol concentrations. To avoid auto-oxidation, 
10 µl BHT (25 mg/mL ethanol) was added per 1 mL of EDTA plasma, immediately after 
centrifugation. All serum and plasma samples were snap frozen in liquid nitrogen and stored 
at −80 °C until analysis.
Sitosterol and campesterol concentrations were analysed using gas chromatography – flame 
ion detection (GC-FID) as described previously [12] and concentrations are expressed as 
mg/dL. 7β-Hydroxy(OH)-campesterol, 7β-OH-sitosterol, 7-keto-campesterol and 7-keto-
sitosterol were analysed by gas chromatography-mass spectroscopy (GC-MS/MS) according 
to the procedure as described by Husche et al [13] with minor modifications related to the 
use of a GC-MS triplequad in stead of a GC-MS singlequad and are expressed as ng/mL. 
Statistics
All data are presented as means ± standard deviations (SD). Differences in baseline 
concentrations between the test meals were statistically evaluated using univariate analysis 
of variance (ANOVA) with diet as fixed factor and subject as random factor. Changes from 
baseline were analysed using linear mixed models with diet and time as within-subject 
fixed factors, and with diet-time interaction. If the interaction term was not statistically 
significant, it was omitted from the model. If the interaction term, factor time or factor diet 
was significant, Bonferroni’s correction for multiple comparisons was used. Results were 
considered to be statistically significant if p<0.05. All statistical analyses were performed 
using SPSS 20.0 for Mac Os X (SPSS Inc., Chicago, IL, USA). 
Results
Fasting plasma oxyphytosterol concentrations at the start of the postprandial test day 
(after consuming plant sterol enriched, plant stanol enriched or placebo margarines for 4 
weeks) were not different (Table 5.2). The postprandial responses in plasma oxyphytosterol 
concentrations are presented in Figure 5.2.  There was a significant diet*time interaction 
for 7β-OH-campesterol concentrations during the postprandial period (p<0.05). Following 
Bonferroni’s correction for multiple comparisons, concentrations were significantly higher 
after consumption of a mixed meal enriched with plant sterol esters compared with the control 
meal at T240 (p<0.01), T360 (p<0.001) and T480 (p<0.001). Moreover, concentrations were 
higher after the plant sterol enriched meal compared with the plant stanol enriched meal 
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at T360 (p<0.001) and T480 (p<0.01). Also for postprandial 7β-OH-sitosterol concentrations, 
a significant diet*time interaction (p<0.05) was found. Following Bonferroni’s correction, 
concentrations were higher after consumption of a mixed meal enriched with plant sterol 
esters compared with the plant stanol meal at T360 (p<0.01) and T480 (p<0.05). These data 
indicate that 7β-OH-campesterol and 7β-OH-sitosterol concentrations were only increased 
after the second meal (i.e. lunch without added plant sterols/stanols and cholesterol). For 
postprandial 7-keto-campesterol concentrations, there was only a significant time effect. 
Concentrations were increased at T360 and T480 compared with T0 (p<0.05), compared 
with T60 (p<0.01) and compared with T240 (p<0.001). Postprandial 7-keto-sitosterol 
concentrations were increased at T480 compared with T240 (p<0.01).
Table 5.2. Fasting plant sterol and oxyphytosterol concentrations after consumption of 
plant sterol enriched, plant stanol enriched or placebo margarines (n=10)
Control 
period 
Plant sterol 
period
Plant stanol 
period
Campesterol (mg/dL) 0.56 ± 0.21 0.89 ± 0.2613 0.35 ± 0.11
Sitosterol (mg/dL) 0.32 ± 0.11 0.41 ± 0.112,3 0.22 ± 0.06
7β-OH-campesterol (ng/mL) 0.39 ± 0.15 0.37 ± 0.08 0.33 ± 0.08
7β-OH-sitosterol (ng/mL) 0.57 ± 0.25 0.50 ± 0.14 0.51 ± 0.20
7-keto-OH-campesterol (ng/mL) 0.94 ± 0.26 0.96 ± 0.17 0.91 ± 0.11
7-keto-OH-sitosterol (ng/mL) 2.35 ± 0.67 2.76 ± 0.82 2.87 ± 0.76
significantly different compared with control period 1(p<0.001), 2(p<0.01)
significantly different compared with plant stanol period 3(p<0.001) 
Besides oxyphytosterol concentrations, we also quantified non-oxidized plant sterol 
concentrations since these are the potential substrates to be oxidized. Fasting serum 
campesterol and sitosterol concentrations were higher after the plant sterol intervention 
compared with the plant stanol and control intervention (Table 5.2). The postprandial 
responses in serum campesterol and sitosterol concentrations are presented in Figure 5.3. 
Serum campesterol concentrations were increased after a mixed meal enriched with plant 
sterol esters compared with plant stanol esters (diet effect; p<0.05). Postprandial serum 
campesterol concentrations were also significant for the factor time; concentrations were 
higher at T360 and T480 compared with T60 (p<0.05 and p<0.01, respectively). Changes 
in sitosterol concentration were significant for diet (sterol > stanol, p<0.01) and for time 
(T480 > T60, p<0.01). In line with the oxyphytosterol concentrations, serum plant sterol 
concentrations were particularly increased after the second meal. Postprandial sitosterol 
and campesterol concentrations were comparable after a mixed meal enriched with plant 
stanol esters compared with the control intervention.
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Figure 5.2. Plasma concentrations of (A) 7β-OH-campesterol, (B), 7β-OH-sitosterol, (C), 7-keto-campesterol and (D) 
7-keto-sitosterol after consumption of a shake containing no, or 3.0 gram of plant sterols or plant stanols. Data are 
presented as mean ± SEM.  
A: significantly different from control period *(p<0.01), **(p<0.001), significantly different from stanol period 
#(p<0.01), # #(p<0.001)
B: significantly different from stanol period *(p<0.05), **(p<0.01)
C: significant time effect, T360 > T0: and T480 > T0 *(p<0.01)
D: significant time effect, T480 > T240 *(p<0.01)
Figure 5.3. Serum concentrations of (A) campesterol and (B) sitosterol after consumption of a shake containing no, 
or 3.0 gram of plant sterols or plant stanols. Data are presented as mean ± SEM. 
A: Significant diet effect, sterol > stanol #(p<0.05), significant time effect, T360 > T60 *(p<0.05) and T480 > T60 
**(p<0.01) 
B: Significant diet effect, sterol > stanol #(p<0.01), significant time effect, T480 > T60 *(p<0.01) 
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Discussion
Earlier, we have found that daily consumption of a plant sterol enriched diet increased 
fasting serum plant sterol concentrations, but did not elevate plasma oxyphytosterol 
concentrations. Here, we show that consumption of a mixed meal enriched with plant sterol 
esters increased postprandial serum plant sterol and plasma oxyphytosterol concentrations 
as compared to a mixed meal or a mixed meal enriched with plant stanol esters. Interestingly, 
these higher plant sterol and oxyphytosterol concentrations were particularly present after 
consumption of a second meal.
Plant sterols share structural similarities to cholesterol and also have the typical double 
bond between C5-C6 in the steroid nucleus. Therefore, plant sterols are – analogue to 
cholesterol – prone to reactive oxidative species (ROS)-mediated oxidation [14]. Plant 
stanols lack this double bond and can therefore not be oxidized by ROS. Since plant 
sterol oxidation products are present in foods [15, 16], circulating plant sterol oxidation 
products can either result from dietary absorption or from endogenous oxidation of 
non-oxidized plant sterols. Oxyphytosterols have been identified in foods such as heated 
vegetable oils, infant milk formulas, parenteral nutrition, French fries, potato chips and 
coffee beans [17-20]. However, the main sources of dietary oxyphytosterols are plant sterol 
enriched products and a recommended daily consumption of 20-25 gram of spread can 
provide up to 1.7 mg oxyphytosterols [21]. We here show that postprandial oxyphytosterol 
concentrations increase after consumption of plant sterol enriched margarine. However, 
given the experimental design, we cannot distinguish between oxyphytosterols originating 
from dietary absorption and from endogenous oxidation. Therefore, we can only speculate 
on their origin. 
The postprandial patterns of non-oxidized plant sterol concentrations are suggestive for a 
second meal response as already reported in 1998 for dietary cholesterol [22-24], which 
states that cholesterol from the first meal is secreted via intestinally derived chylomicrons 
during subsequent meal consumptions. This might explain why most studies so far did not 
report increased postprandial plant sterol concentrations after plant sterol consumption. In 
two studies, blood sampling may have been too late after consumption of the meals [25, 
26], while in another 4-hour study a second meal was not included [27]. Plasma 7β-OH-
phytosterol concentrations demonstrated a comparable second meal response, since peak 
concentrations were seen two hours after consumption of the second meal. This suggests 
that oxyphytosterols present in the shake were absorbed in the enterocytes after the 
first meal (breakfast) and released after the second meal (lunch). Alternatively, one can 
speculate that plant sterols in the shake were absorbed after the first meal followed by 
endogenous oxidation and appearance in the circulation. It could also be possible that plant 
sterols undergo enterohepatic recycling, implying that they are absorbed after the first 
meal, oxidized in the liver and then secreted back into the intestinal lumen via bile, after 
which absorption of oxidized plant sterols might take place. 
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In the plant sterol enriched margarine, sitosterol concentrations were higher than those of 
campesterol. Also, concentrations of sitosterol oxidation products were higher than those 
of campesterol oxidation products. In humans, it has consistently been shown that non-
oxidized campesterol is better absorbed than sitosterol, resulting in higher fasting serum 
concentrations [4, 28]. This is also reflected in our postprandial data, where postprandial 
increases in serum campesterol are higher than those of sitosterol after consumption of 
the plant sterol enriched shake. Postprandial oxycampesterol responses were also larger 
than oxysitosterol responses (peak change of 0.06 vs. 0.03 ng/mL). This would suggest 
that – analogue to non-oxidized plant sterols – campesterol oxidation products are better 
absorbed (or less efficiently excreted) than sitosterol oxidation products. Rodent models 
have been used to measure lymphatic recovery to estimate oxyphytosterol absorption 
rates and indeed reported that campesterol oxidation products were better absorbed 
than sitosterol oxidation products [29, 30]. However, when fasting plasma oxyphytosterol 
concentrations are compared, absolute plasma 7β-OH-sitosterol concentrations are higher 
than those of 7β-OH-campesterol (0.57 vs. 0.39 ng/mL, in control period). This is clearly 
different from the non-oxidized sterols, where campesterol concentrations are higher than 
sitosterol concentrations (0.56 vs. 0.32 mg/dL, in control period). This might suggest that 
sitosterol is preferentially oxidized (either in enterocytes or in the circulation) and that 
(part of) oxyphytosterol concentrations originate from endogenous oxidation of circulating 
plant sterols. However, we have reported previously that after plant sterol consumption 
fasting oxyphytosterol concentrations were not increased despite increased plant sterol 
concentrations (+36-50%), suggesting that the availability of substrate does not influence 
oxidation rates of serum plant sterol concentrations. Another argument for endogenous 
oxidation relates to oxyphytosterol differences between subjects [31], which might be 
attributed to different absorption rates or differences in endogenous oxidation of circulating 
plant sterols. The latter is probably more plausible, since other oxidative stress markers 
were also higher in subjects with increased oxyphytosterol concentrations. 
In a previous study, fasting 7β-OH-campesterol concentrations and – when standardized 
for cholesterol – also 7-keto-campesterol levels oxyphytosterols were reduced after plant 
stanol consumption [3]. We hypothesized that oxyphytosterol absorption – analogue 
to non-oxidized plant sterol absorption – is inhibited after consumption of plant stanol 
enriched products. Postprandial oxyphytosterol concentrations were not changed after 
plant stanol consumption, suggesting that postprandial oxyphytosterol absorption is not 
inhibited and oxyphytosterol concentrations in the postprandial phase might origin from 
endogenous formation. However, postprandial non-oxidized plant sterol concentrations 
were also not changed, while plant stanol consumption inhibits dietary absorption of plant 
sterols and reduces fasting plant sterol concentrations. However, this does not exclude that 
postprandial oxyphytosterols could still originate from dietary absorption. Also, levels of 
plant sterols and oxyphytosterol in the plant stanol enriched margarine may have been 
too low to observe clear changes. To provide definite answers to the question whether 
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plasma oxyphytosterols result from absorption or from endogenous oxidation of circulating 
plant sterols, studies using labelled non-oxidized plant sterols and subsequent enrichment 
in labelled plasma oxyphytosterols should be performed. In addition, postprandial plant 
sterol and oxyphytosterol curves demonstrate that future studies demand longer-term 
postprandial follow-up periods and inclusion of multiple meals or incorporation of labelled 
(oxy)phytosterols to assess origin. It would also be interesting to assess whether single or 
multiple daily intakes of plant sterol enriched products would lead to different changes in 
circulating oxyphytosterol concentrations.
In conclusion, while we previously reported that four weeks plant sterol enriched margarine 
consumption did not change fasting oxyphytosterol concentrations, we show here for the first 
time that postprandial oxyphytosterol concentrations increase after consumption of a mixed 
meal enriched with plant sterol esters. Data regarding the origin of these oxyphytosterols, i.e. 
absorption from diet, endogenous formation as well as further oxyphytosterol metabolism 
in humans is missing and further research is needed to understand the possible relationship 
between (postprandial) plant sterol and oxyphytosterol concentrations and CVD risk.
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Abstract
The low-density lipoprotein cholesterol (LDL-C) lowering effect of plant sterols and stanols 
has unequivocally been established in numerous studies whereas more recently, a possible 
triacylglycerol (TAG) lowering effect also received attention. A potential TAG lowering 
effect of plant sterol and plant stanol consumption is interesting not only in a fasting state, 
but particularly when present in a postprandial state, since elevated postprandial TAG 
concentrations are emerging as an important cardiovascular disease (CVD) risk factor. The 
objective of this study was to examine the 8-hour postprandial response after consuming 
plant sterol or plant stanol ester enriched margarine as part of a mixed meal. 
This postprandial study was part of a randomised, double-blind, cross-over study in which 42 
healthy subjects (18-70 years) consumed for 4 weeks a plant sterol enriched (3 g/d of plant 
sterols), a plant stanol enriched (3 g/d of plant stanols), and a control margarine separated 
by wash-out periods of 4 weeks. At the end of each intervention period, subjects underwent 
a meal test in which they consumed a shake enriched with either 3 g of plant sterol esters 
(sterol period), 3g of plant stanol esters (stanol period) or no addition (control period). Blood 
sampling was performed up to 8-hours and subjects received a second shake without plant 
sterols or stanols after 4 hours. This prolonged protocol enabled us to evaluate effects on 
the 2nd meal response as well. To evaluate postprandial responses, incremental areas under 
the curves (iAUC) were calculated. The TAG and apoB48 iAUC of the total (0-8 hours) and 
1st meal (0-4 hours) responses were comparable between the three test meals. However, 
the TAG and apoB48 iAUC after the second meal responses (4-8 hours) were higher in 
the stanol period compared to the sterol period. This 2nd meal response after plant stanol 
consumption was more pronounced with increasing age and might be related to a change 
in intestinal TAG absorption or a delay in lipoprotein clearance. This study demonstrates an 
age-dependent increase in postprandial TAG and apoB48 responses after plant stanol ester 
consumption. Further validation of these results is warranted, particularly since the effect 
was most pronounced at a higher age, i.e. the target population of plant sterol and plant 
stanol consumption. 
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Introduction
It has unequivocally been established that a daily consumption of plant sterol- and plant 
stanol enriched products reduces fasting serum low-density lipoprotein cholesterol 
(LDL-C) concentrations [1]. Functional foods enriched with plant sterols and plant stanols, 
as part of a healthy diet, have therefore been advocated in the management of mild 
hypercholesterolemia [2, 3]. Except for LDL-C, more recent studies have also suggested 
that plant sterols and plant stanols lower serum triacylglycerol (TAG) concentrations [4, 5]. 
Prospective and case-control studies have identified high fasting serum TAG concentrations 
as an independent risk marker for CVD, which are routinely measured to assess CVD risk 
[6]. However, most people are in a non-fasting state for most part of the day and non-
fasting serum TAG concentrations are an emerging marker contributing to CVD risk due 
to the postprandial atherogenicity of TAG-rich (remnant) lipoprotein particles [6, 7]. 
Indeed, independent of other risk markers, non-fasting TAG concentrations estimated CVD 
risk more precisely than fasting TAG concentrations did [8, 9]. Besides non-fasting TAG 
concentrations, remnant cholesterol (cholesterol present in TAG-rich particles during the 
fasting and non-fasting state) may be an important CVD risk marker [3, 10], illustrating the 
importance of including postprandial lipoprotein metabolism to assess CVD risk. Therefore, 
evaluation of the effects of plant sterol and plant stanol consumption on postprandial lipid 
metabolism is warranted. So far, only three studies have addressed postprandial lipid and 
lipoprotein responses after plant stanol ester intake [11-13], while there are no reports 
on postprandial responses after plant sterol ester intake. Although these three studies 
have their limitations with respect to assessing postprandial responses, they do suggest 
that chronic or acute consumption of plant stanol esters does not affect postprandial lipid 
and lipoprotein concentrations. This is remarkable, since it is generally acknowledged that 
lipoprotein metabolism is affected by plant stanol and sterol ester consumption in fasting 
state through inhibition of intestinal cholesterol absorption [14]. The mechanism underlying 
the reduction in fasting serum TAGs is not known, but was suggested to be due to a reduced 
intestinal fatty acid absorption, at least in mice [15]. This illustrates that there is a need for 
a more detailed knowledge regarding postprandial effects of plant sterol and stanol ester 
consumption on lipoprotein metabolism. Therefore, the objective of the present study was 
to examine the 8-hour postprandial response after consuming plant sterol or plant stanol 
ester enriched margarines as part of a shake. Since the appearance of dietary cholesterol in 
the circulation is delayed [16-18], we decided to provide a second mixed meal after 4 hours. 
This postprandial meal test was performed after completing a 4-week intervention period 
during which subjects consumed plant sterol or plant stanol ester enriched margarine on a 
daily basis. 
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Subjects and Methods
Subjects
Details of the study have been described previously, when the effects of the intervention 
on fasting lipoprotein and oxyphytosterol concentrations were reported [19]. Briefly, 
subjects were recruited in Maastricht and met the following criteria: 18-70 years of 
age; body mass index (BMI) between 20-30 kg/m2; no active cardiovascular disease or 
severe medical period during the past 5 years that might interfere with the study and no 
use of lipid-lowering medication or a medically prescribed diet. In addition, serum total 
cholesterol concentrations were <7.8 mmol/L; serum TAG concentrations <3.0 mmol/L and 
plasma glucose concentrations <6.1 mmol/L, as determined during two screening visits. All 
participants gave their written informed consent before entering the study. The medical 
ethical committee of the Maastricht University Medical Centre+ (MUMC+) had approved 
the protocol and the trial is registered at clinicaltrials.gov as NCT01559428. 
Diet and Design
The complete 20 weeks intervention study was a randomised placebo-controlled crossover 
trial, which consisted of three intervention periods of 4 weeks, separated by washout 
periods of 4 weeks [19]. Subjects replaced their own spread with the test margarine of 
which 20 gram had to be consumed on a daily basis. The margarines provided no, or 3.0 
gram of plant sterols or stanols per day.  At the end of each of the three intervention periods 
a postprandial test was carried out. Subjects were asked not to perform any strenuous 
exercise, not to consume alcohol, and to refrain from high-fat foods on the day prior to the 
postprandial test days. Subjects arrived at the university by public transport or by car after 
a 12-hour overnight fast. An intravenous cannula was placed in an antecubital vein and a 
fasting blood sample was collected (T=0 min). Subjects were then asked to consume the test 
meal within 10 minutes. The test meal was provided as a shake and contained no, or 3.0 
gram of plant sterols or stanols provided as their fatty acid esters, similar to the intervention 
of the preceding 4-week intervention period. This breakfast shake contained 250 mg 
cholesterol and in addition 100.000 IU oil-soluble vitamin A (retinyl palmitate). Subsequent 
blood samples were drawn after 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420 and 480 
minutes. Following the blood sample after 240 minutes (approximately around lunch 
time), subjects received a second meal, which consisted again of a shake. This lunch shake 
contained no cholesterol, no plant sterols or stanols and no vitamin A. The composition of 
the two shakes is shown in Table 6.1. Subjects were not allowed to eat anything else, but 
were allowed to drink water (±500 mL) throughout the entire test day.
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Table 6.1. Composition of the breakfast shakes enriched with plant sterol or stanol esters 
and the lunch shake
Breakfast shake; 
sterol/stanol period
Breakfast shake; 
control period
Lunch shake
Energy (MJ) 3.15 3.14 3.16
Fat (en%) 59.6 59.5 60.1
  SAFA (en%) 24.7 27.8 23.4
  MUFA (en%) 20.9 18.8 22.2
  PUFA (en%) 10.1 9.1 12.2
Protein (en%) 6.2 6.2 4.2
Carbohydrate (en%) 35.2 35.3 36.4
Cholesterol (mg) 250.2 250.2 17.3
Plant sterol or stanol 
esters (g)
3.0 - -
Retinyl palmitate (IU) 100.000 100.000 -
Values are means ± SD. All subjects (n=43) received the three breakfast shakes in random order.
1SAFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, CHO: 
carbohydrates
Blood sampling and analyses
A clotting tube and a sodium fluoride (NaF) tube (Becton, Dickinson and Company, Franklin 
Lakes, NY, USA) were sampled at each time point. Serum was obtained from the clotting 
tube by low-speed centrifugation at 1300x g for 15 min at room temperature, at least half an 
hour after venipuncture and was used for the analysis of TAG, apolipoprotein (apo) B48 and 
insulin concentrations. Plasma was obtained by low-speed centrifugation of the NaF tube 
at 1300x g for 15 min at 4 ºC and was used for the analysis of plasma glucose and retinyl 
palmitate (RP) concentrations. All serum and plasma samples were snap frozen in liquid 
nitrogen and stored at −80 °C until analysis.
Plasma glucose concentrations (Roche Diagnostic Systems, Hoffmann-La Roche) and serum 
TAG concentrations (GPO Trinder; Sigma-Aldrich) with correction for free glycerol were 
measured at baseline and after 15, 30, 45, 60 and 90 minutes, and at hourly intervals up 
to 8 hours. Serum insulin concentrations were measured at baseline and after 30, 45, 60 
and 90 minutes and at hourly intervals up to 8 hours with a human insulin-specific RIA kit 
(Linco Research). Serum apoB48 concentrations were measured at baseline and after 30 
minutes and at hourly intervals up to 8 hours with an ELISA kit (Shibayagi). Retinyl palmitate 
concentrations were measured at baseline and after 15, 30, 45, 60 and 90 minutes and at 
hourly intervals up to 8 hours with high-performance liquid chromatography in a randomly 
selected subgroup of 13 subjects (4 men, 9 women). All samples from one subject were 
analysed within one run at the end of the study.
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Statistics
All data are presented as means ± standard deviations (SD). To evaluate the overall 
postprandial responses, the incremental areas under the curve (iAUC) were calculated using 
the trapezoidal rule. We assessed the total postprandial response (0-8 hours), as well as the 
first meal response (0-4 hours) and second meal response (4-8 hours). Maximal changes were 
calculated by subtracting fasting concentrations (T=0) from the maximal concentrations. 
Differences in fasting concentrations, iAUC and maximal changes between the test meals 
were statistically evaluated by repeated-measures analysis of variance (ANOVA) with diet as 
within subject factor. We also evaluated whether the observed postprandial changes were 
dependent on gender, body mass index (BMI) or age. There were, however, no gender or 
BMI effects present. The interaction term diet*age was significant for TAG iAUC (total and 2nd 
meal responses), for glucose iAUC (total response), but not for apoB48 iAUC. This indicated 
that dietary effects were influenced by age and diet effects were therefore further evaluated 
per age category (category I: 18-35y (n=17), category II: 36-52y (n=11) and category III: 53-
69y (n=14)). Results were considered to be statistically significant if p < 0.05. All statistical 
analyses were performed using SPSS 18.0 for Mac Os X and adjusted for Bonferroni’s 
correction for multiple comparisons when appropriate (SPSS Inc., Chicago, IL, USA). 
Results 
The study was completed by 43 subjects [19]. However, for one woman it was not possible 
to insert the cannula and results of the present postprandial study therefore refer to 42 
subjects  (Table 6.2). 
Table 6.2. Characteristics of the subjects 
All subjects
18-69y (n=42)
Age category I
18-35y (n=17)
Age category II
36-52y (n=11)
Age category III
53-69y (n=14)
Age (y) 42 ± 18 23 ± 4 46 ± 4 62 ± 4
Male / female (n) 17 / 25 5 / 12 4 / 7 8 / 6
Weight (kg) 73.5 ± 11.3 73.0 ± 11.4 68.5 ± 12.6 78.2 ± 8.8
Height (m) 1.72 ± 0.09 1.74 ± 0.10 1.69 ± 0.11 1.73 ± 0.06
BMI (kg/m2) 24.7 ± 2.8 24.1 ± 2.3 23.9 ± 3.1 26.1 ± 2.7
Glucose (mmol/L) 5.26 ± 0.55 4.82 ± 0.23 5.42 ± 0.361 5.66 ± 0.581
TCH (mmol/L) 5.73 ± 1.13 5.09 ± 0.95 5.62 ± 1.15 6.60 ± 0.741,3
HDL-C (mmol/L) 1.69 ± 0.38 1.64 ± 0.36 1.81 ± 0.39 1.66 ± 0.39
TC/HDL ratio 3.52 ± 1.03 3.22 ± 0.90 3.16 ± 0.70 4.19 ± 1.112,3
TAG (mmol/L) 1.13 ± 0.46 1.15 ± 0.50 1.13 ± 0.49 1.09 ± 0.41
Values are means ± SD
Significantly different compared with age category I 1(p<0.01), 2(p<0.05)
Significantly different compared with age category II 3(p<0.05)
93
PHYTOSTEROL CONSUMPTION & POSTPRANDIAL METABOLISM
Postprandial lipemia
Fasting serum TAG and apoB48 concentrations were not different after the three intervention 
periods. The postprandial responses in serum TAG concentrations are presented in Figure 
6.1 and Table 6.3. Serum TAG concentrations gradually increased after consumption of 
the first meal to peak at 3-4 hours. A second peak was observed already one hour after 
consumption of the second meal (after 5 hours). The TAG iAUC of the total TAG response 
(iAUCT) and after the 1st meal (iAUC1) and 2nd meal (iAUC2) were comparable between the 
test meals in the first age category (18-35 y). In the second age category (36-52 y), iAUCT and 
iAUC1 were comparable between the test meals, but there was a trend for a higher iAUC2 
in the stanol period as compared with the sterol period (difference of 46.8 ± 58.8 mmol/L/
min; p=0.07). In the third age category (53-69 y), iAUCT and iAUC1 were again comparable 
between the test meals, but there was a significantly higher iAUC2 in the stanol period as 
compared with the sterol period (63.1 ± 53.0 mmol/L/min; p<0.01) and the control period 
(43.2 ± 52.4 mmol/L/min; p<0.05). 
Age was positively correlated with iAUCT in all three intervention periods (control: r=0.47; 
p<0.01, sterol: r=0.44; p<0.01, stanol: r=0.56; p<0.01), while the correlation between age and 
iAUC2 was only significant in the stanol period (r=0.57; p<0.01). The maximal TAG (maxTAG) 
concentration increased with age in all three periods (control: r=0.49; p<0.01, sterol: r=0.36; 
p<0.05, stanol: r=0.45; p<0.01). In addition, there was a trend towards a higher maxTAG 
after stanol consumption compared with sterol consumption in age category II (0.60 ± 0.74; 
mmol/L; p=0.07). 
The postprandial responses in serum apoB48 concentrations are presented in Figure 2 
and Table 4. Interestingly, serum apoB48 concentrations displayed a much earlier peak 
(60 minutes-3 hours) after the first meal as compared with the TAG response (3-4 hours). 
Another clear difference is that the time-to-peak after the second meal was delayed from the 
younger to the older age categories (i.e. from 5 hours to 6 hours after meal ingestion), which 
was not seen in the postprandial TAG response. ApoB48 iAUCT and iAUC1 were comparable 
between the three test meals in all age categories. The apoB48 iAUC2 was comparable in 
the first two age categories, but in age category III the iAUC2 after stanol consumption was 
increased as compared with the sterol period (67.1 ± 77.0 mg/L/min; p<0.05) and tended 
to be higher iAUC2 after stanol consumption compared with the control period (43.1 ± 64.5 
mg/L/min; p=0.08). 
Age was positively correlated with iAUCT in the stanol period (r=0.47; p<0.01) and with 
iAUC2 in the control and stanol period (r=0.32; p<0.05 and r=0.43; p<0.01, respectively). 
The maximal apoB48 (maxApoB48) concentration correlated with age in the stanol period 
(r=0.43; p<0.01), but not in the sterol and control period. In addition, there was a trend 
towards a higher maxApoB48 after stanol consumption compared with the control period in 
age category III (2.9 ± 4.2 mg/L; p=0.07).  
Retinyl palmitate was incorporated only in the breakfast shake and appearance in the 
circulation provides information about the lipid content of the chylomicron fraction, 
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whereas apoB48 provides information about the number of particles [20, 21]. Postprandial 
plasma retinyl palmitate concentrations (shown in Figure 6.3, panel A) were determined in 
13 subjects and the curve closely resembled the serum TAG curve, showing a first meal peak 
between 3-4 hours and a second meal peak one hour after consuming the lunch shake. Due 
to the smaller sample size (n=13 instead of n=42), no statistical analyses in age subgroups 
were performed on the retinyl palmitate data. Changes in postprandial TAG concentrations 
always consist of a combined effect of changes in chylomicron and very low-density 
lipoprotein (VLDL) particle numbers and composition. 
Figure 6.1. Serum triglyceride concentrations in (A) age category I: 18-35 years, (B) age category II: 36-52 years, (C) 
age category III: 53-69 years after consumption of a mixed meal containing no, or 3.0 gram of plant sterols or plant 
stanols. Inserts show second meal response (4-8 hours). Data are presented as mean ± SEM.  
B: trend different iAUC2 between stanol and sterol period *(p=0.07) 
C: significantly different iAUC2 between stanol and control period #(p<0.05) and stanol and sterol period **(p<0.01)
To visualize the postprandial lipid response of the first 4 hours, we plotted retinyl palmitate 
concentrations as ratio over serum apoB48 concentrations (Figure 6.3, panel B), which gives 
information about the amount of TAG derived from the diet as compared to chylomicron 
particles in the circulation and specifically provides information about the lipid content of 
chylomicrons, e.g. their size [22].  Figures 2A-C show increases in apoB48 concentrations up 
to 60 minutes, after which concentrations remain relatively stable up to 4 hours, indicating 
that production rate of chylomicrons equals their clearance rate. 
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Figure 6.2. Serum apoB48 concentrations in (A) age category I: 18-35 years, (B) age category II: 36-52 years, (C) 
age category III: 53-69 years after consumption of a mixed meal containing no, or 3.0 gram of plant sterols or plant 
stanols. Inserts show second meal response (4-8 hours). Data are presented as mean ± SEM.  
C: significantly different iAUC2 between stanol and sterol period *(p<0.05) and trend different iAUC2 between stanol 
and control period #(p=0.08)
This observation combined with Figure 3B, shows that TAG-poor chylomicrons are produced 
during the first hour, after which the dietary TAG content of chylomicrons (e.g. size) increases 
up to 4 hours. No diet effects were observed for RP/ApoB48 ratios. Due to the smaller sample 
size, no statistical analyses in age subgroups were performed.
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Postprandial glycaemia
Fasting glucose and insulin concentrations were comparable between the three test 
days. Postprandial plasma glucose concentrations increased during the first 30 min after 
consumption of the first meal, returned to baseline after 60 min and remained below 
baseline till consumption of the second meal (Figure 6.4). Plasma glucose concentrations 
were maximally increased one hour after consumption of the second meal. Glucose iAUCT 
was higher in the stanol period compared with the sterol period in age category I (229.4 
± 108.1 vs. 168.5 ± 106.4 mmol/L/min; p<0.05; data not shown). Postprandial glucose 
responses did not differ between the test meals in age category II and III. Serum insulin 
concentrations were maximally increased 30 min after first meal consumption and returned 
to baseline concentrations after 180 min. A second (smaller) peak was observed after 
consumption of the second meal. No diet effects were observed for postprandial insulin 
responses in all subjects or in the different age categories. 
Figure 6.3. (A) Plasma retinyl palmitate concentrations and (B) ratio retinyl palmitate/apoB48 (n=13) after 
consumption of a mixed meal containing no, or 3.0 gram of plant sterols or plant stanols. Insert shows second meal 
response (4-8 hours). Data are presented as mean ± SEM.
Figure 6.4. (A) Plasma glucose and (B) insulin concentrations (n=42) after consumption of a mixed meal containing 
no, or 3.0 gram of plant sterols or plant stanols. Data are presented as mean ± SEM.  
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Discussion
In this randomised controlled trial, we found an increased TAG and apoB48 second meal 
response in subjects aged between 53 and 69 years after consuming a mixed meal enriched 
with plant stanol esters as compared to a mixed meal with or without plant sterol esters. 
The LDL-C lowering effect of plant sterol and plant stanols is well known, but recent 
studies have suggested that plant sterol and plant stanol esters also reduce fasting TAG 
concentrations [1, 5] by a so far unknown mechanism. Although fasting and postprandial 
TAG concentrations are positively associated with CVD risk [7-9], only three studies so far 
have addressed the postprandial effects of foods enriched with plant stanol esters on lipid 
and lipoprotein metabolism. Relas et al. performed two postprandial mixed meal studies 
enriched with plant stanol esters: a 24-hour study with 3.0g of plant stanol esters after a 
2-week intervention period and an acute study with 1.0g of plant stanol esters [12, 13]. 
In both studies, the addition of plant stanol esters to a high-fat breakfast did not affect 
postprandial cholesterol and TAG concentrations in serum or in lipoprotein fractions. Gylling 
et al. provided a low-fat breakfast containing 4.5g of plant stanol esters after a 10-week 
intervention period (daily intake 8.8g of plant stanol esters) [11]. Unfortunately, changes 
in serum TAG and apoB48 concentrations were not determined in that study. The different 
postprandial study designs complicates the comparison to our study, especially because we 
found that plant stanol esters affect the second meal TAG and apoB48 response by using a 
sequential meal protocol with regular blood sampling. We demonstrated that the iAUC for 
TAG and apoB48 responses were similar after the first meal, while these responses were 
increased after consumption of the second meal in the plant stanol period. This effect was 
stronger with increasing age and more evident compared to the sterol period than to the 
control period. The second meal response predominantly addresses a potential change in 
TAG clearance [23, 24] and suggests that postprandial TAG and chylomicron particle clearance 
are less efficient after plant stanol consumption. LPL may play a crucial role in this respect. 
After plant stanol consumption, plasma plant sterol concentrations decrease [25], which 
may offer an explanation for the delay in TAG clearance. Theoretically, LPL activity might be 
decreased by reduced plant sterol concentrations through several mechanisms. LPL activity 
is regulated at the level of gene transcription by peroxisome proliferator activated receptor 
(PPAR)-α and –γ. Although studies on the effects of plant sterols and stanols on PPAR is 
scarce, a study performed in mice reported reduced plasma and hepatic TAG concentrations 
in response to plant sterol consumption with an unexpected reduction in intestinal PPARα 
mRNA expression and no change in hepatic PPARα mRNA expression [15]. Plat et al. found 
in peripheral mononuclear blood cells from metabolic syndrome patients after plant stanol 
consumption, no change in PPARα or liver X receptor (LXR) expression, although serum TAG 
concentrations were reduced [26]. Future studies are needed to elucidate whether changes 
in local PPAR expression in for example adipose and/or skeletal muscle might play a role 
in LPL modulation after plant sterol or stanol consumption. Also, other modulators of LPL 
activity, such as apoCII and apoCIII could have been affected by a change in plant sterol 
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concentrations and would definitely be interesting for future research. Another explanation 
for the second meal effect after plant stanol ester consumption might be found in changed 
oxyphytosterol concentrations (oxidized plant sterols). We have already reported that plant 
stanol consumption reduced fasting oxyphytosterol concentrations [19]. Oxysterols (oxidized 
cholesterol) are natural ligands of LXR, which in turn induce LPL expression. There are some 
suggestions that oxyphytosterols also activate LXR, which could lead to an induction of LPL 
expression. If so, a positive effect of oxyphytosterols on LPL activity might be lost after plant 
stanol consumption, which could have resulted in decreased TAG clearance. 
The increase in TAG concentrations after consumption of a second meal seems to contradict 
recent findings of reduced fasting TAGs concentrations after plant stanol consumption [4, 
5]. However, reductions in fasting TAG concentrations were only observed in subjects with 
elevated fasting TAG concentrations and there is no data describing the effect of plant 
sterol and plant stanol consumption on postprandial responses in these populations. In the 
present study in apparently healthy, slightly hypercholesterolemic, normotriglyceridemic 
subjects, no effects of plant sterol and stanol esters on fasting TAGs were found [19], while 
postprandial TAG and apoB48 responses were increased in the plant stanol ester group. 
For now, it remains speculative whether the same observation on postprandial TAGs 
would have been found in a population with elevated fasting TAGs. It should however be 
noted that the observed plant stanol effect after consumption of a second meal was only 
present in older subjects, which may form a relatively large part of the target population 
for the consumption of plant sterol and plant stanol enriched products i.e. subjects with 
mild hypercholesterolemia (consensus paper). As reported before, non-fasting TAG 
concentrations are an emerging CVD risk marker and these findings need to be confirmed 
and evaluated into more detail. 
This study also addresses the difference in conclusions that could be made after single meal 
consumption or after including a second meal, which highlights the metabolic consequences 
of sequential meal consumption in general. Unfortunately, different postprandial lipoprotein 
fractions were not collected in this study, but the addition of RP to the first breakfast meal 
gives us some opportunity to speculate concerning the postprandial lipemic response. 
After absorption, RP associates with chylomicrons and their remnants until taken up - 
without being re-secreted - by the liver, providing information regarding the lipid content 
of chylomicrons [21, 27]. In contrast, apoB48 concentrations provide information regarding 
the number of chylomicron particles [20]. Even though RP has several drawbacks, i.e. mainly 
accurate in early postprandial period (0-9h) [21], it provides clear evidence for a second meal 
effect. The fact that a RP peak is seen one hour after consumption of the lunch shake (while 
no RP was present in the lunch shake), indicates that this second meal induced chylomicron 
appearance containing fat from the previous breakfast shake. This illustrates the importance 
of choosing the appropriate study design to address a certain research question, especially 
when investigating nutritional effects on postprandial lipid responses. The postprandial 
response after the first meal shows a discrepancy between TAG and apoB48 concentrations, 
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i.e. an earlier rise and decrease to baseline in apoB48 concentrations as compared to TAG 
concentrations. By calculating ratios of dietary TAG concentrations to apoB48 concentrations, 
we have proposed that TAG-enrichment of chylomicrons continues to increase up to 4 
hours without a concomitant increase in apoB48 concentrations after the first hour. This 
suggests that more TAG-rich chylomicrons are produced and our proposed ratios are in line 
with literature, which states that dietary lipid transport following a meal is mainly through 
increased chylomicron particle size with a relatively lesser increase in particle numbers, i.e. 
an increase in lipid content per chylomicron [28]. 
In conclusion, this study demonstrates an age-dependent increase in the postprandial 
TAG and apoB48 response after plant stanol ester consumption as part of a mixed meal, 
compared to a control meal and to a meal enriched in plant sterol esters. Further research 
is warranted to validate these results. Also, the mechanism by which plant sterols and plant 
stanols exert different effects on postprandial lipemic responses needs to be investigated, 
whether this observation maintains in subjects with elevated fasting TAGs, and if these effects 
have health consequences. In addition, our findings highlight the impact of sequential meal 
consumption as it provides more detailed information on postprandial lipid and lipoprotein 
responses. 
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Abstract
Consumption of plant sterol enriched products increases serum plant sterol concentrations. 
Plant sterols can be oxidized and form oxyphytosterols (plant sterol oxidation products). We 
have previously shown that fasting oxyphytosterol concentrations are not increased when 
healthy subjects consumed a plant sterol or a plant stanol enriched margarine (3.0 g/d of 
plant sterols or stanols) for 4 weeks. Now we have examined the effects of 4 weeks vitamin E 
or lipoic acid supplementation on fasting plasma oxyphytosterol concentrations in subjects 
with impaired glucose tolerance (IGT) or type II diabetes. For this, 20 subjects with IGT or type 
II diabetes consumed for 4 weeks in a random order placebo capsules, vitamin E capsules 
(804 mg/d) or lipoic acid capsules (600 mg/d). Plasma oxyphytosterol and oxycholesterol 
concentrations were determined in butylated hydroxytoluene (BHT)-enriched EDTA plasma 
via GC-MS. In addition, markers reflecting oxidative stress (oxidized LDL levels and MDA 
concentrations) and antioxidant capacity (TEAC assay, uric acid concentrations and GSH/
GSSG) were also measured. 
Oxyphytosterol concentrations were higher in subjects with IGT or type II diabetes as 
compared to concentrations in healthy subjects. Despite these higher values, plasma 
oxyphytosterol and oxycholesterol were not reduced after consumption of vitamin E or 
lipoic acid for 4 weeks. In addition, none of the other markers reflecting oxidative stress and 
anti-oxidative capacity were changed after consuming high-doses of these two antioxidants 
for 4 weeks. In conclusion, we demonstrated that the higher oxyphytosterol concentrations 
in subjects with impaired glucose tolerance or type II diabetes are not reduced by vitamin E 
and lipoic acid supplementation. 
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Introduction
Consumption of plant sterol enriched products reduces fasting serum low-density lipoprotein 
cholesterol (LDL-C) concentrations. However, as shown by a recent meta-analysis, at the 
same time serum concentrations of sitosterol increases by 31% [CI: 26-37%] and those of 
campesterol by 37% [CI: 29-45] at recommended intakes of 1.6 g/d [1]. Whether these 
increased plant sterol concentrations have an impact on CVD risk has been subject of debate 
for many years now, as epidemiological studies have reported contradictive findings [2, 3]. 
Previously, we have postulated that this controversy might relate to the fact whether plant 
sterols are oxidized or not [4]. Cholesterol and plant sterols share structural similarities 
and can therefore both be oxidized to form either oxycholesterols (cholesterol oxidation 
products) or oxyphytosterols (plant sterol oxidation products) [5]. While oxycholesterol 
concentrations have been characterised as an oxidative stress marker [6], information 
regarding oxyphytosterol metabolism and their health effects in humans is scarce. In fact, 
there is a clear lack of knowledge regarding absorption, endogenous formation via (ROS-
mediated) oxidation of circulating plant sterols, and potential effects of other dietary 
components on circulating serum oxyphytosterol concentrations. We have previously shown 
that increased dietary plant sterol consumption did not change fasting oxyphytosterol 
concentrations, despite elevated fasting plant sterol concentrations. However, postprandial 
oxyphytosterol concentrations increased after consumption of a high-fat meal enriched with 
plant sterol esters [7]. Information of dietary antioxidant supplementation on circulating 
oxyphytosterol concentrations in metabolically stressed subjects would expand our 
knowledge on oxyphytosterol metabolism in humans. Therefore, the objective of this study 
was to examine changes in plasma oxyphytosterol concentrations after 4 weeks vitamin 
E or lipoic acid supplementation in subjects with impaired glucose tolerance or diabetes 
type II (DMII), who are characterized by increased oxidative stress. These two antioxidants 
were chosen since vitamin E is a typical fat-soluble antioxidant, while lipoic acid is a fat- and 
water-soluble antioxidant and both vitamin E and lipoic have been show to reduce oxidative 
markers in type II diabetics.
Subjects and Methods
Subjects 
The study population consisted of 20 men and women with impaired glucose tolerance 
(IGT) or type II diabetes. They were recruited via announcements in local newspapers in 
Maastricht and surroundings between October 2012 and March 2013. Subjects were invited 
for two screening visits if they met the following criteria: aged between 18 and 75 years, 
BMI between 20 and 35 kg/m2, no active cardiovascular disease or severe medical condition 
that might interfere with the study and no use of insulin or lipid-lowering medication. 
During screening visits, weight and height were measured and a fasting blood sample was 
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drawn to determine lipid and lipoprotein concentrations. The diagnosis of type II diabetes 
or IGT was based on the use of oral hypoglycemic agents or an oral glucose tolerance test. 
Only subjects without diagnosed diabetes underwent an oral glucose tolerance test to verify 
potential presence of impaired glucose tolerance. For this, subject consumed 82.5 gram of 
dextrose monohydrate dissolved in 250 mL of tap water and plasma glucose concentrations 
were measured after 2 hours with an value between 7.8 -11.1 mmol/L defined as having 
IGT [8]. Twenty subjects of which 8 subjects with type II diabetes and 12 subjects with IGT 
were enrolled and completed the study. Baseline characteristics are shown in Table 7.1. 
All participants gave written informed consent before entering the study. The protocol was 
approved by the medical ethical committee of the Maastricht University Medical Centre+ 
(MUMC+) and the trial is registered at clinicaltrials.gov as NCT01984567.
Table 7.1. Baseline characteristics 
Age (years) 63.1 ± 5.8
Male / Female (n) 16 / 4
Weight (kg) 90.1 ± 13.6
Height (m) 1.75 ± 0.1
BMI (kg/m2) 29.5 ± 3.7
Total cholesterol (mmol/L) 5.3 ± 0.9
Diets and design
The study had a randomised placebo-controlled cross-over design and consisted of three 
intervention periods of 4 weeks, separated by washout periods of 4 weeks. Subjects were 
allocated to the intervention periods in a randomised order, based upon a computer-
generated table with random numbers. During each period, subjects were asked to 
consume daily either three placebo capsules, three capsules containing R-vitamin E (268 
mg three times; 804 mg a day) or three capsules containing R-lipoic acid (200 mg three 
times; 600 mg a day). They were instructed to consume one capsule during each meal with 
a glass of water. Subjects visited the university at the start of each period, and again after 
3 and 4 weeks of intervention. They were provided with at least the amount of capsules 
needed for 4 weeks and excess capsules were returned at the end of each intervention 
period. Subjects completed a validated food frequency questionnaire (FFQ) at the end of 
each intervention periods and a dietician checked these questionnaires to calculate energy 
and nutrient intakes over the previous 4 weeks using the Dutch food composition table. 
Subjects were asked not to change their habitual diet, level of physical exercise or use of 
alcohol throughout the three intervention periods in the study.
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Blood sampling
Blood was sampled after an overnight fast at the start of each intervention period and after 3 
and 4 weeks of intervention. The same person performed all venipunctures at approximately 
the same time of the day at the same day of the week. 
A clotting tube (Becton, Dickinson and Company, Franklin Lakes, NY, USA) was sampled at 
each occasion and serum was obtained by low-speed centrifugation at 1300 g for 15 min 
at room temperature, at least half an hour after venipuncture. Serum was stored at -80 ºC 
and used for analysis of lipid and (apo)lipoprotein concentrations, hsCRP concentrations, 
iron status parameters (total iron, ferritin and transferrin), copper status parameters (i.e. 
copper and ceruloplasmin), inflammatory markers and cellular adhesion molecules. EDTA 
tubes (Becton, Dickinson and Company, Franklin Lakes, NY, USA) were sampled at the end 
of each period in weeks 3 and 4 and plasma was obtained by low-speed centrifugation at 
1300 g for 15 min at 4 ºC. To avoid auto-oxidation, 10 ml butylated hydroxytoluene (BHT; 
25 mg/mL ethanol) was added per 1 mL of EDTA plasma, immediately after centrifugation 
and then stored at -80 ºC. BHT-enriched plasma was used for analysis of oxyphytosterol, 
oxycholesterol, oxidized LDL and malondialdehyde (MDA) concentrations. Fresh whole EDTA 
blood was sampled in week 4 and was used for the isolation of red blood cells (RBCs) as 
described previously [9]. BHT was added to the RBC and PBMC fraction, stored at -80 ºC 
and used for the analysis of oxyphytosterol and oxysterol concentrations. Heparin tubes 
(Becton, Dickinson and Company, Franklin Lakes, NY, USA) were also sampled in week 4 
and plasma was obtained by low-speed centrifugation at 1300 g for 15 min at 4 ºC. Heparin 
plasma was used for the analyses of the trolox equivalent antioxidant capacity (TEAC) assay 
and uric acid concentrations. For this, 10% TCA was added to the plasma (1:1) followed 
by centrifugation (13.000 rpm, 5 min at 4 ºC). Whole heparin blood was sampled in week 
4 and 1.3% 5-Sulfosalicylic Acid (SSA) in 10 mM HCL was added for the analysis of GSH/
GSSG. Fresh whole heparin blood was used for the analysis of HbA1c concentrations. An 
Acid Citrate Dextrose (ACD) tube was sampled at the end of each period and was used for 
the isolation of blood platelets. BHT was added to the platelets fraction, stored at -80 ºC and 
used for the analysis of oxyphytosterol and oxycholesterol concentrations. A NaF tube was 
sampled at the end of each period and plasma was obtained by low-speed centrifugation at 
1300 g for 15 min at 4 ºC. NaF plasma was stored at -80 ºC and was used for the analysis of 
glucose concentrations. 
Analyses
Total cholesterol (CHOD-PAP method; Roche Diagnostic, Mannheim, Germany), high-
density lipoprotein cholesterol (HDL-C) (CHOD-PAP method; Roche Diagnostics, Mannheim, 
Germany) after precipitation of apoB-containing lipoproteins with phosphotungstic acid and 
magnesium ions, and triacylglycerol (TAG) concentrations, with correction for free glycerol, 
were analysed in serum enzymatically (GPO-Trinder; Sigma-Aldrich Corp., St. Louis, MO, 
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USA). LDL-C concentrations were calculated according to the Friedewald equation [10]. 
Apolipoprotein concentrations (apoA1 and apoB100) were analysed using highly sensitive 
immunoturbidimetric assays (Horiba ABX, Montpellier, France). Serum hs-CRP concentrations 
(Kamiya Biomedical Company, Seattle, USA) and glucose concentrations (Roche Diagnostics 
Systems, Hoffmann-La Roche Ltd., Basel, Switzerland) were also analysed enzymatically. All 
samples from one subject were analysed within one run at the end of the study. Glycated 
haemoglobin (HbA1c) was measured by high-pressure liquid chromatography (HPLC) (Bio-
Rad variant II, Bio-Rad Laboratories, Inc.). Sitosterol and campesterol concentrations were 
analysed using liquid chromatography-flame ion detection (LC-FID) as described previously 
[11]. Concentrations are expressed as mg/dL and as 102 μmol/mmol total cholesterol. 
Oxyphytosterol concentrations (7α-hydroxy(OH)-campesterol, 7α-OH-sitosterol, 7β-OH-
campesterol, 7β-OH-sitosterol, 7-keto-campesterol and 7-keto-sitosterol) and oxycholesterol 
concentrations (7α-OH-cholesterol, 7β-OH-cholesterol and 7-keto-cholesterol) in plasma as 
well as in RBC ‘s, PBMC’s and platelets were analysed by gas-liquid chromatography-mass 
spectroscopy (GC-MS) according to the procedure as described by Husche et al [12] and 
expressed as ng/mL, ng/mg or as pg/mg. Oxycholesterol and oxyphytosterol concentrations 
in plasma were also standardized for cholesterol concentrations and expressed as nmol/
mmol cholesterol. Oxidized LDL (oxLDL) was measured by chemiluminescent ELISA by 
determining the content of oxidized phospholipids per particle of apoB100 (oxidized 
phospholipids:apoB100 ratio) as described elsewhere [13]. Iron and copper status 
parameters were analysed as previously described [29]. MDA concentrations (oxidative 
stress marker), trolox equivalent, GSH/GSSG and uric acid concentrations (antioxidative 
markers) were analysed as previously described [14, 15]. Plasma inflammatory markers 
(Il-6 and TNFα), cellular adhesion molecules (E-selectin, P-selectin, soluble (s) ICAM-1, 
sICAM-3 and sVCAM-1), thrombomodulin and serum amyloid A (SAA) were measured with 
a commercially available Multi Spot ELISA kit (Meso Scale Discovery). Fibroblast Growth 
Factor 21 (FGF-21) and 19 (FGF-19) concentrations were measured with a single spot ELISA 
kit (R&D systems). All analyses were performed in samples from week 4, except for lipid, 
(apo)lipoprotein and hsCRP concentrations which were measured in weeks 3 and 4 and 
averaged for data analysis. 
Statistics
Effects of vitamin E and lipoic acid supplementation were evaluated by a univariate analysis 
of variance (ANOVA) with subject number as a random factor. When dietary effects 
reached statistical significance (p<0.05), diets were compared pairwise using a Bonferroni’s 
correction. Oxyphytosterol and oxycholesterol levels in RBC, PBMC and blood platelet 
fraction were not normally distributed and were therefore reported as medians with ranges 
and differences between treatments were evaluated by a Friedman’s test. Oxyphytosterol 
concentrations in healthy subjects were measured in our previous study using exactly the 
111
ANTIOXIDANT CONSUMPTION, DIABETIC SUBJECTS & FASTING OXYPHYTOSTEROLS
same method [4] and compared to those of subjects with IGT or type II diabetes by an 
unpaired Student’s T-test. All statistical analyses were performed using SPSS 20.0 for Mac 
Os X (SPSS Inc., Chicago, IL, USA).
Results
Average daily intakes of energy, fibre, and cholesterol, and the proportions of energy from 
protein, carbohydrates, total fat, saturated fatty acids, monounsaturated fatty acids, and 
polyunsaturated fatty acids, and habitual vitamin E intake as calculated from the FFQ’s did 
not differ between the three intervention periods (Table 7.2).
Table 7.2. Daily dietary intake during the study 
Control period Vitamin E period Lipoic acid period
Energy (MJ) 8.3 ± 2.8 8.3 ± 2.3 8.3 ± 2.3
Fat (energy%)
  SAFAa
  MUFAa
  PUFAa
38.2 ± 7.4
11.8 ± 3.1
13.6 ± 2.9
9.0 ± 3.8
37.0 ± 6.5
11.6 ± 2.3
13.4 ± 3.2
8.4 ± 2.6
36.7 ± 6.7
12.1 ± 2.9
12.8 ± 3.2
8.3 ± 2.9
Protein (energy%) 16.4 ± 4.1 16.4 ± 3.4 16.1 ± 2.9
CHOa (energy%) 41.0 ± 5.7 42.3 ± 6.4 42.8 ± 6.1
Alcohol (energy%) 1.9 ± 2.7 1.8 ± 2.3 1.7 ± 2.4
Fibre (g/day) 23.4 ± 10.0 24.1 ± 5.6 24.2 ± 6.0
Cholesterol (mg/day) 204 ± 66 201 ± 56 196 ± 64
Vitamin E (mg/day)b 13.9 ± 7.4 13.2 ± 5.3 13.1 ± 5.5
Values are means ± S.D. All subjects (n=20) received the three dietary periods in random order.
a SAFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, CHO: 
carbohydrates
b dietary vitamin E intake without capsule supplementation  
Fasting oxyphytosterol concentrations after the control period in subjects with IGT or type II 
diabetes were compared with those from a previous study with healthy subjects during the 
control period [4]. Oxyphytosterol concentrations were comparable between subjects with 
IGT and type II diabetes. Figure 7.1 shows that 7α-OH-campesterol and 7α-OH-sitosterol 
were significantly higher in subjects with IGT or type II diabetes compared with healthy 
subjects (p<0.001). 7β-OH-campesterol concentrations were comparable between the 
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two populations, while 7β-OH-sitosterol concentrations were higher in subjects with IGT 
or type II diabetes compared with healthy subjects (p<0.001). Concentrations of 7-keto-
campesterol and 7-keto-sitosterol were also significantly higher in subjects with IGT or type 
II diabetes compared with healthy subjects (p<0.001). Thus, these findings suggest that IGT 
and diabetic patients had increased oxidative stress. 
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Figure 7.1. Fasting plasma oxyphytosterol concentrations after a control period in healthy subjects and subjects 
with IGT or type II diabetes (*p<0.001)
Fasting oxyphytosterol and oxycholesterol levels in plasma, RBC’s, and platelets in subjects 
with IGT or type II diabetes are shown in Table 7.3. In PBMC’s, oxyphytosterol levels were 
below the detection limit. Plasma 7α-OH-, 7β-OH- and 7-keto-cholesterol, -campesterol and 
-sitosterol concentrations were comparable in the vitamin E, lipoic acid and control periods. 
Cholesterol-standardized oxyphytosterol and oxycholesterol levels showed similar results. 
In RBC’s, oxycholesterol concentrations were comparable during the vitamin E, lipoic acid 
and control periods. For the oxyphytosterols, 7-keto-campesterol median levels were lower 
in the vitamin E period as compared to the control period (37 [23-87] pg/mg and 51 [31-331] 
pg/mg respectively; p<0.05), while the other oxyphytosterol isoforms were comparable at 
the end of the three periods. In blood platelets, 7α-OH-, 7β-OH- and 7-keto-cholesterol, 
-campesterol and -sitosterol levels were comparable in the vitamin E, lipoic acid and control 
periods. In the PBMC fraction, 7β-OH-cholesterol median levels were higher in the vitamin 
E period compared to the control period (223 [2-9925] pg/mg and 174 [22-16997] pg/mg 
respectively; p<0.05) while the other cholesterol oxidation levels were comparable in the 
vitamin E, lipoic acid and control periods. 
Serum total cholesterol concentrations were 0.26 ± 0.35 mmol/L higher at the end of 
the vitamin E period (4.9%; p<0.05) as compared with the lipoic acid period and 0.23 ± 
0.44 mmol/l (4.2%; p<0.05) higher as compared with the control period. This was also 
reflected in the total cholesterol/HDL cholesterol ratio, which was increased in the vitamin 
E period by 0.27 ± 0.40 (5.6%; p<0.01) compared with the control period, while there was 
a trend towards reduction in the lipoic acid period (-4.4%; p=0.06). Also serum apoB100 
concentrations were higher in the vitamin E period compared with the lipoic acid (0.05 ± 
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0.08 g/L; p<0.05) and control periods (0.07 ± 0.10 g/L p<0.01). Finally, apoA1 concentrations 
were also increased in the vitamin E period compared with lipoic acid (0.06 ± 0.08 g/L; 
p<0.01) and control periods (0.05 ± 0.09 g/L; p<0.05). No differences were found in serum 
TAG and HDL-C concentrations between the three periods.
Table 7.4 shows markers reflecting oxidative stress and antioxidative capacity. Oxidized LDL 
levels and MDA concentrations, which are both markers of oxidative stress, were comparable 
at the end of the three intervention periods. 
In addition, parameters reflecting antioxidative capacity did not differ between the vitamin 
E, lipoic acid and control periods. Also plasma cytokines, cellular adhesion molecules, and 
iron and copper status were comparable between the three periods (Table 7.5). 
Plasma glucose, HbA1c, FGF-19, FGF-21, serum plant sterols and lathosterol and cholestanol 
concentrations were comparable between the vitamin E, lipoic acid and control periods 
(Table 7.6). 
Correlations
In the control period, positive correlations were found between plasma 7α-OH-campesterol 
and 7α-OH-sitosterol concentrations (r=0.845; p<0.001), between 7β-OH-cholesterol and 
7β-OH-sitosterol concentrations (r=0.625; p<0.01), and between 7-keto-campesterol and 
7-keto-sitosterol concentrations (r=0.902; p<0.001). Although plasma concentrations 
between the different oxyphytosterol isoforms also correlated significantly, correlations were 
less strong than between similar isoforms. Also in RBC’s and platelets, oxycampesterol and 
oxysitosterol levels were correlated, although stronger correlations were seen in platelets 
compared with RBC’s (Table 7.7). Plasma and RBC oxyphytosterol levels, plasma and platelet 
oxyphytosterol levels and RBC and platelets oxyphytosterol levels did not correlate. 
In plasma 7α-OH-cholesterol and 7α-OH-campesterol concentrations were significantly 
correlated (r=0.535; p<0.02), whereas plasma 7α-OH-cholesterol and 7α-OH-sitosterol 
concentrations were not (r=0.288; p=0.232). 7β-OH-cholesterol and 7β-OH-campesterol 
concentrations correlated significantly (r=0.502; p<0.05) and there was a trend towards 
a correlation between 7β-OH-cholesterol and 7β-OH-sitosterol (r=0.407; p=0.084). There 
were no correlations between 7-keto-cholesterol concentrations and 7-keto-campesterol or 
between 7-keto-cholesterol and 7-keto-sitosterol concentrations. Oxidized LDL levels only 
correlated with 7-keto-cholesterol concentrations. 
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Table 7.3. Effect of vitamin E and lipoic acid supplementation on oxyphytosterol and 
oxycholesterol concentrations in plasma, RBC’s and platelets 
Control period Vitamin E period Lipoic acid period
Plasma (ng/mL)
7α-OH-cholesterol 48.83 ± 32.10 50.33 ± 31.13 52.97 ± 33.08
7α-OH-campesterol 0.20 ± 0.09 0.22 ± 0.12 0.18 ± 0.10
7α-OH-sitosterol 0.46 ± 0.23 0.51 ± 0.27 0.53 ± 0.21
7β-OH-cholesterol 8.82 ± 4.03 8.95 ± 4.07 8.32 ± 4.03
7β-OH-campesterol 0.33 ± 0.17 0.35 ± 0.27 0.35 ± 0.26
7β-OH-sitosterol 3.73 ± 1.63 4.05 ± 1.61 4.51 ± 2.21
7-keto-cholesterol 23.53 ± 10.36 26.44 ± 12.90 21.74 ± 7.76
7-keto-campesterol 2.71 ± 1.20 2.59 ± 1.15 2.81 ± 1.39
7-keto-sitosterol 6.50 ± 3.07 7.21 ± 3.82 7.70 ± 3.23
Sum oxycholesterol 80.64 ± 37.90 88.93 ± 40.54 83.03 ± 39.0
Sum oxyphytosterol 13.28 ± 5.22 14.93 ± 5.65 16.32 ± 6.61
RBC’s (oxyphytosterols: pg/mg, oxycholesterol: ng/mg)
7α-OH-cholesterol 1.0 (0.3-24.8) 0.4 (0.2-1.0) 0.4 (0.2-19.4)
7α-OH-campesterol 2.5 (1.6-76.0) 2.3 (0.7-3.8) 6.2 (0.85-74.6)
7α-OH-sitosterol 8.8 (4.0-80.1) 7.2 (2.1-11.0) 6.8 (3.4-81.4)
7β-OH-cholesterol 1.4 (0.2-35.3) 0.4 (0.2-1.3) 0.4 (0.1-28.2)
7β-OH-campesterol 2.6 (0-76.8) 1.5 (0-3.6) 1.9 (0.1-109.0)
7β-OH-sitosterol 20.7 (11.5-122.7) 18.5 (4.5-24.8) 18.4 (3.7-127.0)
7-keto-cholesterol 3.3 (0.8-95.9) 1.3 (0.7-3.9) 1.1 (0.8-115.7)
7-keto-campesterol 51.0 (31.4-330.7) 36.7 (23.4-86.6)a 40.2 (23.7-301.7)
7-keto-sitosterol 91.3 (65.8-333.0) 89.0 (45.5-157.1) 81.7 (43.1-282.6)
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Sum oxycholesterol 5.6 (1.6-156.0) 2.1 (1.1-6.1) 2.0 (1.3-161.4)
Sum oxyphytosterol 180.3 (24.9-992.2) 156.4 (76.4-271.3) 153.0 (75.3-885.1)
Platelets (pg/mg)
7α-OH-cholesterol 72.6 (23.1-229.0) 86.2 (31.9-504.7) 107.6 (7.0-400.1)
7α-OH-campesterol 3.6 (0.9-18.2) 5.0 (1.8-26.2) 2.6 (1.1-13.8)
7α-OH-sitosterol 16.2 (5.2-63.4) 19.0 (5.2-98.4) 7.0 (5.1-65.3)
7β-OH-cholesterol 81.3 (24.6-328.5) 115.0 (33.9-536.4) 104.0 (27.7-371.4)
7β-OH-campesterol 2.6 (1.2-15.0) 2.4 (0-23.2) 3.0 (0.5-15.1)
7β-OH-sitosterol 30.6 (4.1-101.0) 30.8 (4.6-145.8) 16.4 (2.8-122.5)
7-keto-cholesterol 345.4 (19.0-1068.6) 376.5 (36.9-1185.2) 234.1 (61.8-2110.9)
7-keto-campesterol 254.0 (71.2-757.0) 253.4 (63.5-1260.9) 112.0 (69.8-884.2)
7-keto-sitosterol 444.9 (152.8-
1227.8)
469.8 (156.0-
2075.6)
233.4 (155.2-1618.9)
Sum oxycholesterol 560.4 (66.7-1472.5) 642.0 (102.6-
2104.7)
465.1 (112.7-2833.8)
Sum oxyphytosterol 752.5 (245.9-
2169.4)
779.6 (234.8-
3564.5)
357.5 (248.6-2670.8)
PBMC’s (pg/mg)
7α-OH-cholesterol 291.5 (57.0-6840.1) 462.5 (64.6-5201.5) 226.5 (63.3-1895.2)
7β-OH-cholesterol 173.5 (21.6-16997.1) 223.4 (1.81-9924.9)a 178.4 (18.8-9287.7)
7-keto-cholesterol 184.1 (97.3-665.8) 183.3 (49.3-1013.6) 191.5 (64.7-81761.8)
Sum oxycholesterol 999.4 
(282.1-24078.0)
1146.6 
(1.81-15470.9)
1116.5 
(401.6-82869.8)
Values are means ± SD or median (ranges) (n=20)
a Significantly different compared with control period (p<0.05)
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Table 7.4. Effect of vitamin E and lipoic acid supplementation on oxidative and 
antioxidative parameters 
Control period Vitamin E period Lipoic acid period
OxLDL (oxidized 
phospholipids:apoB100 ratio)
0.05 ± 0.07 0.04 ± 0.06 0.04 ± 0.06
MDA (μmol/L) 2.2 ± 0.4 2.1 ± 0.4 2.0 ± 0.3
Trolox equivalent (μmol/L) 489.5 ± 73.7 479.3 ± 77.8 493.6 ± 90.1
GSH/GSSG 49.4 ± 30.8 44.7 ± 22.8 50.0 ± 27.2
Uric acid (μmol/L) 312.4 ± 59.8 313.5 ± 59.4 321.3 ± 70.4
Values are means ± SD (n=20)
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Table 7.5. Effect of vitamin E and lipoic acid supplementation on plasma inflammatory 
markers, cellular adhesion molecules and iron and copper status parameters
Control period Vitamin E period Lipoic acid period
Inflammation
CRP (g/L) 2.75 ± 2.49 2.33 ± 1.60 3.58 ± 4.78
IL-6 (ng/mL) 1.18 ± 0.45 1.21 ± 0.52 1.18 ± 0.47
TNFa (ng/mL) 3.65 ± 1.04 3.67 ± 1.02 3.79 ± 0.95
Thrombomodulin (ng/mL) 5.11 ± 1.38 5.04 ± 1.40 5.05 ± 1.34
SAA (mg/L) 8.88 ± 11.40 6.05 ± 4.56 8.47 ± 5.30
Cellular adhesion 
E-selectin (ng/mL) 27.00 ± 9.67 30.01 ± 12.93 29.74 ± 13.17
P-selectin (ng/mL) 65.54 ± 18.65 68.30 ± 22.18 69.79 ± 24.74
sICAM-1 (ng/mL) 267.75 ± 55.85 269.55 ± 60.37 277.40 ± 65.36
sICAM-3 (ng/mL) 0.58 ± 0.15 0.62 ± 0.17 0.60 ± 0.17
VCAM-1 (ng/mL) 428.45 ± 117.41 426.00 ± 119.21 423.55 ± 98.91
Iron and copper status
Total iron (μmol/l) 14.48 ± 4.32 15.72 ± 4.83 15.69 ± 5.83
Ferritin (μg/L) 140.95 ± 199.80 139.48 ± 166.61 147.48 ± 174.53
Transferrin (g/L) 2.74 ± 0.46 2.70 ± 0.37 2.68 ± 0.38
Transferrin saturation (%) 21.96 ± 8.02 24.08 ± 9.22 24.10 ± 10.22
Copper (μmol/L) 12.24 ± 1.64 11.93 ± 1.61 12.02 ± 1.51
Ceruloplasmin (g/L) 0.25 ± 0.05 0.24 ± 0.02 0.24 ± 0.03
Values are means ± SD (n=20)
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Table 7.6. Effect of vitamin E and lipoic acid supplementation on plasma glucose, serum 
lipid and lipoprotein concentrations and serum plant sterol, lathosterol and cholestanol 
concentrations
Control period Vitamin E period Lipoic acid period
Glucose (mmol/L) 7.26 ± 1.64 7.29 ± 1.68 7.16 ± 1.47
HbA1c (%) 6.18 ± 0.86 6.19 ± 0.84 6.22 ± 0.85
FGF-19 (pg/mL) 46 ± 45 49 ± 47 50 ± 54
FGF-21 (pg/mL) 400 ± 263 486 ± 278 437 ± 227
Total cholesterol (mmol/L) 5.28 ± 0.97 5.52 ± 0.901,3 5.28 ± 0.96
LDL cholesterol (mmol/L) 3.30 ± 0.89 3.44 ± 0.903 3.21 ± 0.86
HDL cholesterol (mmol/L) 1.34 ± 0.27 1.30 ± 0.25 1.30 ± 0.25
Total cholesterol/HDL 4.12 ± 0.90 4.38 ± 1.012, 5 4.18 ± 0.89
Triacylglycerol (mmol/L) 1.62 ± 0.64 1.72 ± 0.65 1.73 ± 0.66
ApoB100 (g/L) 1.04 ± 0.19 1.11 ± 0.202,3 1.06 ±0.19
ApoA1 (g/L) 1.41 ± 0.22 1.45 ± 0.201,4 1.40 ± 0.22
Sitosterol* 1.40 ± 0.83 1.48 ± 0.84 1.40 ± 0.72
Campesterol* 2.03 ± 1.11 2.08 ± 1.17 2.00 ± 1.12
Lathosterol* 1.64 ± 0.62 1.60 ± 0.49 1.54 ± 0.53
Cholestanol* 2.07 ± 0.37 2.05 ± 0.35 2.04 ± 0.34
Values are means ± SD and *sterols are expressed as 102x µmol/mmol cholesterol.
Significantly different compared with control period:  1(p<0.05), 2(p<0.01)
Significantly different compared with lipoic acid period 3(p<0.05), 4(p<0.01), 5(p=0.06)
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Table 7.7. Oxyphytosterol correlations within plasma and within tissue (RBC’s & platelets) 
in control period
Parameter Parameter Compartment Correlation* p-value
7α-OH-campesterol 7α-OH-sitosterol Plasma 0.845 <0.001
7β-OH-campesterol 7β-OH-sitosterol Plasma 0.625 <0.01
7-keto-campesterol 7-keto-sitosterol Plasma 0.902 <0.001
7α-OH-campesterol 7β-OH-campesterol Plasma 0.442 0.058
7-keto-campesterol Plasma -0.408 0.083
7β-OH-campesterol 7-keto-campesterol Plasma -0.071 0.773
7α-OH-sitosterol 7β-OH-sitosterol Plasma 0.678 <0.01
7-keto-sitosterol Plasma -0.067 0.785
7β-OH-sitosterol 7-keto-sitosterol Plasma 0.538 <0.015
7α-OH-campesterol 7β-OH-campesterol RBC 0.922 <0.001
7-keto-campesterol RBC 0.390 0.110
7β-OH-campesterol 7-keto-campesterol RBC 0.420 0.080
7α-OH-sitosterol 7β-OH-sitosterol RBC 0.798 <0.001
7-keto-sitosterol RBC 0.440 0.07
7β-OH-sitosterol 7-keto-sitosterol RBC 0.340 0.152
7α-OH-campesterol 7β-OH-campesterol Platelets 0.577 <0.01
7-keto-campesterol Platelets 0.746 <0.001
7β-OH-campesterol 7-keto-campesterol Platelets 0.653 <0.01
7α-OH-sitosterol 7β-OH-sitosterol Platelets 0.809 <0.001
7-keto-sitosterol Platelets 0.741 <0.001
7β-OH-sitosterol 7-keto-sitosterol Platelets 0.794 <0.001
* correlations in plasma concentrations were determined with Pearson’s correlation and correlations in RBC and 
platelet levels were determined with Spearman’s rho correlation
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Discussion
This study demonstrates that circulating oxyphytosterol as well as oxycholesterol 
concentrations are not lowered by vitamin E or lipoic acid supplementation in metabolically 
stressed subjects with IGT or type II diabetes.
There is a clear lack of knowledge which factors affect oxyphytosterol concentrations in 
plasma and tissues. We have earlier shown that consumption of plant sterol enriched 
products did not increase fasting plasma oxyphytosterol concentrations, despite an 
increase in fasting serum non-oxidized plant sterol concentrations [4]. Now, we have 
evaluated whether plasma oxyphytosterol concentrations are reduced after antioxidant 
supplementation. However, circulating oxyphytosterol concentrations were not reduced 
after consumption of vitamin E or lipoic acid for 4 weeks. In addition, none of the other 
oxidative stress markers were changed and parameters reflecting anti-oxidative capacity did 
also not change after consuming these antioxidants for 4 weeks. This was rather unexpected 
and the question is why these antioxidants did not have an effect. Potential factors that 
could have affected the outcome are the population, the dose and the duration of the 
intervention period. The present study was performed in a population which consisted 
of subjects with IGT or type II diabetes, a population that is generally recognized for their 
increased oxidative stress [16]. This allowed us to compare oxyphytosterol concentrations 
between healthy subjects from our earlier study and those in our subjects with increased 
oxidative stress. Oxidative stress plays an important role in the initiation and progression 
of type II diabetes and these subjects have increased oxidized LDL-C and oxycholesterol 
concentrations [17]. We here demonstrate for the first time that not only oxycholesterol, but 
also plasma oxyphytosterol concentrations are higher in subjects with IGT or type II diabetes 
as compared with healthy subjects. Circulating oxycampesterol concentrations were 122% 
higher and oxysitosterol concentrations were 83% higher, while plant sterol concentrations 
were comparable between the two populations. Almost all oxyphytosterol isoforms were 
higher in IGT and diabetic subjects, except 7β-OH-campesterol concentrations, which were 
comparable. Regarding the dose and the duration, both vitamin E and lipoic acid have 
been shown to reduce oxidative stress markers in various populations in both short-term 
(<6 weeks) and in longer-term studies [18, 19]. For example, vitamin E consumption (400 
mg/d) for 3 months reduced MDA concentrations in a study with 80 type 2 diabetic patients 
showed [20]. In patients with carotid atherosclerosis 6 weeks of vitamin E (900 mg/d) 
supplementation reduced 7β-OH-cholesterol levels [21]. Plasma MDA and oxycholesterol 
concentrations were also measured in our study, but were not changed after high-dose 
vitamin E supplementation. As reviewed by Pazdro et al. most studies have demonstrated 
convincingly that vitamin E protects against lipid peroxidation in diabetic subjects, while 
effects on protein and DNA oxidation are less clear [22]. Intravenous lipoic acid therapy 
(600 mg/d) reduced MDA and prostaglandin concentrations already after two weeks 
in 13 obese subjects with impaired glucose tolerance [23], while 8 weeks oral lipoic acid 
supplementation (1200 mg/d) in obese subjects failed to reduce oxLDL and prostaglandin 
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concentrations [24]. This may suggest that intravenous lipoic acid supplementation is more 
effective than oral supplementation in human subjects [24], which might explain the lack 
of effect in our study. However, Marangon et al. used a comparable oral dose of lipoic acid, 
e.g. 600 mg/d and demonstrated a decrease in urinary isoprostane concentrations and 
a reduction in LDL oxidative susceptibility in 31 healthy subjects [25]. Their intervention 
period lasted 2 months and it might be postulated that our intervention period of 4 weeks 
was too short to induce changes in oxidative stress markers. This overview illustrates that 
there is no clear explanation for the lack of effect when considering population, dose and 
study duration. 
Besides evaluating effects on oxidative parameters we also measured a panel of markers 
reflecting antioxidative capacity. Previous studies showed an increase in endogenous 
antioxidant enzyme activities after vitamin E consumption (400 mg/d) in type II diabetic 
subjects [20, 26]. In addition, lipoic acid increased intracellular glutathione concentrations 
in a variety of cell types and tissues [27, 28]. However, we were not able to demonstrate an 
improvement in these anti-oxidative markers in plasma concentrations of subjects with IGT 
or type II diabetes after vitamin E or lipoic acid consumption. 
Whether increased oxyphytosterol concentrations are potentially atherogenic remains 
to be determined. If so, it would be of interest to further characterize oxyphytosterol 
concentrations in different (diseased) population and assess which dietary interventions 
might be successful in reducing plant sterol oxidation products. In our earlier study with 
healthy control subjects we tried to assess whether oxidation of plant sterols might be iron 
or copper-mediated [29]. In that study, oxLDL concentrations correlated positively with 
three different iron status markers, while no correlations were observed between any of 
the three iron status markers and oxyphytosterol concentrations, suggesting that oxidation 
of plant sterols might not be iron-mediated. Copper status markers did not correlate with 
oxLDL or with oxyphytosterol concentrations. Iron status markers and copper status markers 
were again determined in the current study. Serum concentrations in the IGT and diabetic 
population were lower as compared to healthy subjects. The observation that iron and 
copper concentrations are lower while oxyphytosterol concentrations are higher in IGT and 
diabetic patients may suggest that oxidation of plant sterols is not regulated at all via iron 
or copper-mediated oxidation. However, iron status parameters were also not correlated 
with oxycholesterol concentrations. This suggest that the relation between oxycholesterol 
and iron or copper-mediated oxidation is not as straightforward, even though it is generally 
assumed that cholesterol oxidation is (partly) regulated via iron or copper-mediated 
oxidation [30].
An important question is not only whether plasma oxyphytosterol concentrations are 
changed after vitamin E or lipoic acid, but also what happens with oxyphytosterols inside 
tissues. Schött et al. recently determined oxyphytosterol concentrations in plasma and 
aortic valve cusps in patients undergoing elective aortic valve replacement due to severe 
aortic stenosis [31]. Oxyphytosterol isoforms correlated significantly within plasma and 
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within tissue [aortic valve cusps], while a correlation between plasma and aortic valve 
cusp tissue was lacking. These results are (partly) in agreement with our study, since we 
also observed no relation between plasma and blood cell oxyphytosterol concentrations, 
while the different oxyphytosterol isoforms within the various cells types did correlate. We 
therefore suggest that oxidation of plant sterols might occur locally within tissues and does 
not originate from uptake via plasma, which might explain the lack of correlation between 
plasma and tissue concentrations. However, vitamin E and lipoic acid failed to reduced 
oxyphytosterol and oxycholesterol values in RBC’s and platelet fractions.
Rather unexpected findings in this study were increased serum lipid and (apo)lipoprotein 
concentrations in the vitamin E period compared with lipoic acid and control periods. This 
effect was consistent since cholesterol (total and LDL-C) and its carrier (apoB100) were 
increased. ApoA1 concentrations were increased in the vitamin E period, even though 
HDL-C concentrations were comparable in all three period. This cholesterol-raising effect of 
vitamin E was unanticipated and has only been described a few times before [19, 32]. Daily 
intake of vitamin E capsules cannot explain the observed effect, since they only provided 
minor amounts of linoleic and oleic acid. Changes in dietary intake are also highly unlikely, 
since food frequency questionnaires showed comparable dietary intake in all three periods. 
For now, we have no obvious explanation for this highly unexpected effect of vitamin E 
supplementation.
In conclusion, we here show that circulating oxyphytosterol concentrations are not reduced 
by vitamin E and lipoic acid supplementation, while we previously demonstrated that 
oxyphytosterol concentration are not increased after plant sterol consumption. However, 
oxyphytosterol concentrations clearly differ between healthy subjects and subjects with 
impaired glucose tolerance or type II diabetes. The possible clinical implications of these 
differences in oxyphytosterol concentrations and whether these may have an impact on 
CVD risk in IGT or type II diabetic subjects remains to be determined. 
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Introduction
Functional foods enriched with plant sterols and plant stanols have been demonstrated 
to lower LDL-C concentrations in numerous intervention studies. Several meta-analyses 
have summarized this evidence and described the dose-response LDL-C lowering effect of 
plant sterols and plant stanols [1-3]. However, guidelines are not unanimous with respect 
to consumption of plant sterol and stanol enriched foods. A European Atherosclerosis 
Consensus (EAS) panel recommended the use of functional foods with plant sterols and 
stanols in patients with high cholesterol levels at intermediate and low global cardiovascular 
risk that do not qualify for pharmacotherapy. In addition, the panel concluded that plant 
sterol and stanols could be considered in (very) high-risk patients who do not reach their 
LDL-C targets on pharmacotherapy or in those with statin intolerance [4]. On the other hand, 
recently updated guidelines from the National Institute of Health and Clinical Excellence 
(NICE) advice against the use of plant sterols or stanols for the prevention of CVD in subjects 
treated for primary and secondary prevention or in subjects with diabetes (type I and II) [5]. 
This inconsistency in guidelines is partly explained by a lack of endpoint studies for plant 
sterol and plant stanol consumption and because there are uncertainties regarding health 
effects of increased plant sterol concentrations after plant sterol consumption, which is a 
hotly debated topic. In addition, plant sterols are susceptible to oxidation and can form 
plant sterol oxidation products (oxyphytosterols). Information regarding oxyphytosterol 
metabolism is very scarce. For example, it is not known 1) which factors affect circulating 
oxyphytosterol concentrations, 2) if and how these oxidation products are related to 
metabolic health parameters and 3) whether they are atherogenic as suggested earlier for 
oxycholesterol concentrations. Information regarding plant sterols and plant stanols in the 
postprandial phase is also limited and it is not known 1) what the effects are of a mixed meal 
rich in plant sterols and plant stanols on postprandial lipid and glucose responses and 2) 
whether postprandial oxyphytosterol concentrations are affected by plant sterol and plant 
stanol consumption.
Therefore, we aimed to investigate whether fasting oxyphytosterol concentrations are 
affected by dietary determinants, such as plant sterol and plant stanol consumption and 
antioxidant supplementation and whether oxyphytosterol concentrations differ between 
populations. In addition, we also evaluated effects of plant sterol and plant stanol 
consumption in the postprandial state, by assessing effects on lipid, lipoprotein and glucose 
responses and effects on postprandial oxyphytosterol concentrations. 
Increased plant sterol concentration and CVD risk
Plant sterols and plant stanols are structurally related to cholesterol and have cellular functions 
in plants analogous to those of cholesterol in animals. The difference between plant sterols 
and cholesterol resides in the side-chain, while plant stanols are the saturated derivative of 
plant sterols. The main sources of plant sterols are vegetable oils, cereals, vegetables, fruits, 
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nuts and seeds, with a mean daily intake that ranges between 200 and 300 mg/d, but can be 
as high as 600 mg/d in vegetarians. Plant stanols are less abundant in nature, with a mean 
daily intake of 17-24 mg/d [6]. Plant sterols and plant sterols (together with cholesterol 
and other lipophilic substances) are incorporated into mixed micelles that serve as vehicles 
to deliver these products to the brush border membrane. Here they are taken up into 
the enterocyte by Niemann-Pick C1-Like1 (NPC1L1), which is a general sterol transporter 
protein. After uptake into enterocytes, plant sterol and stanols are excreted back from the 
intestinal mucosa into the intestinal lumen by the ATP-binding cassette (ABC) transporters 
ABCG5/8. Absorption rates are very low, i.e. 0.5-2% for plant sterols and 0.04-0.2% for plant 
stanols [7]. Once present in the circulation, plant sterols and plant stanols are cleared by the 
liver and rapidly secreted from the liver into bile by hepatic ABCG5/G8 transporters. Due to 
low absorption and high biliary secretion rates, circulating concentrations of plant sterols 
and plant stanols are low, with plant sterol concentrations ranging from 0.3-1.0 mg/dL and 
plant stanol concentrations ranging from 0.002-0.012 mg/dL [8, 9]. Consuming plant sterol 
enriched food products increases circulating plant sterol concentrations. A recent meta-
analysis by Ras et al. included 41 studies with 2084 subjects and showed that an average 
plant sterol intake of 1.6 g/d resulted in 31.3% increase in sitosterol and 37.3% increase 
in campesterol concentrations [10]. Plant stanol enriched products increase plant stanol 
concentrations (increase of 0.012-0.028 mg/dL at an intake of 0.6 ± 0.4 g/d) and additionally 
reduce serum plant sterol concentrations with observed reductions ranging from 16-23% 
[11]. The (patho)-physiological relevance of increased plant sterol concentrations after plant 
sterol consumption has been subject of scientific debate for two different reasons. First, 
questions were raised regarding the safety of elevated serum plant sterol concentrations 
after the identification of phytosterolemia, a rare genetic disorder. Subjects suffering from 
phytosterolemia have a mutation in the ABCG5/8 genes, which causes a lower secretion rate 
of plant sterols and stanols from enterocytes into the intestinal lumen and from hepatocytes 
into the bile ducts. Subjects have very high plant sterol concentrations and often have an 
early onset of atherosclerosis, while serum cholesterol concentrations are not always 
elevated [12]. However, recent evidence reports phytosterolemic patients with high plant 
sterol concentrations, but without any signs of atherosclerotic disease [13]. This observation 
suggests that the relation between extremely high plant sterol concentrations and CVD 
risk is not as straightforward as once thought, but rather more complicated. This might be 
explained by the presence of an additional second trigger that together with elevated plant 
sterols results in premature atherosclerosis. A second reason why increased plant sterol 
concentrations have been implicated as a CVD risk factor relates to epidemiological studies 
that demonstrated positive associations between plant sterol concentrations and CVD risk 
[14, 15]. However, this relation is again not as straightforward, since there are also studies 
that show negative associations and studies that do not report any association between 
plant sterol concentrations and CVD risk [16-18]. Although speculations have been raised, 
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such as use of different study designs and adjustments for potential confounding variables, 
the reason for this controversy in epidemiological studies is not known. 
Fasting oxycholesterol and oxyphytosterol concentrations 
Due to the presence of a double bond between C5-C6, cholesterol and plant sterols can 
be oxidized resulting in the formation of oxycholesterols and oxyphytosterols. Since plant 
stanols lack this double bind in their ring structure, they cannot be oxidized [19]. Cholesterol 
oxidation products have been studied more intensively than plant sterol oxidation products. 
This relates to the fact that cholesterol is associated with development of atherosclerosis, is 
endogenously produced and plasma (oxy)cholesterol concentrations are higher than (oxy)
phytosterol concentrations [20]. Brooks et al. first identified cholesterol oxidation products 
in human atheromatous plaques in 1966 [21], while plant sterol oxidation products were 
identified in 1983 in plasma of patients with Waldenström’s macroglobulaemia [22]. In 1999, 
Grandgirard et al. measured oxyphytosterols in healthy subjects with a concentration of 0.3 
μg/mL [23]. Hereafter, oxyphytosterols have been determined in plasma of phytosterolemic 
patients, where a concentration of 4.7 μg/mL (sitosterol oxidation products) was 
determined, representing 1.4% of circulating sitosterol concentrations [24]. A few years 
later, oxyphytosterols were again measured in healthy subjects, but now with a lower 
limit of detection, in a range of 0.005-0.057 μg/mL, which is a 100 times lower than the 
first measurement in 1999. Since then, oxyphytosterols have been determined by several 
research groups worldwide and due to the variability in measuring techniques combined 
with very low circulating concentrations, large variations were present in oxyphytosterol 
concentrations [25-27]. During recent years, methods for the analysis of oxyphytosterols 
have improved and oxyphytosterol concentrations between 0.1 and 4.9 ng/mL are reported 
in healthy subjects [26-28], which are still 10-100 times lower than plasma concentrations 
found for oxycholesterol [29]. Figure 8.1 demonstrates cholesterol and oxycholesterol 
concentrations (A) and plant sterol and oxyphytosterol concentrations (B) in our population 
of healthy subjects in a control period. In this population, 0.006% of cholesterol was oxidized, 
while 0.06% of plant sterols were present as oxyphytosterols, which is a factor 10 higher. 
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Figure 8.1. (Oxy)cholesterol (panel A) and (oxy)phytosterol concentrations (panel B) in healthy subjects in a control 
period (means ± SD). Units differ for non-oxidized and oxidized sterols (mg/dL vs. ng/mL), while the scales differ 
between (oxy)cholesterol (0-300 mg/dL and 0-300 ng/mL) and (oxy)phytosterol concentrations (0-6 mg/dL and 
0-6 ng/mL).
Table 8.1 shows the sum of oxyphytosterol concentrations in healthy subjects, of whom 
subjects were identified as low or high oxidizers, and in subjects with impaired glucose 
tolerance or type II diabetes. This data shows a clear distinction between these populations 
and this is the first time that this comparison is made, since oxyphytosterol concentrations 
were previously only determined in healthy subjects and in phytosterolemic patients. 
Importantly, it was also measured with the same method in the same lab, which is important 
regarding the above-mentioned variation in measuring assays between laboratories. 
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Table 8.1. Oxyphytosterol concentrations in healthy subjects and subjects with impaired 
glucose tolerance (IGT) or type II diabetes (DMII)
Sum OPS (ng/mL)a
Low oxidizers (n=3) 3.6 ± 0.01
Healthy subjects (n=37) 4.7 ± 1.1
High oxidizers (n=3) 6.4 ± 2.2
IGT and DMII subjects (n=20) 13.9 ± 5.3
Values are expressed as means ± SD
a Sum OPS consists of 7α-OH-campesterol, 7α-OH-sitosterol, 7β-OH-campesterol, 7β-OH-sitosterol, 7-keto-
campesterol and 7-keto-sitosterol 
This difference between healthy and diabetic subjects with respect to oxyphytosterol 
concentrations is also reflected in oxycholesterol concentrations. Arca et al. measured 
7β-OH-cholesterol and 7-keto-cholesterol in healthy subjects and in familial combined 
hyperlipidemic (FCHL) patients as a marker of oxidative stress [30]. They already established 
that these concentrations differ significantly from each other in these two populations. Since 
we measured oxyphytosterol concentration in our type II diabetic subjects, we were able 
to compare this data (Table 8.2) demonstrating that 7β-OH-cholesterol differed markedly 
between the populations, while this distinction was less clear for 7-keto-cholesterol 
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concentrations.  Data shown in Table 8.1 and Table 8.2 suggest that there is a strong shared 
oxidative component in oxycholesterol and oxyphytosterol concentrations.
Table 8.2. Oxycholesterol concentrations in healthy and subjects with IGT or DMII and in familial 
combined hyperlipidemic (FCHL) patients
7β-OH-cholesterol (ng/mL) 7-keto-cholesterol (ng/mL)
Healthy subjects (n=54)a 4.7 ± 1.3 12.2 ± 7.0
DMII subjects (n=20) 8.3 ± 4.0 23.5 ± 10.4
FCHL patients (n=45) 17.7 ± 13.8 25.5 ± 15.2
Values are expressed a means ± SD
a Data from healthy subjects and FCHL patients were derived from Arca et al. [30] and data from DMII subjects 
are derived from this thesis.
Dietary interventions and fasting oxyphytosterol concentrations
We were able to establish that oxyphytosterol concentrations are clearly different between 
subjects but it would be of interest to investigate whether oxyphytosterol concentrations 
can be influenced by nutritional interventions. For this reason, we performed our 
first intervention study as described in chapter 3, to evaluate whether oxyphytosterol 
concentrations would change after plant sterol and plant stanol consumption. As expected, 
campesterol concentrations increased by 50% and sitosterol concentrations increased by 
36% after consumption of plant sterol enriched margarine, while reductions of 38% and 
35% in campesterol and sitosterol concentrations were found after consumption of plant 
stanol enriched margarine for 4 weeks. These changes are line with literature, as recently 
described in a meta-analysis by Ras et al. [10]. However, despite these increases in plant 
sterol concentrations, circulating oxyphytosterol concentrations did not change after plant 
sterol consumption, while reductions in 7β-OH-campesterol concentrations and – when 
standardized for cholesterol – also 7-keto-campesterol concentrations were seen after plant 
stanol consumption. These data suggest that circulating oxyphytosterol concentrations are 
influenced by additional factors besides the presence of substrate, i.e. non-oxidized plant 
sterols in plasma. On the other hand, a study by Husche et al. reported a significant 87% 
increase in 7β-OH-sitosterol concentrations in healthy subjects after consumption of 3.0 g/d 
plant sterol enriched margarine for 4 week [26]. Both studies used the same margarine and 
plasma samples were also determined in the same laboratory. While our study was a double 
blind randomised cross-over trial, Husche’s study had a smaller sample-size and lacked a 
control group, which might explain (part of) this apparent discrepancy. However, both 
studies demonstrated that increases in serum plant sterol concentrations after plant sterol 
consumption does not correlate with changes in plasma oxyphytosterol concentrations. In 
addition, serum plant sterol concentrations and circulating oxyphytosterol concentrations 
also did not correlate in the control period. 
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As discussed previously, controversies exist regarding increased plant sterol concentrations 
and an increased CVD risk in epidemiological studies. A potential answer explaining this 
controversy might be found in increased oxyphytosterol concentrations. For now, our 
data suggests that an increase in serum plant sterol concentrations does not change 
circulating oxyphytosterol concentrations and might therefore not explain discrepancies 
in epidemiological studies. However, to definitely answer this question, oxyphytosterol 
concentrations should be measured in epidemiological studies that report contradictive 
results on the association between plant sterol concentrations and CVD risk. As mentioned 
before, serum plant sterol concentrations and circulating oxyphytosterol concentrations 
do not correlate cross-sectional nor after plant sterol consumption. On the other hand, 
oxyphytosterol concentrations correlated well between different periods in the same 
subjects, indicating that plasma oxyphytosterol concentrations seem to be consistent within 
subjects under different dietary circumstances. This resulted in the identification of ‘low and 
high oxidizers’ as described in chapter 4, who differed with respect to their oxyphytosterol 
concentrations. To assess whether these differences also extend to other oxidized 
compounds, oxycholesterol and oxidized LDL (oxLDL) concentrations were determined and 
these oxidative stress markers also differed between low and high oxidizers, highlighting that 
there is an oxidative component that determines circulating oxyphytosterol concentrations 
in healthy human subjects. In vivo oxidation is often catalysed by iron ions, which can 
generate hydroxyl radicals from hydrogen peroxide. We demonstrated a positive correlation 
between iron stores and oxLDL concentrations, while plasma oxyphytosterol concentration 
were not correlated with iron status markers. This suggests that different pathways are 
responsible for oxidation of plant sterols and LDL particles. On the other hand, oxycholesterol 
concentrations were positively associated with serum ferritin concentrations in a large cohort 
of Finnish men [31], while we were not able to show correlations with iron status markers 
and oxycholesterol concentrations in 20 subjects with impaired glucose tolerance or type 
II diabetes (chapter 7). To investigate the role of oxidative stress on plasma oxyphytosterol 
concentrations, we investigated whether plasma oxyphytosterol concentrations might be 
changed after antioxidant supplementation. For cholesterol oxidation products, antioxidant 
supplementation has been shown to reduce cholesterol oxidation products in previous 
studies. Szuchman et al. showed that patients with diabetes and hypercholesterolemia have 
higher oxycholesterol concentrations than control subjects [32]. In addition, consumption 
of pomegranate juice (high in antioxidants) suppressed the capacity of diabetic blood to 
oxidize an exogenous oxidative stress marker and the ratio oxycholesterol/total cholesterol 
was reduced by 93%. A study performed in patients with carotid atherosclerosis showed 
reductions in 7β-OH-cholesterol after 6 weeks of vitamin E (900 mg/d) supplementation [33]. 
In chapter 7, we described the first study that evaluated potential changes in oxyphytosterol 
concentrations after antioxidant supplementation. The study was performed with 20 
subjects with impaired glucose tolerance of type 2 diabetes who received daily vitamin E 
(804 mg) and lipoic acid (600 mg) capsules for 4 weeks in a randomised cross-over trial. 
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We showed that oxyphytosterol concentrations were not changed after 4 weeks high-dose 
antioxidant supplementation. Besides comparable oxyphytosterol concentrations in the 
vitamin E, lipoic acid and control period, other oxidation parameters such as oxycholesterol, 
oxLDL and MDA levels were also not changed after vitamin E or lipoic acid supplementation. 
To summarize the two described intervention studies: we attempted to change plasma 
oxyphytosterol concentrations by providing more substrate, e.g. increased plant sterol 
concentrations and enabling a greater anti-oxidative capacity, e.g. by supplementing of 
vitamin E and lipoic acid. Except for small reductions in 7β-OH-campesterol and 7-keto-
campesterol after plant stanol consumption, fasting oxyphytosterol concentrations were 
not changed, at least not by the nutritional means described in this thesis.  
Oxyphytosterol concentrations in serum versus tissue 
Oxyphytosterol concentrations are mainly determined in plasma, while information 
regarding tissue concentrations is scarcer. Oxycholesterols have been analysed into 
more detail since certain oxycholesterols (mainly side-chain oxidation products) carry 
out important functions within the body such as ligands for the nuclear receptors liver 
X receptor (LXR)α and LXRβ and as intermediates in bile acid biosynthesis [34]. ROS-
mediated oxycholesterols are suggested to be associated with initiation and progression of 
atherosclerosis 7β-OH-cholesterol and 7-keto-cholesterol concentrations have been found 
in atherosclerotic plaques [35]. Staprans et al. showed that dietary α-epoxy cholesterol is 
incorporated into chylomicrons (CM) and CM-remnants and then transferred to LDL and HDL 
implying that transportation of oxycholesterols to different tissues within the body occurs 
through lipoproteins [36]. The addition of oxyphytosterols to the diet on tissue level has also 
been investigated. Oxyphytosterols were fed to hamsters at different concentrations and 
the same oxyphytosterols isoforms were measured in heart, kidney, liver and aortic tissue. 
A higher oxyphytosterol content in the diet resulting in a dose-dependent oxyphytosterol 
increase in the different tissues, while very low dietary oxyphytosterols resulted in hardly 
detectable plasma and tissue levels, implying that small amounts of oxyphytosterols can 
probably be eliminated fast by the animals. Oxyphytosterol concentrations were lower in 
liver tissue compared to kidney en heart tissue, which might reflect a higher metabolic rate 
in this organ [37]. The provided diets contained more oxysitosterols than oxycampesterols 
and sitosterol oxidation products were consistently higher in plasma and tissue than 
campesterol oxidation products. To assess the effect of oxysterol or oxyphytosterol 
consumption on atherosclerotic lesion formation, female LDL receptor+/- mice were fed a 
control diet, a high-fat oxycholesterol diet or a high-fat oxyphytosterol diet. The addition 
of oxycholesterol and oxyphytosterols to an atherogenic high-fat diet resulted in a higher 
proportion of severe lesions and in addition, oxyphytosterol levels were the highest in the 
groups receiving the oxyphytosterol diet, indicating that diet-derived oxyphytosterols are 
incorporated into lesions. Unfortunately, plasma and tissue oxyphytosterol concentrations 
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could not be compared, since plasma oxyphytosterol concentrations were not measured in 
this study [38]. In patients undergoing elective aortic valve replacement due to severe aortic 
stenosis, oxyphytosterol concentrations were measured in plasma and in tissue (aortic valve 
cusps). While there was a strong correlation between different oxyphytosterol isoforms 
within plasma and within issue, a correlation between plasma and aortic tissue was lacking 
[39]. This data is in agreement with our study in type II diabetic subjects, where we measured 
oxyphytosterol concentrations in red blood cells and in platelets and also did not report a 
correlation between plasma and tissue concentrations. However, a study performed in male 
apoE-/- mice did report significant correlations between oxyphytosterol concentrations in 
plasma and aortic tissue [40]. In this study, mice received daily intraperitoneal injections 
over 4 weeks with cholesterol, sitosterol, 7β-OH-cholesterol, 7β-OH-sitosterol or a control 
vehicle. Compared to the control period, daily injections of cholesterol did not result in 
increased serum or aortic cholesterol concentrations, while injections of 7β-OH-cholesterol 
increased 7β-OH-cholesterol concentrations in serum but not in aortic tissue. On the other 
hand, sitosterol and 7β-OH-sitosterol concentrations both increased in serum and in the 
arterial wall after injection of sitosterol and 7β-OH-sitosterol, respectively. An explanation 
why this study reports a correlation between plasma and tissue concentrations, whereas 
previous studies were not able to show this correlation, might be explained by the method 
of intraperitoneal injections. Injecting a substance results in high plasma concentrations, 
which probably will lead to an incorporation of the injected substance into tissues, causing 
plasma and tissue concentrations to correlate, which might explain the lack of correlation 
in the patients that underwent elective aortic valve replacement and in our type II diabetic 
subjects. 
Postprandial oxyphytosterol responses after plant sterol and plant stanol consumption
Besides fasting oxyphytosterol concentrations, we were also able to measure postprandial 
oxyphytosterol concentrations after consumption of a mixed meal enriched with plant 
sterol and plant stanol esters. We already established that fasting oxyphytosterol 
concentrations did not change after plant sterol consumption. In chapter 5, we assessed 
postprandial oxyphytosterol concentrations and demonstrated that postprandial 
oxyphytosterol concentrations are increased after plant sterol consumption. Serum (non-
oxidized) campesterol and sitosterol concentrations increased in parallel with 7β-OH-
campesterol and 7β-OH-sitosterol after plant sterol consumption, while 7-keto-phytosterol 
concentrations only changed over time without a plant sterol effect. The question whether 
postprandial plant sterol oxidation products are formed endogenously or absorbed from 
the diet is difficult to answer, since the consumed margarine contained plant sterols as 
well as oxyphytosterols. Therefore, we can only speculate on the origin of postprandial 
oxyphytosterol concentrations. Linseisen et al. measured postprandial oxycholesterol 
concentrations in five healthy subjects, which consumed a meal rich in cholesterol and in 
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cholesterol oxidation products [41]. Analogue to our observation regarding postprandial 
oxyphytosterol concentrations, oxycholesterol concentrations increased in parallel with non-
oxidized cholesterol concentrations and the authors concluded that absorption patterns of 
non-oxidized and oxidized cholesterol are comparable with differences in the bioavailability 
of single oxycholesterol isoforms. Another indication that circulating oxyphytosterol 
concentration predominantly origin from dietary absorption is presented in the study by 
Weingärtner et al, who reported that mice injected with non-oxidized cholesterol or sitosterol 
did not show an increase in plasma oxycholesterols or oxyphytosterols concentrations, 
suggesting that there was no endogenous formation, at least not in the circulation [40]. 
Tomoyori et al. suggested that campesterol oxidation products have a higher absorption rate 
than sitosterol oxidation products in rats [42]. If this holds also true in the human situation, 
then these higher absorption rates are reflected in postprandial concentrations but not in 
fasting oxyphytosterol concentrations, since fasting oxysitosterol concentrations are higher 
than oxycampesterol concentrations. For non-oxidized plant sterols, it has been shown that 
campesterol is better absorbed than sitosterol and this is reflected in both fasting as well as 
postprandial concentrations [7]. In addition, the postprandial pattern of plant sterols and 
oxyphytosterols resembles the second meal effect as described for cholesterol, which states 
that cholesterol from a first meal is secreted during subsequent meal consumptions [43-
45]. Based on our postprandial data and this possible second meal effect, we suggest that 
plasma oxyphytosterol concentrations predominantly originate form dietary absorption. 
The question remains how to explain the difference between fasting oxycampesterol and 
oxysitosterol concentrations. If indeed absorption rates of campesterol oxidation products 
are higher as suggested from animal data, than clearance rates probably differ between 
campesterol and sitosterol oxidation products. To provide a definite answer to the question 
whether plasma plant sterol oxidation products result from endogenous formation or 
dietary absorption, future studies should be performed where labelled non-oxidized plant 
sterols are consumed and subsequent enrichment in labelled plasma oxyphytosterols are 
measured in plasma.
Postprandial metabolic responses after plant sterol and plant stanol consumption
The LDL-lowering effect of plant sterols and plant stanols has been demonstrated in 
numerous studies. However, recent studies have suggested that plant sterols and plant 
stanols also lower fasting triacylglycerol (TAG) concentrations, especially in individuals with 
elevated baseline TAG concentrations [46, 47]. Although high fasting TAG concentrations are 
independent risk marker for CVD [48], non-fasting serum TAG concentrations are emerging as 
an important CVD risk marker due to the postprandial atherogenicity of TAG-rich (remnant) 
lipoprotein particles [49, 50]. Most people are in the non-fasting state or postprandial state 
for most part of the day and in chapter 6, we examined the 8-hour postprandial response 
after consuming plant sterol or plant stanol ester enriched margarines as part of a shake. 
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We demonstrated a similar response in TAG and apolipoprotein (apo) B48 concentrations 
after the first meal, while these responses were increased after consumption of the 
second meal in the plant stanol period. This effect was stronger with increasing age and 
more evident compared to the sterol period than to the control period. Previous studies 
suggest that chronic or acute plant stanol consumption does not affect postprandial lipid 
and lipoprotein concentrations [51-53]. Although these studies have some limitations, they 
also differ from our study design since we used a sequential meal protocol with regular 
blood sampling. As described by Jackson, a sequential two-meal protocol provides a more 
physiological challenge to detect subtle changes in TAG metabolism, especially after the 
second meal consumption when the clearance cascade is stressed [54]. Since the observed 
plant stanol effect was only evident after consumption of the second meal, this suggests 
that the activity of enzymes involved in processing of TAG-rich lipoproteins (TRLs) or the 
rate of clearance of TRL remnants by receptor-mediated processed was affected. In general, 
the increase of the postprandial TAG concentrations correlates positively with age and our 
observed effect was more prominent with an increase in age [55]. The most important 
determinant of postprandial TRL accumulation is the capacity of lipoprotein lipase (LPL) to 
hydrolyse TAG, thus to convert very low-density lipoproteins (VLDL) and chylomicrons into 
remnants. A decrease in LPL activity would probably be the most likely explanation for the 
observed plant stanol effect. Possibilities might be found in modulators of LPL activity; such 
as changed local peroxisome proliferator activated receptor (PPAR)-α and –γ expression in 
adipose and/or skeletal muscle or increased serum apoCIII concentrations after plant stanol 
consumption. Increased levels of apoCIII are associated with an impaired catabolism of 
TRLs and reducing apoCIII concentrations has gained much attention as a potential target to 
correct hypertriglyceridemia in subjects with type II diabetes of insulin resistance [56]. As 
mentioned before, recent studies reported reduced fasting TAG concentrations after plant 
stanol consumption, while we report an increase in postprandial TAG concentrations after 
consumption of a second meal. However, reductions in fasting TAG concentrations were 
only observed in subjects with elevated fasting TAG concentrations while our population 
consisted of healthy subjects and as expected, we were not able to demonstrate a 
reduction in fasting TAG concentrations in this population. There are no studies available 
that investigated postprandial responses after plant sterol and plant stanol consumption 
in subjects with higher baseline TAG concentrations. However, Bozetto et al. investigated 
whether ezetimibe, a cholesterol-lowering drug that acts through a reduction in cholesterol 
absorption – analogue to plant sterols and plant stanol – affects postprandial TRL’s in 
subjects with type II diabetes. They reported that a 6-week treatment with ezetimibe and 
simvastatin, compared to simvastatin alone, reduced fasting and postprandial TAG and 
apoB48 concentrations [57]. The reduced postprandial responses mainly reflected the 
chronic action of ezetimibe to reduce cholesterol absorption, since fasting TAG and apoB48 
concentrations were also reduced. Plant sterols and plant stanols also reduce cholesterol 
absorption – although to a lesser extent than ezetimibe – but this was not reflected in the 
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postprandial responses. However, as indicated, our population consisted of healthy subjects 
while the ezetimibe study was performed in type II diabetic subjects. It remains to be 
determined how postprandial responses are changed after consumption of plant sterols 
and plant stanols in subjects with elevated TAG concentrations or in subjects with type II 
diabetes.
Conclusion and future directions
This thesis describes that fasting oxyphytosterol concentrations differ between low and 
high oxidizers and between healthy and diabetic subjects. Whether these differences in 
oxyphytosterol concentrations have an impact on CVD risk remains to be determined in future 
studies. Fasting oxyphytosterol concentrations were not increased after daily consumption 
of a plant sterol enriched margarine for a period of 4 weeks, while plant stanol consumption 
reduced 7β-OH-campesterol concentrations and – when standardized for cholesterol – 
also 7-keto-campesterol levels. In addition, high-dose antioxidant supplementation (804 
mg/d vitamin E and 600 mg/d lipoic acid) for a period of 4 weeks did not change plasma or 
blood cell oxyphytosterol concentrations in type II diabetic subjects. In contrast to fasting 
oxyphytosterol concentrations, postprandial oxyphytosterol concentrations did increase 
after plant sterol consumption. Against our expectations, postprandial TAG and apoB48 
responses were increased after consumption of a mixed meal rich in plant stanols, which 
might be explained by a reduced postprandial LPL activity although underlying mechanisms 
remain to be elucidated. 
Future directions regarding oxyphytosterols
Future studies should be carried out to assess whether oxyphytosterols causes metabolic 
disturbances and if they are atherogenic as suggested earlier for oxycholesterol 
concentrations. In addition, relationships between plasma vs. tissue concentrations of 
oxyphytosterols should be further evaluated, which may also provide insight into the site 
of oxidation. Furthermore, oxyphytosterol concentrations have only been determined in 
healthy subjects, in subjects with impaired glucose tolerance or type II diabetes and in 
phytosterolemic patients. Characterization of oxyphytosterols in other populations, such 
as patients with atherosclerotic disease or neurodegenerative diseases would expand our 
knowledge on the role of oxyphytosterol concentrations in the metabolism of (diseased) 
populations. In addition, measurement of oxyphytosterols in phytosterolemic patients 
with and without atherosclerotic disease could provide more information on the potential 
atherogenicity of oxidized plant sterols. Whether oxyphytosterols are derived from 
endogenous formation of absorption from the diet can only be answered by a study in which 
labelled non-oxidized plant sterols are consumed and subsequent enrichment in labelled 
plasma oxyphytosterols is measured.
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Future directions regarding postprandial lipid metabolism
Postprandial lipid responses were increased after consumption of a mixed meal rich in plant 
stanols. To provide more insight into postprandial responses after plant sterol and plant 
stanol consumption, kinetic studies should be performed in which lipoprotein production 
and clearance can be further evaluated. An increased postprandial lipid response was 
in contrast to our expectations since fasting TAG may be reduced after plant sterol and 
stanol consumption. However, this TAG-lowering effect was seen in subjects with elevated 
baseline TAG concentrations and it would be interesting to assess whether postprandial 
lipid responses are different in diabetic subjects or in subjects with high baseline TAG 
concentration compared with healthy subjects.
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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in many parts 
of the world. Risk factors to develop CVD include cigarette smoking, high blood pressure, 
diabetes mellitus, obesity and an unfavourable serum lipoprotein profile, such as elevated 
low-density lipoprotein cholesterol (LDL-C) concentrations. Dietary lifestyle changes are 
important to reduce CVD risk and in this context the development of functional foods that 
lower serum LDL-C concentrations has been groundbreaking. Plant sterols and plant stanols 
are lipid-like compounds that share structural similarities with cholesterol. They consist of 
a steroid nucleus with a double bond present at C5-C6. There are various plant sterols that 
differ only in the side-chain configuration. Plant stanols are the saturated derivative of plant 
sterols. Plant sterols and plant stanols have been incorporated in a variety of functional 
foods and consumption of approximately 2.5-3.0 g/d of plant sterols or plant stanols can 
lower serum LDL-C concentrations up to 12%. In addition, consuming plant sterol enriched 
products will increase serum plant sterol concentrations, while the consumption of plant 
stanols will decrease plant sterol concentrations. Plant sterols are susceptible to oxidation 
and can form oxyphytosterols, while plant stanols cannot be oxidized since they lack a 
double bond in their ring structure. 
The aim of the studies described in this thesis was to investigate the effects of plant sterol and 
plant stanol consumption on lipoprotein metabolism and oxyphytosterol concentrations in 
the fasting and postprandial state and to evaluate the effects of antioxidant supplementation 
on plasma oxyphytosterol concentrations.
Chapter 2 is an overview of the available literature regarding various aspects of using plant 
sterols and plant stanols in the treatment of dyslipidaemia. Besides the well-known LDL-C 
lowering effect of plant sterols and plant stanols, this chapter also describes their beneficial 
effects on triacylglycerol (TAG) concentrations and provides an overview of arguments 
used in the ongoing debate whether increased plant sterol concentrations are associated 
with an increased CVD risk. In chapter 3, we investigated the effects of plant sterol and 
plant stanol consumption on fasting plasma oxyphytosterol concentrations in healthy 
human subjects. For this, 43 healthy subjects (18-70 years) participated in a randomised, 
double-blind, cross-over study and consumed for 4 weeks a plant sterol enriched (3.0 g/d 
of plant sterols), a plant stanol enriched (3.0 g/d of plant stanols), and a control margarine 
separated by wash-out periods of 4 weeks. Compared with control, LDL-C concentrations 
were reduced after plant sterol (-8.1%) and after plant stanol consumption (-7.8%), but 
oxyphytosterol concentrations were not changed after plant sterol consumption. However, 
7β-OH-campesterol concentrations were reduced after plant stanol consumption by 0.07 
ng/mL (~14%) and by 0.07 ng/mL (~15%) compared with the control and sterol margarines. 
We concluded from this study that a daily consumption of a plant sterol enriched margarine 
for a period of 4 weeks does not increase fasting plasma oxyphytosterol concentrations, 
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while minor reductions were seen after plant stanol consumption. This study showed 
large but consistent differences in oxyphytosterol concentrations between individuals. In 
chapter 4, we tried to identify factors that might explain these inter-individual differences in 
plasma oxyphytosterol concentrations. This study demonstrated that plasma oxyphytosterol 
concentrations do not correlate with serum non-oxidized plant sterol concentrations and 
that plasma oxyphytosterol concentrations remained relatively stable over time. We 
identified six subjects with consistently low or high plasma oxyphytosterol concentrations 
during all three dietary interventions, which were also reflected in oxidized LDL (oxLDL) 
concentrations. Oxidative and anti-oxidative capacity markers, such as iron/copper status, 
α-tocopherol concentrations and TEAC values were measured but could not explain 
differences between the high and low plasma oxyphytosterol concentrations. Besides the 
effect of plant sterol and plant stanol consumption on fasting oxyphytosterol concentrations, 
we also evaluated postprandial plasma oxyphytosterol concentrations after consumption of 
a plant sterol or stanol enriched mixed meal (chapter 5). Humans are in a non-fasting state 
for most part of the day and to investigate effects on oxyphytosterol concentrations during 
the postprandial state, 10 healthy subjects consumed a shake (50 g of fat, 12 g of protein, 67 
g of carbohydrates), containing no, or 3.0 g of plant sterols or plant stanols. Blood samples 
were taken up to 8 hours and after 4 hours subjects received a second shake (without 
plant sterols or plant stanols). This postprandial meal test was performed at the end of 
each of the three intervention periods in which subjects consumed 20 gram of margarine 
on a daily basis, providing them with no, or 3.0 gram of plant sterols or stanols per day. 
7β-OH-campesterol and 7β-OH-sitosterol concentrations increased after consumption of 
a mixed meal enriched with plant sterol esters compared with a mixed meal or a mixed 
meal enriched with plant stanol esters. These higher oxyphytosterol concentrations were 
particularly present after consumption of a second meal. A comparable postprandial pattern 
was seen for non-oxidized campesterol and sitosterol concentrations, which also increased 
after a mixed meal enriched with plant sterol esters compared with a control or plant stanol 
meal. We speculated whether plasma oxyphytosterols originate from dietary absorption 
or endogenous formation and suggested that plasma oxyphytosterol concentrations most 
likely are derived form dietary absorption. However, a definite answer to this question can 
only be provided by a study in which labelled non-oxidized plant sterols are consumed and 
enrichment in labelled plasma oxyphytosterols is measured. Recent studies have suggested 
that consumption of plant sterol and plant stanol enriched products not only lower LDL-C 
concentration, but also reduce fasting TAG concentrations, especially in subjects with higher 
TAG concentrations. Since humans are in a non-fasting state for most part of the day and 
non-fasting serum TAG concentrations are emerging as an important CVD risk marker, we 
investigated the effects of plant sterol or plant stanol consumption on postprandial lipid 
and glucose and metabolism (chapter 6). For this, 42 healthy subjects underwent a meal 
test at the end of each intervention period, in which they consumed a shake containing no, 
or 3.0 g of plant sterols or plant stanols. Blood sampling was performed up to 8 hours and 
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subjects received a second shake without plant sterols or stanols after 4 hours. Incremental 
areas under the curves (iAUC) were calculated to evaluate the total (0-8 hours), first meal 
(0-4 hours) and second meal (4-8 hours) postprandial responses. TAG and apolipoprotein 
(apo) B48 of the total and first meal response were comparable between the three meals, 
while TAG and apoB48 responses after the second meal were higher after consumption 
op the plant stanol enriched shake compared with the control shake and the plant sterol 
enriched shake. This increased TAG and apoB48 response after the second meal was more 
pronounced with increasing age and statistically higher compared with the sterol shake 
than with the control shake. We suggested that consumption of plant stanols might have 
affected the clearance rate of TAG-rich lipoproteins (TRLs), but to provide more insight into 
postprandial responses, future studies should assess lipoprotein production and clearance 
after plant sterol and stanol consumption. As mentioned, we were not able to demonstrate 
a change in fasting oxyphytosterol concentrations in healthy subjects after consumption of 
a plant sterol or a plant stanol enriched margarine. In chapter 7, we describe the results 
of a human intervention study in subjects with impaired glucose tolerance (IGT) or type II 
diabetes, in which the effects of vitamin E or lipoic acid supplementation on fasting plasma 
oxyphytosterol concentrations are studied. Twenty subjects with IGT or type II diabetes 
consumed for 4 weeks placebo capsules, vitamin E capsules (804 mg/d) or lipoic acid 
capsules (600 mg/d) and oxyphytosterol concentrations were higher in subjects with IGT or 
type II diabetes as compared to concentrations in healthy subjects. However, fasting plasma 
oxyphytosterol were not reduced after consumption of vitamin E or lipoic acid for 4 weeks. 
In addition, other markers reflecting oxidative stress (oxycholesterol, MDA concentrations 
and oxidized LDL levels) and antioxidant capacity (TEAC assay, uric acid concentrations and 
GSH/GSSG) were also not changed after 4 weeks high-dose antioxidant supplementation. 
In conclusion, fasting oxyphytosterol concentrations differ between healthy subjects and 
subjects with impaired glucose tolerance or type II diabetes. In healthy subjects, fasting 
oxyphytosterol concentrations are not increased after consumption of a plant sterol 
enriched margarine for 4 weeks, while a plant stanol enriched reduced 7β-OH-campesterol 
concentrations. In addition, vitamin E or lipoic acid consumption did not change fasting 
oxyphytosterol concentrations in subjects with IGT or type II diabetes. Furthermore, 
postprandial plant sterol and oxyphytosterol concentrations increased after consumption 
of a mixed meal enriched with plant sterols compared to a mixed meal alone, or enriched 
with plant stanols. This increase was particularly evident after the second meal, which is 
indicative for a second meal response, which has also been described for cholesterol. Finally, 
postprandial TAG and apoB48 concentrations increased age-dependently after plant stanol 
consumption as part of a mixed meal, compared to a control meal and a meal rich in plant 
sterols. 
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Hart- en vaatziekten (HVZ) zijn wereldwijd de belangrijkste oorzaak van ziekte en sterfte. 
Risicofactoren om HVZ te ontwikkelen zijn roken, een hoge bloeddruk, suikerziekte, 
overgewicht en een ongunstig serum lipidenprofiel, zoals een verhoogd cholesterolgehalte 
in de laag-dichtheid lipoproteïnen (LDL-C). Het risico om HVZ te ontwikkelen kan verlaagd 
worden door het voedingspatroon te veranderen en functionele voedingsmiddelen, die het 
LDL-C gehalte verlagen, spelen hierbij een belangrijke rol. Plantensterolen en plantenstanolen 
zijn vetachtige stoffen, die lijken op cholesterol. Zowel plantensterolen als plantenstanolen 
worden verwerkt in functionele voedingsmiddelen en het LDL-C gehalte kan tot 12% worden 
verlaagd als er dagelijks 2.5-3.0 g/d plantensterolen of plantenstanolen worden gegeten. 
Daarnaast stijgt het gehalte plantensterolen in het bloed na het eten van plantensterolen, 
terwijl het gehalte plantensterolen in het bloed daalt na het eten van plantenstanolen. 
Omdat plantenstanolen een iets andere structuur hebben dan plantensterolen, kunnen de 
plantenstanolen niet oxideren.
Het doel van de studies die beschreven staan in dit proefschrift, was om het effect te 
onderzoeken van de consumptie van plantensterolen en plantenstanolen op de stofwisseling 
van lipoproteïnen en oxyphytosterolconcentraties in de gevaste staat en na de maaltijd. 
Daarnaast zijn de effecten van antioxidant suppletie op plasma oxyphytosterolconcentraties 
onderzocht.
In hoofdstuk 2 wordt een overzicht weergegeven van de beschikbare literatuur over de 
verschillende aspecten van het gebruik van plantensterolen en plantenstanolen bij de 
behandeling van een ongunstig lipidenprofiel. Naast het bekende LDL-C- verlagend effect van 
plantensterolen en plantenstanolen, worden in dit hoofdstuk ook de gunstige effecten op het 
triacylglycerol (TAG)-gehalte beschreven en er wordt een overzicht gegeven van de argumenten 
die gebruikt worden in de discussie rondom verhoogde plantensterolconcentraties en een 
verhoogd risico op HVZ. In hoofdstuk 3 onderzochten we de effecten van de consumptie van 
plantensterolen en plantenstanolen op de gevaste oxyphytosterolconcentraties in gezonde 
proefpersonen. Aan deze studie hebben 43 gezonde personen (18-70 jaar) deelgenomen 
en zij hebben gedurende 4 weken een plantensterol-verrijkte (3.0 g/d), een plantenstanol-
verrijkte (3.0 g/d) en een controle margarine gegeten, gescheiden door een rustperiode van 
4 weken. Ten opzichte van de controle margarine, was het LDL-C gehalte verlaagd na het 
eten van de plantensterol-verrijkte margarine (-8.1%) en na het eten van de plantenstanol-
verrijkte margarine (-7.8%), maar de oxyphytosterolconcentraties waren niet veranderd na 
het eten van de plantensterol-verrijkte margarine. Daarentegen waren de 7β-hydroxy(OH)-
campesterolconcentraties verlaagd na het eten van de plantenstanol-verrijkte margarine; er 
was namelijk een verlaging van 0.07 ng/mL (~14%) vergeleken met de controle margarine en 
een verlaging van 0.07 ng/mL (15%) vergeleken met de plantensterol-verrijkte margarine. 
Uit deze studie konden we concluderen dat na een dagelijkse consumptie van plantensterol-
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verrijkte margarine gedurende 4 weken, gevaste oxyphytosterolconcentraties niet 
toenemen, maar dat plasma oxyphytosterolconcentraties enigszins dalen na het eten van 
plantenstanol-verrijkte margarine. Deze studie toonde aan dat er grote, maar consistente 
verschillen bestaan in oxyphytosterolconcentraties tussen verschillende mensen. In 
hoofdstuk 4 hebben we geprobeerd om factoren te vinden die deze verschillen tussen 
mensen in plasma oxyphytosterolconcentraties zouden kunnen verklaren. Deze studie 
toonde aan dat plasma oxyphytosterolconcentraties niet correleren met niet-geoxideerde 
plantensterolconcentraties en dat plasma oxyphytosterolconcentraties relatief stabiel zijn 
gedurende een langere periode. We identificeerden zes personen met consistente lage 
of hoge plasma oxyphytosterolconcentraties gedurende alle drie voedingsinterventies. 
Deze lage of hoge oxyphytosterolconcentraties waren ook terug te zien in de geoxideerde 
LDL (oxLDL) concentraties. Oxidatieve en antioxidative capaciteit markers, zoals ijzer/
koperstatus , vitamine E-concentraties en TEAC waardes werden gemeten maar deze konden 
de verschillen tussen de hoge en lage plasma oxyphytosterolconcentraties niet verklaren. 
Naast het effect van de consumptie van plantensterolen en plantenstanolen op gevaste 
oxyphytosterolconcentraties, hebben wij ook de plasma oxyphytosterolconcentraties na de 
maaltijd gemeten na de consumptie van een gemengde maaltijd rijk aan plantensterolen 
of plantenstanolen (hoofdstuk 5). Tijdens het grootste gedeelte van de dag zijn mensen in 
een niet-gevaste staat en om het effect op de oxyphytosterolconcentraties na de maaltijd te 
onderzoeken, hebben 10 gezonden proefpersonen een shake gegeten (50 g vet, 12 g eiwit, 
67 g koolhydraten), met of zonder 3.0 g plantensterolen of plantenstanolen. Gedurende 
deze 8-uur durende testdag werden bloedmonsters afgenomen en na 4 uur werd weer 
een shake gegeten, maar nu zonder toegevoegde plantensterolen of plantenstanolen. 
Deze testdag werd uitgevoerd aan het einde van elk van de drie interventieperioden 
waarbij proefpersonen dagelijks 20 gram margarine hebben gegeten (met of zonder 3.0 g 
plantensterolen of plantenstanolen). 7β-OH-campesterol- en 7β-OH-sitosterolconcentraties 
waren verhoogd na het eten van de plant sterol-verrijkte shake vergeleken met de 
plant stanol-verrijkte shake en de controle shake. Oxyphytosterolconcentraties waren 
vooral hoger na het eten van de tweede shake. De niet-geoxideerde campesterol- en 
sitosterolconcentraties vertoonden een vergelijkbaar  patroon na de maaltijd, aangezien 
deze ook toenamen na het eten van de plant sterol-verrijkte shake vergeleken met de plant 
stanol-verrijkte shake en de controle shake. De vraag of plasma oxyphytosterolconcentraties 
afkomstig zijn uit de voeding of dat deze gevormd worden in het lichaam, kan alleen worden 
beantwoord door gelabelde niet-geoxideerde plantensterolen te eten en vervolgens een 
verrijking in gelabelde plasma oxyphytosterolen te meten in het bloed. Recente studies 
hebben gesuggereerd dat de het eten van producten verrijkt met plantensterolen en 
plantenstanolen niet alleen het LDL-C gehalte verlagen maar ook het TAG gehalte in het 
bloed kunnen verlagen, vooral bij personen met verhoogde TAG-concentraties. Aangezien 
mensen het grootste gedeelte van de dag in een niet-gevaste staat zijn en niet-gevaste TAG-
concentraties een belangrijke risicofactor zijn om HVZ te ontwikkelen, onderzochten wij het 
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effect van het eten van plantensterolen en plantenstanolen op de vet- en glucosestofwisseling 
na de maaltijd (hoofdstuk 6). Om dit te onderzoeken, hebben 42 gezonden proefpersonen 
aan het  einde van elk van de drie interventieperioden een shake gegeten (met of zonder 
3.0 g plantensterolen of plantenstanolen). Bloedafnames werden afgenomen tot 8 uur 
na het eten van de shake en na 4 uur werd weer een shake gegeten, maar nu zonder 
toegevoegde plantensterolen of plantenstanolen. De oppervlakte onder de curves (iAUC) 
werden berekend om de responsen na de maaltijd te vergelijken tussen de interventies 
en dit werd gedaan voor de totale periode (0-8 uur), de periode na de eerste maaltijd (0-4 
uur) en de periode na de tweede maaltijd (4-8 uur). De TAG en apolipoproteine (apo)B48-
concentraties na de totale en de eerste maaltijd responsen waren vergelijkbaar tussen de 
drie interventies, waarbij TAG en apoB48 responsen na de tweede maaltijd hoger waren na 
het eten van een plant stanol-verrijkte shake vergeleken met de plant sterol-verrijkte shake 
en de controle shake. Deze verhoogde TAG en apoB48 responsen na de tweede maaltijd 
waren meer uitgesproken met toenemende leeftijd en hoger in vergelijking met de plant 
sterol verrijkte-shake dan met de controle shake. We suggereerden dat de consumptie van 
plantenstanolen een effect zou kunnen gehad op de klaring van TAG-rijke lipoproteïnen 
(TRL), maar om meer inzicht te krijgen in de responsen na het eten van producten rijk 
aan plantensterolen en plantenstanolen, zal de productie en de klaring van lipoproteïnen 
verder moeten worden bestudeerd in toekomstige studies. Zoals al eerder hier beschreven, 
hebben wij geen verandering gevonden in gevaste oxyphytosterolconcentraties na het eten 
van een margarine rijk aan plantensterolen of plantenstanolen. In hoofdstuk 7 beschrijven 
we de resultaten van een studie in personen met een verminderde glucosetolerantie 
(IGT) of  met type II diabetes, waarbij de effecten van vitamine E of liponzuur suppletie op 
gevaste oxyphytosterolconcentraties worden bestudeerd. Twintig proefpersonen met IGT of 
diabetes type II hebben gedurende 4 weken elke dag placebo capsules, vitamine E capsules 
(804 mg/d) of liponzuur capsules (600 mg/d) ingenomen en oxyphytosterolconcentraties 
waren hoger bij proefpersonen met IGT of diabetes type II in vergelijking met gezonde 
proefpersonen. Echter, na de inname van vitamine E of liponzuur gedurende 4 weken was 
er geen verlaging in de gevaste oxyphytosterolconcentraties. Daarnaast waren andere 
markers die oxidatieve stress weergeven (oxycholesterol, MDA-concentraties en oxLDL) 
en antioxidant weergeven in het lichaam (TEAC assay , urinezuur en GSH/GSSG) ook niet 
veranderd na een hoge dosis antioxidant inname gedurende 4 weken.
In conclusie, gevaste oxyphytosterolconcentraties verschillen tussen gezonde 
proefpersonen en proefpersonen met een verminderde glucosetolerantie of diabetes type 
II. Het eten van een plant sterol-verrijkte margarine gedurende 4 weken zorgt niet voor 
een toename in gevaste oxyphytosterolconcentraties in gezonde proefpersonen, terwijl 
7β-OH-campesterolconcentraties verlaagd waren na het eten van een plant stanol-verrijkte 
margarine. Bovendien heeft de inname van vitamine E of liponzuur geen effect op gevaste 
oxyphytosterolconcentraties bij personen met IGT of diabetes type II. Daarnaast waren 
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plantensterol en oxyphytosterolconcentraties na de maaltijd verhoogd na het eten van een 
gemengde maaltijd verrijkt met plantensterolen in vergelijking met een gemengde maaltijd 
alleen, of een maaltijd verrijkt met plantenstanolen. Deze toename was vooral duidelijk 
te zien na het eten van een tweede maaltijd, wat duidt op een tweede maaltijd response 
zoals al eerder werd beschreven voor cholesterol. Tenslotte stijgen postprandiale TAG- en 
apoB48-concentraties na het eten van een plant stanol-verrijkte shake vergeleken met een 
plant sterol-verrijkte shake en een controle shake, een effect wat meer uitgesproken is met 
toenemende leeftijd.
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